%PDF-1.3%‚„œ”
3 0 obj<</AcroForm 216 0 R/DefaultGray 214 0 R/DefaultRGB 215 0 R/Metadata 217 0 R/OCProperties<</D<</Order[]/RBGroups[]>>/OCGs[218 0 R]>>/Pages 213 0 R/Type/Catalog>>endobj216 0 obj<</DA(/Helv 0 Tf 0 g )/DR<</Encoding<</PDFDocEncoding 219 0 R>>/Font<</Helv 220 0 R/ZaDb 221 0 R>>>>/Fields 222 0 R>>endobj214 0 obj[/CalGray<</Gamma 1.9/WhitePoint[0.9643 1 0.8251]>>]endobj215 0 obj[/CalRGB<</Gamma[1.9 1.9 1.9]/Matrix[0.511 0.2903 0.0273 0.3264 0.6499 0.1279 0.1268 0.0598 0.6699]/WhitePoint[0.9643 1 0.8251]>>]endobj217 0 obj<</Length 3654/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c001 79.675d0f7, 2023/06/11-19:21:16        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <dc:format>application/pdf</dc:format>
         <dc:creator>
            <rdf:Seq>
               <rdf:li>Unknown</rdf:li>
            </rdf:Seq>
         </dc:creator>
         <dc:description>
            <rdf:Alt>
               <rdf:li xml:lang="x-default"/>
            </rdf:Alt>
         </dc:description>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">20892LBL.PDF</rdf:li>
            </rdf:Alt>
         </dc:title>
         <pdf:CreationDate--Text>Monday, September 28, 1998 3:41:15 PM</pdf:CreationDate--Text>
         <pdf:Keywords/>
         <pdf:Producer>Acrobat PDFWriter 3.02 for Windows</pdf:Producer>
         <xmp:CreatorTool>Microsoft Word </xmp:CreatorTool>
         <xmp:ModifyDate>2024-06-12T15:33:11-04:00</xmp:ModifyDate>
         <xmp:MetadataDate>2024-06-12T15:33:11-04:00</xmp:MetadataDate>
         <xmpMM:DocumentID>uuid:89dd1197-9c9a-4750-9e13-af316831c4b4</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:351b3a92-8a85-4678-8352-e6b92eab0720</xmpMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                           
<?xpacket end="w"?>
endstreamendobj213 0 obj<</Count 11/Kids[5 0 R 128 0 R]/MediaBox[0 0 612 792]/Type/Pages>>endobj5 0 obj<</Count 6/Kids[4 0 R 48 0 R 67 0 R 82 0 R 97 0 R 112 0 R]/Parent 213 0 R/Type/Pages>>endobj128 0 obj<</Count 5/Kids[127 0 R 143 0 R 158 0 R 173 0 R 188 0 R]/Parent 213 0 R/Type/Pages>>endobj127 0 obj<</Contents 223 0 R/Parent 128 0 R/Resources<</ColorSpace<</CS0 224 0 R/CS1 225 0 R>>/ExtGState<</GS0 226 0 R>>/Font<</TT0 6 0 R/TT1 19 0 R/TT2 25 0 R>>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<</Fm0 227 0 R/Im0 130 0 R/Im1 136 0 R>>>>/Type/Page>>endobj143 0 obj<</Contents 228 0 R/Parent 128 0 R/Resources<</ColorSpace<</CS0 229 0 R/CS1 230 0 R>>/ExtGState<</GS0 231 0 R>>/Font<</TT0 6 0 R/TT1 19 0 R/TT2 25 0 R/TT3 22 0 R>>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<</Fm0 232 0 R/Im0 145 0 R/Im1 151 0 R>>>>/Type/Page>>endobj158 0 obj<</Contents 233 0 R/Parent 128 0 R/Resources<</ColorSpace<</CS0 234 0 R/CS1 235 0 R>>/ExtGState<</GS0 236 0 R>>/Font<</TT0 6 0 R/TT1 22 0 R/TT2 25 0 R/TT3 19 0 R/TT4 43 0 R>>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<</Fm0 237 0 R/Im0 160 0 R/Im1 166 0 R>>>>/Type/Page>>endobj173 0 obj<</Contents 238 0 R/Parent 128 0 R/Resources<</ColorSpace<</CS0 239 0 R/CS1 240 0 R>>/ExtGState<</GS0 241 0 R>>/Font<</TT0 6 0 R/TT1 25 0 R/TT2 19 0 R/TT3 43 0 R>>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<</Fm0 242 0 R/Im0 175 0 R/Im1 181 0 R>>>>/Type/Page>>endobj188 0 obj<</Contents 243 0 R/Parent 128 0 R/Resources<</ColorSpace<</CS0 244 0 R/CS1 245 0 R>>/ExtGState<</GS0 246 0 R>>/Font<</TT0 6 0 R/TT1 19 0 R>>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<</Fm0 247 0 R/Im0 190 0 R/Im1 196 0 R>>>>/Type/Page>>endobj243 0 obj<</Length 3002>>stream
q
1 0 0 1 -21.069 -159.084717 cm
0 0 612 792 re
W n
1 0 0 1 21.069 159.084717 cm
BT
0 0 0 rg
/TT0 7.92 Tf
0.0166 Tc -0.0583 Tw 86.931 589.235 Td
(ANTHRA PHARMACEUTICALS, INC.)Tj
-0.032 Tc -0.0098 Tw 0 -9.36 TD
(AD 32)Tj
-0.0421 Tc 0 Tw T*
(NDA 20,892)Tj
0 Tc -0.0418 Tw 421.2 0 Td
( )Tj
-0.0835 Tc 0 Tw (11)Tj
ET
q
437.76 0 0 -7.68 86.451 569.555283 cm
/Im0 Do
Q
q
1 0 0 1 -21.069 -159.084717 cm
108 726.96 432 0.96 re
f
Q
q
437.76 0 0 -7.68 86.451 569.555283 cm
/Im1 Do
Q
q
1 0 0 1 -21.069 -159.084717 cm
0 0 0 RG
0.24 w 1 j 1 J 
108 726.96 432 0.96 re
S
Q
BT
/TT1 10.08 Tf
-0.0247 Tc 86.931 529.955 Td
(REFERENCES)Tj
/TT0 11.04 Tf
0.0763 Tc 0 -36 TD
(1.)Tj
0.0657 Tc -0.0148 Tw 36 0 Td
(Recommendations for the Safe Handling of Parenteral Antineo)Tj
0.0215 Tc 0.0294 Tw (plastic Drugs,)Tj
0.0497 Tc 0.0012 Tw 0 -12.96 TD
(NIH Publication No. 83-2621.  For sale by the Superintendent of Document\s,)Tj
0.07 Tc -0.0192 Tw T*
(U.S. Government Printing office, Washington, DC 20402.)Tj
0.0763 Tc 0 Tw -36 -25.92 Td
(2.)Tj
0.0386 Tc 0.0123 Tw 36 0 Td
(AMA Council Report, Guidelines for Handling Parenteral Antineoplastics. \)Tj
0.0549 Tc -0.004 Tw T*
(JAMA, 1985; 2.53\(11\):1590-1592.)Tj
0.0763 Tc 0 Tw -36 -25.92 Td
(3.)Tj
0.0377 Tc 0.0132 Tw 36 0 Td
(National Study Commission on Cytotoxic Exposure - Recommendations for)Tj
0.0468 Tc 0.0041 Tw T*
(Handling Cytotoxic Agents.  Available from Louis P. Jeffrey, ScD., Chair\man,)Tj
0.0376 Tc 0.0133 Tw T*
(National Study Commission on Cytotoxic Exposure, Massachusetts College o\f)Tj
0.0576 Tc -0.0067 Tw T*
(Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston,)Tj
0.0449 Tc 0.0059 Tw T*
(Massachusetts 02115.)Tj
0.0763 Tc 0 Tw -36 -25.92 Td
(4.)Tj
0.0431 Tc 0.0078 Tw 36 0 Td
(Clinical Oncological Society of Australia, Guidelines and Recommendation\s for)Tj
0.0598 Tc -0.0089 Tw T*
(Safe Handling of Antineoplastic Agents.  Med J Australia, 1983; 1:426-42\8.)Tj
0.0763 Tc 0 Tw -36 -25.92 Td
(5.)Tj
0.0617 Tc -0.0109 Tw 36 0 Td
(Jones RB, et al: Safe Handling Of Chemotherapeutic Agents: A Report from\ the)Tj
0.0291 Tc 0.0218 Tw T*
(Mount Sinai Medical Center.  CA - A Cancer Journal for Clinicians, 1983;\)Tj
0.0509 Tc 0 Tw T*
(\(Sept/Oct\) 258-263.)Tj
0.0763 Tc -36 -25.92 Td
(6.)Tj
0.0374 Tc 0.0135 Tw 36 0 Td
(American Society of Hospital Pharmacists Technical Assistance Bulletin o\n)Tj
0.0471 Tc 0.0038 Tw T*
(Handling Cytotoxic and Hazardous Drugs.  Am J. Hosp Pharm, 1990; 47:1033\)Tj
-0.0763 Tc 0 Tw (-)Tj
0.0916 Tc T*
(1049.)Tj
0.0763 Tc -36 -25.92 Td
(7.)Tj
0.0425 Tc 0.0084 Tw 36 0 Td
(Controlling Occupational Exposure to Hazardous Drugs.  \(OSHA Work-Pract\ice)Tj
0.0473 Tc 0.0036 Tw T*
(Guidelines\),  Am J Health-Syst Pharm, 1996; 53:1669-1685.)Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS0 gs
/Fm0 Do
Q
EMC 

endstreamendobj247 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240612153311-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 248 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 249 0 R/LastModified(D:20240612153311-04'00')/Private/Header>>>>/Resources 250 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj190 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 189 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im25/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj196 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 195 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im26/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj195 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj189 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj248 0 obj<</OCGs 218 0 R/Type/OCMD>>endobj250 0 obj<</Font 251 0 R>>endobj251 0 obj<</ArialRoundedMTBold 252 0 R>>endobj252 0 obj<</BaseFont/ArialRoundedMTBold/Encoding/WinAnsiEncoding/FirstChar 0/FontDescriptor 253 0 R/LastChar 255/Subtype/TrueType/Type/Font/Widths[500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 250 333 479 552 594 854 760 240 354 354 438 583 313 333 313 281 594 594 594 594 594 594 594 594 594 594 313 313 583 583 583 573 979 719 719 740 740 667 604 792 760 313 573 740 604 833 760 792 667 792 719 667 625 760 688 938 604 625 646 354 281 354 583 500 333 594 625 594 625 594 333 625 604 271 271 573 271 885 604 604 625 625 438 542 354 604 542 813 521 542 521 385 281 385 583 354 594 354 313 594 458 1000 594 594 333 1208 667 365 1031 354 500 354 354 313 313 458 458 354 500 1000 333 1000 542 365 958 354 500 625 250 333 594 594 552 625 281 594 333 740 375 594 583 333 740 500 396 583 354 354 333 615 563 313 333 354 385 594 854 854 854 573 719 719 719 719 719 719 990 740 667 667 667 667 313 313 313 313 740 760 792 792 792 792 792 583 792 760 760 760 760 625 667 594 594 594 594 594 594 594 927 594 594 594 594 594 271 271 271 271 604 604 604 604 604 604 604 583 604 604 604 604 604 542 625 542]>>endobj253 0 obj<</Ascent 946/CapHeight 728/Descent -211/Flags 32/FontBBox[-174 -211 1185 946]/FontFamily(Arial Rounded MT Bold)/FontFile2 254 0 R/FontName/ArialRoundedMTBold/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 132/Type/FontDescriptor/XHeight 530>>endobj254 0 obj<</Filter/FlateDecode/Length 31995/Length1 45260>>stream
Hâ‹VyXGØÈ9ÄP¯@\Ñ5rÃ@7˜Â¡9Ç"„Hs4–:”Õ·	3´äääÇEEÉ≤j0í¨F"(EÖ≈¨Gƒƒ+o4[Qt]˝cøo≥˚m◊W_˜{ıﬁ´ﬂ´˜´Æ ¿Pêò@ë-ö{u∂j˙ ‡?éKÙÙRkñΩ ¿¶Í$rïTÎ ¯, €) 0=‰Y4∫·¡¶X Ï¿ê•j”T¯—bq¯PÆKSŒO2ˇq õXPúNHM‚âÿ‰„˘•C≈–}&+†úÂ—È*:G4:vîó¬¯-Ûù:¡C|Ä≤x ∏∑îπ‘¥◊u2 ªC`¸ï4GÀ≤`@,{FCT-U…ï5Îû ÿ◊¥ä4Ñ6PÁC\µ:B[ßød¿1¥œÑù—ﬂåo¿øﬂ|–ˇ/b~«Ã-R˛#Ü	Ra‡üÇ™ÉÅ¡Ã9¶#õ∞◊ù√`1˛ÉUëÄ≈cÇ◊4;Û@Hã2@P–∞è76}3À≤ñû]üzÔp«a¿É…E˘Àµòôà{Kf”ˇÔ◊π\˘Î˝Üßiñò≈+ú¬ë‚VÿPs:Àƒ⁄4ZM√5$h‹≥1™∏÷C$ÑéL$”‘4Z-˜¿Ω1‹8¿≥v{9ÄÜkT*B''•J4QìJgKuü)SíT:°£–PÃ—Œ"–Û¡±˛'ŸŒ
8ÊÔÂÌËò¸G@–o{=o0ı´ ¶/DÙz––A	åqµK£lÿß‚È'"ñG∆Ω§´£Ûd^˛™.Û_lÀ[ÊÌu=¥&ãZwÚÑlw»mGvÊ=k†‰«û›\lÚ%IÈÎdSq«”}ßÃ^\|º¶V4Ìñ¶M·ãú_ú∆Œæ≤Êªiùœ6Ÿﬂô≠oøtˇ“ÂÊ ?Ø¸6Ù´qŒì&Ì∂GòêTˇT&ƒu¯ËÅÃπÖ;Úè)r™º2uVü|Äÿ•`SÆNÚ±ˇ<!f⁄∞ºâ¬ÖÁ¢Dih®Á˝˘Ç™‘¶x∏”Çï°Ì´É⁄[|"⁄3ˇîÒçﬁ>¿Œ7¶ÊƒxØG÷±Î◊ˇΩ)`V◊£ıä‚€‚∂ÊééˆèÓ≤ ∫√•◊ÉqªZ3xH‰P=ÏÆﬂ∫∞ˆÙäû™oé˘6ï≠*hvjNî¨}0ÚHˇ1ÓÑç(ôÌ´ àuôçN%ËlçnﬁÀöÚﬁ™© s5ËI™4ëñ™¥§:M$tY§ú@4˜¡º¨›ß∆°S¢C√¢ßDã?DC√√#„≈ë‘EÓËèæ9G?˝1_‹ÛˇùÖÅÅ∏ó7˛ª¯øü¿˚8‹·ÅﬁK_$zËrUÒéXYÃ∏êÿïyıî∑€°≥Õf˙¸z≥¯Öôy˚˜J˛ºı∆√ÇÉ[Îóè˘yqí%57Á€õÁçI]´ìÊld= ¨íÙÕ%Áúì<œµŸK˝æ(˘§66ÊÊù`Á˝í“%#Àï˘ı1¢Mskw˚ùÎ3v‘ñΩ≈a÷ áÉ¨ ó±«üπô˜l·πΩΩ˚Ê˜±˚6åÀµ◊›Ârë5Q¯B∞ú±&yã¨Ÿ™*Ø˜»ó¸#ß%•ÛLeëç;v]Õe;wÎÑ¨|v’"3€ı¸{èlcœõ¨.≥T&Ω‡˙nj.‹vô•-w[,]˝U/cÀû¶TYÿ∏%Œ^õùW<Uòé~pÊ)‰o+Ï~à8fµÂB¯Ìëœ¢íñ6Gèπ√O˘ˇ#Ò>|,6f ∞„˚aºÃî˜ŒLˇ-àÔ˛qø˝ì«Ù[ﬂ¢ÙJXÖÂFJWKo◊Ó_U,*æXk5áº»Õïs÷∂ﬂ
÷FuFï‹<Àô∞uˇéú‰[O˙‰ëqu<5vwá_µ–ÏÚ/ö±’”Rÿæqπm‚∏ˆ#Ç∞.^˚™∫9ø}ñ◊~ucmÆstò•≤cÛÜ§≤·o€Çzs˜$ÌÓt&ÆUÁî˝Nñ>S∏¯˘aÑ¡¸ÑV•<+˝h'˘i«B≠ªlîc:Ì/£löh‰IÙ˝±√gÌÀœ5u∏¶˚á√{VVMæJùúd∂ı¿Öïl÷53ØõçëpnL›)⁄uzF‘Ÿ …Éë≠«xµï]9>QÙSóJîuΩ´ö◊ñ€º§‚…7‹›ÊÈI˛ÌKnN’F	K0Éi-Ï#*òA,ß[<ò†∞Ì4ß@W‰:[üˇ“Èày„ØùÓÊÉ˚Ω<›åŸˇqx1‡4.;;€#:R–—CÆQy¬[úÜ"içnægB|®qçNÎÅ Ê£	D™á¿»kè)‚#óÒX»@ﬂ2ç§·Ñ—h∏RJQ®7*DcIπNCAÉ8$R%©ê“§Fçfy·<ÃÃËœ±F¶'‚÷òïQ0µÊŒêRÈpÎ—5nâX
ìB°“®∏#Ê`‘0˘6É·√!FçÆ?ÏÀqﬁ;∆ﬂªâv:…ô¢ú¢=G%•W$[ìdª¯F¨˚ÆkÔ”∫nzª¶f¶+W‰¥§ΩJ¸u∑®ı⁄ùsvô3>‚1Á√-<ˇô?â82aV˜˛≠S∆&õcOd˘›9à≤+‹OâC:Ó!Ág'âÚ [¢∞ûñ’-iî±Œ∫S1Áª∫◊’›q0}ú}n¢J[ÉÿÛ˙WfÑ5¡ ∆3~e±òª”ó%K_≥<ÀÖØùûæ˘◊Äu}ûaª¸`±·Ì{ÚH#*ÉÒÀ„c∆[¸‡-›ñâò‰∏Ï–ÑÀ‚`0ºo≥¸^≥·]¨QPÌT·ö76ù¶µTêßÁ˚ü∏›¿¨”òµ‚tíBÂÑé&SIπî&P≤ü∏∆¢îëΩ:"ï–j9!@•jJ“öIA3
•h)ßïÛπT¶l.!ßQZ#@Èt\èWqçºç◊IÂ¥Ò`ÇGM®5ç∫@$Æ\ì2‡ú$KJ*•2•…õ—@•t˜]âQG
U0¥C·BëëIPˇ`æ £ö8∑¯ù…0" uc©|—*â∏°÷Bê¡êƒ,Äh’@ÿ,dQ±äÄ÷∫÷á‘Q\y®TŸjµÆà®∏[\0¿´’j±.«g=}ñºõ ÇÀ;Á˝ıŒõ√êôoÓ˜˚ÓÔwÔwÔLZ™ﬂ€v˙övæ^O2lÑØFTãùJ4;BÙÈIiZÙ*4>zé'Fì¯˜·iT"¥KŒHâèçK35+°ØÔ»w‡%$•…"B*ˆ∆hùKîj+„ÖâîJëLÕJT$ÄUâ•"6D@D≤Ä.˝P Ü∞ÿΩx&k+õ0Ü®É$D£íy ^≤*3»äEj	¡[ïZ…ä’“…D•Òñà’D-7M·ÖJî¨äù Îbœ eD°â’¨XÇÛ D"S£€¶%XïJÉÎëF$W¢/º'U¢ê≤Ì>K¬JâJE:Y°2±T`BÈÂ°ﬂ!•8o;X ï$êUÀL”ÒZD"ÙQ¨ëäîD°Q*‰*âßyë0V*%2πöÁ/1ã$ïò'àÂ2ïdíùgEROú"c’lh˚úgÂ»JID!¢	ïQI$<OL3FÄ≠§*TZ¨«2êÑ!”«ºõã±Ò©X!¢u$IüdJ´ò¯hù™m#à“pgD¶„‚Eœ≈˘Ê‰û≠MHè&©qZÃÉ$}âå&Qz|§3ÉhSâ6**=•m∆ËSÕ{Ü7ª≠Ï£f™…V‰≈+ô5¸øŸÊ„	˙XΩWl|å`§©êpo¡PÅG·‡¬AK›M0àíä;2=ım†(S;zE•$˙t©7Nåï¿k˛}‡cRSü_ß~-x\vÂ˙+ÍBÒ ><òı,8˘’‘—^ΩÔ⁄æT˙ÔﬂmÄƒÌò”öjÕâÀG¶P!Eˆœ?€ú:a“¥Qç˚¸ís«¡£=„¨á<Û“?yî∏pŸññçõG⁄üpo¢≥º)‹˘‚›ûÂ77¥N y˝SÀ√ãÕy”\èæln(ô.Ã·T
r8áhä§ˇ
˙^ç¨-¨⁄D°π\(Ã>)px£R7é∞kyg∞„vﬁuæS¸.ù°=cófS1ˇÈ‰f'ü˚ûïÓW1]Ã≠Ö·Ç–Bœ¨! Çà-$ %Ë!í@—x5˛˜«—–mò5†=Liîÿ—ˆÕ·OÀH÷«¶hì„2»;}ü…Œ“†0N\ª^_w[~°ËE LÁ◊2AWÀ¨2]?=<ærlè˘~ˇä»<îí\d◊œÔXÕ√©xãÛeB±∏œÃ˙Ò!ï>Øè;˛⁄c˝§wDqÑ~o∏cy◊IÂ5W}*tn my4ΩØcÓﬁÒ>˘€,Ü5Kr[˛Y8rHÊΩ.ùÒ*ﬂñC]∆7æùYs®£8ÙΩ)ÚŸUˇ˜üXˇÈKÒÌÏô,Ë◊5y∫øπ±§0wﬁ<·
mÕo«£Ö£ÖæBüa#"ﬁÀùäÍ?˘S"œ|Æú¥1b∫b«˚1oﬁ)˙ı∂ÊTÂÅ0É6’ªŒq»9ˇ±>A˚Ó»÷«ª¸÷Z˘¬⁄Î~9P0lÎvãA#å:hiw€’Ê˘°i∆S"n5Ó ∏s7¡µzbÙ≤íDùŸäœ≠ÍÂ›$Áœ37"Îá˛„z√cA`˝∑õ∆[ÃÃΩ·\ñ∂a—©-˝˚=u∫«@≠.Xq7r}  ªÌó:1¥Ωó∂µd8\|b∫!rô¸Ä<•π◊ZïîçÂ:™î‡ƒ7t˚u/úáWî#ûù]≠€qÜkai’ç◊›∫áç≠]O˚èzıÓ”∑üÉ£ìÛ«˝]à+ﬂmÄ˚¿Aü‚·9‘À[ Ê3|ƒ»Q£}«å˜È¯œ¸D˛‚ I‡Ñ 6x¢4D&WLR™‘ö–∞…S¶~>m˙-DFÈ¢cb„‚g~ëêò§Oûïíöñ>{Œ‹åy_Œ_êπ0+;g—‚%KóÂ.ˇj≈◊+W≠^≥v›7Îˇñ∑!ˇ€çõ6o)ÿZ∏m{—éùªvÔŸ[¸˜í}˚î~wPYyEe’˜á8rÙ«c«Oú<u∫˙LÕŸ⁄sÁ/‘]ºt˘
\Ωv˝∆Oı7o›æ”p◊–ÿ›ô°v®:dB)!•¢¥‘\j]C◊“w9«I/‚H˙>Hd)qÂª‰”|æ-ø'ø7ﬂëﬂüÔ¡‚œ‡Gªü{JçàH†™IIÕ0#ùA§õàÙÈGú	1#˘æá‰IáHî—h¸Ÿ„N„4c∂QlD_[Ì ^ﬂi⁄⁄¢¶%MyxˆlúŸòa»3l7¨0‰v“≥”ﬁ¡Ì'v«Ãëƒöÿyºl?åäÅœﬂ)Å"XKI¸Ka¨Ä-∞vÄ|œ`|-V¬»Öª@1<Åﬂ·)lá}P5∞"!
÷`5>è5˘,úÉKpÍ‡"‹É∏
ó·
ÄXxk·\ÉÎ˜·WX3±™âXπìP_=ÃÇddïäı=f√¯Ê¬<»Ä/aÃá*ÿ1¶Yê‡!ÜzhÇ€p†nÇ£]	ß° °r‡$,ÉS∞YZ`.ÿ a—:æ5ŸxÄqa&qãπ‹óL$¡Ñ3C9uú|éΩáßCiıÄ⁄A-«h•<(W âr¿Ôxç*ø@µZp˝_P±f\˘ñô’%d|◊˝é†gUË≈A(Emv°ñ∞ı]´Q«»{Íöçú“ëq"™á:È`*(∞èy[9X˙Z∏qSπ:ÆÇ+Â2Ãf9Ã¯0É'∆Å·14ÁOŒ+ŒÔúáúËs5Á'èC”7Ë*zΩôûEG“SiÕ£R•TD˘ á¡î;ÂB}lÊ—ó≤ßÏêçˆYS©Y˝	ØêŸsåjjkbUã\N ì%˜=»∆ƒ%Ÿ¨∆X,0{Ón e∂6=¨ªóÒ∫YYZîôjU
ûﬂQwH‚¥∫Réª˘WÓÊÌˆóì∑€„^ı±Múg¸}Ólüø€qL‚ƒ±sÿI¸y∂œ_ql_|N‚$‰√!8ü§)m Vÿ¶Ñï‹¥E∞í	÷µt∞â-™PŸZob’TÑ¶Ic´ˆ—"¥?ZVâN€¥©kúΩw¥lÍ∞ÂÛ˚æ˜ºœ›ÛªﬂÛ{û7«ÕÌ∂⁄2V"]˚x	¯™áºΩ¡˜z™◊Ûé◊SÍ\(ù*°™¸¶ÑËûeJ=%¬ÜwÒ©T]Ì¬:ã]·ˇÃÿ≥Õ%«,˝µ ˛˚ªÓoAˇã≠s.Îı∏Ω8©#ì˛¯—∑,Üú^}¥·ˇ¿2é1Òz“¬oıNh|1úèèm∞›ÍŸ·J2åÎ¬õ“-∏íPÌzªQo◊ìSüÆ¥íJÈñ{Á§û{´R[^^˚ÓJo"=j@M\ùN¨0¬CW# †Áÿè;Ä“n∆H:√l$¨1US§Ë&ß±È¡äÏéM1⁄]h£‹î/qmONé¶”„ƒ3p˚Î…Õ[˜ÌÕdÀ∆±È…’_vßFGS]CB’˚2Y"∑K/`uW°:ÆJ©¶$j(™ ¢îTî+Ä¸iöö€MÎ«˘aú'Ñ#Y„'üî?éÿ[’⁄…éßÂ—8◊èÍ˙$˜Èî
îgîç»'DP9ER—™¥´Mjƒ"!?48–◊ôÂ3\åÒ∑∂ll®∑‘m–W…)@ñ«›Í
¬«≈§A:F∫©2à¶ÑÓµ†7êt‹@i	qChJÔ≈ÖÊG:y|øÈÒ/˚Uø3”;ﬁcîøóçKÂ‡XŒÚ°ˆ=|ñœæÊWÈo∞MÎ∏Â74s°6—+q˚«…]AÏ∑√L~–ñiäyîì>`9OƒgjqH/ëªÉÌÂ[\ ê¸0⁄Óçy[ì?‹“Ûö„ƒÕÚ-°W(%s≤£®Ò®eπPg6ïL0≠Z•rµ`¿ùÕqSNÉ:uÿ:êË\-Ó`êêéwÑIπ0D˛LV0[«N75;õıÎ3-P‚í3¨˜ëÚò≠ÑYÔ#$fCARØ≈v5F}
¬¨ì¯ŒÆìqo†á›÷`?¯Ïâ∂øÎWÀÊÊçÛoÕ«p)µ•%œ:ø˜ΩiÆ82=ˆ˚Ÿßv…‚ªU>¥€ÏŸy†µ<”GON~Â˙Aıøè¥öë/v0˝.ÁhŒøvLû]˙¡˚Üù#´äµ√õÛÂ∑ÀΩ’˚Û£è!ÃÕ¿⁄œe+“HáÛƒÉ‚°).ﬂFã¸b”%‰∆>ïZ—BåÖ— îîÅhü]!'©Ñ){⁄/õ·à*3ß≠^%ßYá&ßQïÊ¥ôRJ(óK†òÀ≈ÄÄèüÇP–JP¨ìn ±‚i‰¡…»CÁj)D\Ÿ(1Îàï≥«'ñáRGw,∑\åu3qì)ËK.û=>πú˘{ÛõÖı`ÃœıDﬁ¯Ùä≠≈Ï´&ªjÏçVá$sÂ¬‡ŸßüsÇy‚X·Ö}Ò=ÖÒΩÒÉ´ÁÆ\z}ˇœÆ13ÀÖ≈}±/çz∂(Èø˜NîÆ7Y•Ω›`¬,yfÌéÙ6Œ∆ÆÇÉ®èÀ®5ÍTH—”=	âZ-tb@C;€¨êœ]Q\–ê
GÎ»o…ª–¶ !ˆ∫á£úµ≈\n*»‹¢0w÷sNW®’,§ö@®ıàÿaõ‡ôQd›$Ñ‰„óä:˘ÕoCv]:ÙÁR	«Güœ?∂‹qÙª€\_‚ò—‚H_?X∂œ:∫ßŸ–L¡7~å‹>9ŸŸπïf%/l=91˝Íﬁ◊âπ	[˝kYûÒúŸf{ﬁﬂÃv∑œ'ú=œæ2–w`v“=}¢º'±ê˜ç‰ú∂Ñg¯ÈOßF
m÷Œ,Óß∞ö-ãZX≈…ƒ(»Œg˙7ÛôÊa˚≈Ú0ÒUåo™Ê‘5î\]'!éÈê¶"Uåë5DD9rc®”Ïbë›9‡Áp^MÂ;≥££_<≈ÓàÜWÄZ{n†SoQ\ˇC˘¬€ÁÀóÔ^î[å]˝Kˇ πŒÒ$æj_’Çåú™Z-£ÃpiÓ_™	Q‹Ó¬,!UÃpí(ÃÔ„¯‡»$üù	vm $∆V¬~˘–’ßb≈[ÉÓÛ?Å‹_~$∑Ñ˜lª|˘ó¬’Ï§úúë5¢$Úr¥WBp™5oT+%ITã®hCç–F@ÅZDÆ¥±¢JcÌ¡y¿	Ã
,<ü'Üê!ë®àC%ã¿º>Ö˛Ÿ±–e¢Cµ⁄≈o◊∫àâq:Î€ƒ2çéÄrÍ…ë•^µ9dﬂê€”≠—˚˝îFrÕ⁄^Ôß´›≤êπÆ@öRt≠çY8ydÃj∞hLilç2∑Åˆ7Dõ“ﬂ∑:¬aè∫{G7ÇnJ
íwqÌ£π:$§ƒ—HDQb †ó(ÈzPn∆ÅK˘˝/Ònπ\^Ñ"n¯À≈õp dP,/ñÔaØ+ÂKp™Òª§â”öeZ%e‘#Ú†ííõëÆÌäØ„]ôôiéå<hlnù∑‰{“v∂˜âŒ∂ZZk;∞_ú"^$^B§Áî-rPR˚Te≈'ÿ+NÌ"Ë˜Ú’\_O/¥˜ˆ‰‡é|$Ãco¨›Åﬂ‚{S!ßíYëBE·C˘çâ.2©ân ∆kár…±—TwÔ∂¨›!bø¢ÁµT±øäRÆ3O¬≥˝º¯Uïˇ§5π[∑WÉπ¶•-ñ ˇ]ågcÊ)…‚Tñq5‚éafÌ#…åÙ2#'rcÕ¡Õé§ûÜz÷†V”¨L°"(£ùÇ8‹®÷à-â†@òY"vE+zdÆ÷áW	Ω®’)êÃ¥D≤ø[zıØ…∆[S‚èßvú-z6ïˇÏôõZ⁄·ôüös7VÓŒ,¸áÎjjÍÃ‚ﬂπ7!$ÑHxê`B$$<B O ‰&ê ÅÂ·¨*WC*Z⁄›jµÏh’Ÿ2ÓÏ ¥Íÿn]∂”qªtú©›ôw∑;u|u«—]ß[Â∫ﬂΩI\⁄?ÓÃù‹Ô;Á¸^'8{¨Èzˇ—'´ﬂ<Z1‹Ò>}˜£Ù3˙_W1\yèl‰Œ£d<”òDæHH¬D<
…ÉWøRí~|6pà1”≥	;›¢∂Qªß˚‰=5a©ô œW‰fõ˜ùP4∫ûºﬁ»∞l;ﬁü¯Î≈®Ä . ã8©ÏNäTê™S
˘HÕtÇÏO„˘I,&’$Ÿae…¬g3QHœ∂ ív≤Ùá◊	Åß—f_\QÎ5¨˚KA„≥es˘H≠@Sj.≤ó}ºˇ›^gwÈPê˛ $yHµïM&≈Ä|Ú≥Ãí˛°R™ÀXv¿e7;ﬁŸS[∏¢ÔÌ˙Ω_ûU¶≥∫Ñ≥üü{9êÅ /Ç2=DíÖB ´Ü@R–9 ê^Ø‰«êºé<Ä§Èƒ∏‹JvÃHã¨1ààH<cÓŒ*k,O	%vº!#	5æò–ÆÎnµ‘®ƒù<ß¬∫{n€˙ô]e´<=ÜÍ√Ûª?≤÷öñÎ¢uΩÂÅ⁄‡éDØ–XÊ™"˚{ªÍ∂…M- $âÕ†l≤Í˝£nˇëJuÔà{ÌØ«j}√ì˘%U≤î7ZÎ˚«¢ç⁄¬Rå›T\Ò	Ó Dr§§2êêPÅOûÅ!Ç∞ì M«°pze4D/U¢Ií8íNC˙21±@::DÀ•…DºÆBs,∑ÆÕÌ∂TöM∫.Ïø‚´IPÊÊdü9≠^¸†Æ*—_©√Êxáp0SÿÇÔ‡^¿H*¶rì	Y*ã£\@*∆÷DÄû#C©ÜXfZDåÛ3b√piµúô@Xî_ıöÅUDØ∞ãc≠¡ó&ÁËïÊ√ÉùÁˆπ^ˇœÃ≈o⁄lZØ*g‹[∑”Zπ√È´y#_ÎéÒä‹>"ÓÑõ3O_uªˆ_O?:4˙•tÆ_≥a’°5ù„ÍÕU˘\+|„ÛË(‹€v\G?fD6“!•…9	rCíP∏ú≠dRÍÖL	ô†.¬°e2Zã X˚ˇò oaï≈–â[B Å¡É9¡‡.Téq®úŸ–Ò´›ˆ·{oùˇ˜∞Á≠c¡˘ÂÖjó8≈o◊oVTtçñ˜⁄ ∑;ë©û™ëﬂ≠ü∫;|l˜?ı˝˛_T™*Ùö≤jãÆ˚≈»˚÷é8Ï?˜úc¶sWuÑ;ã§(ïKT Ú‚¯í>πô≥<6º‰KiÜØx`Hcà·`%éw˙∫Ü'ÃíD	?©é≤‘ˆ|¥oÒÅ∑©Ö;[ÊPOû˚˛b˝¶≥yÎõõ®ø·5≠b∆bs‰‡4ÿÇïvV⁄t§∆	⁄BÈr8 ¶		ÉvE¨“ê»¥	r´/B@B,∏qÀQ”Ô4åí,I8ˇ·,AÈlòö!¥ƒ≥C˙ï÷_íy≈—8§J[æöò,ÈÚ7˜ô˜<ú9˚pê^ ®ùÆçì∂>á≥è˙°=∞´MSgîÍ;9NˇoªÀ∑L‘˝Ï∏V÷3Â€∑∞sÁ˚ ÷ﬂIõ=;À«˜xlˆAÚLˇ∫ÊÌR}u^iª„∆é´l¡∏…AF7J P†èeíÆ‹ËH§0§0≈*AÖ”„U±È0©ç^Ç∂",@èΩl	B‚c0H]ë)Hª˝ÙÜˆ”îÎ¿Âæ·?M÷x~ycÙıO˝ÂÖyŒ¯‰çîy£¬≈_Y—fÏÌ*ﬂ^EL{Í´G~”˘⁄Âqw˚E˙ÒÏßÙ≠œ◊oxªRm◊jÀ™KÙ=Ñ≠2‡-<}`Ïîm/¬µ±ﬁçÉWvÀLJíîπL d-ú‡°x<0@ÿ CŒ#+'#/å¿Dl˝Ê´••”diyÂÔ‰µ*OΩ”‘ﬁ ú5ç3Ã_ÒYâHÜdTö4S"2QÜ‡·à$&	îÄà`z“ON˚Q¢Yr,ﬁäóƒõÏú˛	Ê¯6ì⁄°˙I–°8ŸÃ5Ãm9c⁄—yéõK†(îLâ∞ˇqÒ£†»p*+1ËÒ√qøà'-V¿<}Êû¿}õ~ÇÎB '<=∆?I©ÆÇ'*H¿u ¸µ(@Ø·?
ÅµW¶««˜úÊÃà˙¢B˜8ÀqsË–=òK‡õê–˛g|>à˘·{ø_¥ëèàut§C"ƒA*Ìaz⁄ä±i«È)kZ	•…IôdZL√V’4ô*fSê@“"èñ
í≈D∞(/åM+„ì	Øñ/D$/‰aÎœf%çÙ ¥Ó˘ÓƒÙ?v;:Ü‰™ƒòòøÆJÁ´¶Ã Åˆ≠õÚS‹∑¨m°¨æVé∂c>ÿs©∑9ÿ∂5S£Tj7UVxá⁄(ìŸ©Zµu[Ôˆ˙ÁwÎ´¨>ü’πä©©î^≈˚◊TÖV£µTΩº— 6≤õ%JBÑ∑ƒ)‡3ÔµºJËJ¯—$/õóAÍ-\;•–ïv	2`w—Sz!örŸ'%πíß∆aœ™a√ÅQFFò¶gy«a ﬁ™Ñ`4(å≈"Çì%œF‰ë¢∏àìa-ﬁ9Äan<n,˝ D∑R!˙ò(%Œ¡˛µ≥ã3ßÈ«_:,‘pa«ÉÀ kæ÷ù˚'˝›ôgÙ.˙È‰aàÅ·˚üÄÂ€ÅŒãO5¥.[˝ÌÕëÉˇ=9Gk˝ÌGjRµéºñ)79∑m±∏29%mÍÈõÉ7O¥4ø◊øÒ˚·Y˙ˆµIÚﬁæûÛÅ≤·ß–ÁØaàèoªAﬂû=@ø\0ñ˘ÚWyÙ$˛a10|ÁNèæôíM‹¬]6æº«=àª,C
¥ÇJ*»"<E?^≈Wd……ui¸˛«F•åI£¿ƒQ)ëa"‚FìúÁ‚¨SUb7˘S` .ø∏…RﬁTúï˚ÛõÀ≤ä‰ ≈≥·ﬂœ^∫∫µÆQ'•Ã‰%U¿≠—‘4WΩÙjãõSs◊¿e¢á8t
°ì{/É2îáÏT	3k!»¯B~<*“côR‡TWkPSg>ﬂ…	pBbn¿!!!ÑpK!¬-Ñ·.I(Ñ††®Pe∞“µ∫ä&E´Ïäm]≠€:hµ´≈u€ému«Ÿ≠]/›vwv: lY€ô›iWßj]w÷Ètî˜˚Œ	∑¸ !Á{øÁ}ﬁÁ}µ	†÷ÁZ‡zÄQ2âê'i0L"*æ8&æf="ÆîK2¨oç'§¨◊Á¡—ÃÄR-_Duûå°˚}ÅU‡ˆ–1{Iõ·k†›π¡u˛Ã¿
ﬁdÃ@2≤-Cq¸‰s´o@ô≠Y5JΩ.ƒ¸∏˝Z°ä¬…¯gG6fè¡f(iÄsæ"ÅHõ0=≠5Í°…Ωå#4	rÙ|4¢$gä\gMaûEÏ+eŸ∑ƒbƒ¬óQR¯ë∫CwﬁxÒøÆ©Ï–Øˇ‡? )á<≈∫ ∑F?ûÌ{oK¯˝yyµµ¸Õ˝ˆ[´çΩÕu”üøRo¯≤∑ÿ[Íﬁ»‹{ÜMªi◊ˆ ÜF»èì∞{aR0Lπ®TP–_∞£' 
ΩU- pú∫§HjR,I±vÉJë≤ZÇ√G¢OI—úîïJ—:]`¸»W]ˇ6ı5ŸˆüXÀåµw(:o˛´—‘ˇdˇ˜Â-WôMªˇÒª:+≠,ÍÆ'ä˚:Ôœ©2‘;A…ÏW6§üS∞B¨Pã6ñØ
M8)H‘ÀY€ÅÉH"%^î·X®ë.I7“÷q¢ﬂâu—58‘%g]Ù(~¡]_ÔûõÌ‰¥;xí˙∫:bÜ9j∑XÃ*ËÂk:˚/›ûÌ(.q¿*éAˇuV°¬‘t2ñOqU@üE¢21óEñ’¿6rŸÒ¬Ë«‡˚ZW≠ã°|5N<øÃ<a/.Æb‘°Ó`18,óç¯∑!´ ±j⁄™Z+–ÊCJ)9/k≤†w∏QÙ˘	hJä‘xA†¯¯(ÖsDÇEg¬5
≤*+gûl¨c…ÜDOñ»Ÿ¨±T§ÖõÇ;≈f⁄Û„Îgô{Wá÷]™áæ;‡ÒUfÿí ö#ÎOé⁄∏µ˛√ﬁ;æ@Ω¥WwZq?s∑‹U™8ØÂ˘i†∫>‘∫ıïíÚ÷Ù¥ŒÆ™˙ΩW_bÊ^©Â°•™àNiÜw<	Ô¯3xGñG´Ûpô ^-L!Edúì@lÒ¶ôRÃÚ*≤∫R≠î€QÛ(/¬çæ_‡ëvßÀÁw∫⁄¢ª–œ÷ZóèØaB‡T0ÿ›Ût¨'ÿ?0rÙNå√Ô⁄Á†OöÅïà0)M&íÑ0í ú>öÀñxÆ£∆ÂÛπhﬂõÏ?sÑO»}vó˜òΩãöN‚Fà“«ì	JíP∞+d/¿J7ÈÛÊzF`?ÛK”-wNæaœ»Û⁄mUif[„µ÷⁄∫væ&äÏ˜l€ªr®¸†”›XÎi	9°4ÁÉ¡ñ„¨SHße9BI…Hæ˘◊H™NÃù˜¢πVU†Lí l†ÅxÈº˛,BYo∞—≠.Êò2[ú’ﬁ“dÊƒˇ¸Œ∑|Elî¡˚åÜ¶“öy7zÆ∫◊X‰±ve·™Ôô/C›yô™F7·D √IÇ
Û¨PÜ%”"êKíâÒa	ÊSÃÚŸeK¯Ù¥47Dã˚®´|Õ”∑µ‘Gt(÷π_=ªßÄÛiƒåêC§NC¶
e"!ü2)û	¿Ñ*S0»ÿ<p:ÃŸºE⁄ÿ $<ï™q¯iëX<V¢q¸’˚M’UÕÅêØ)ãöô°≤ö|°¿@ì√÷|üR{ÎJ<y‘7ºwÊÑ~ø/@ÏÎs•{ªÊæ·È∫ºÈÆæß[˝≈{<Ï	∏‹TÒ)ÿ©àC&‹™ta2)MDùí@=ëÇ	“¿^©B¥¥`dÁIàj ’óq±
◊·∂Üj∫q*è.7ßFozÌéfâº´8Ø"øÄØùõ‚‡ÎÈÆ+î≈•„uŒùˆw>Á#6xÙJ£ÓÉ¨Í'∂;YòéN£ÙòP®’ìlR rrAXµb^WÃ¿B ªG,Í
‰†ú$!B√xì˝®?∫»<˛Ì9Ê—GΩ˝AÓº2÷}dÿ·=‹Ω˘è/o^b¶ÔºÀ‹˚À∆ëœÅÍÙY†º>]q‚¡6W¯∆é±œ˜87?Ñ’MAf`óì±ÃÃm+1†L"!iR`∞&>â5 bñ´EX*à Rº=¡Râ–ZXã@ ùîÛuπ9¯,Û»Oª:Ç´¡ÿŸû‡x-ÛÄ˘ÕgüM6V–∏çÈÔıtœØˆ+/û˙Á]|ä°çÌ˝ˆå≈m[ú‚¶¬J1;]b5·YFê•á{B≠*Ä…7ÍEhïZLÍD"CN¬√iXX/[ÍÏò*√aå[*÷g	üu†1t°Xó!ﬂ 	¡∑’≥ÿô˝„ﬁ◊oN3ˇΩ»Ç|·Œ´m1¨\hÙNñX“{>2˙ä
2h£øºq¯Ø@˘7Í Û∂°˛”pˆ(ÛçŒù£K7°áÃX±G§ä∂†‚%¿Ä∞ßÄŸ Q3H>ôç·f †S£ ¸s8…åa˘K€Ä˙†[÷Œ´≈≈ßÛ∏hÖ¿ÑÀ—E∑ÕÅç)Ïp÷{;˚¿∑*Íû/ªtπıµŸ¥¡R[dxâ^;ÿ√<Ç[™ÀJQFﬂ€Í&˚:•Jı∆W€N]’N]:¨RWh=ÓÎ√õ¯ 3ú›Ìµ˜R)há!´û¿ﬁUa.∫¢‹†±8≥òã29Ô‰Öj]Å†º@…K)Ü2˘2ñ"BÆ«·˚ä”±yñ!OáÜaπ™ó¢Æ±&è”%/ç	ïŒ#ûL0?}8;90÷TYXC©j∂ÙÌ>›=πÂ¯ÃÿÓ'g˜^{π™©ºÿ™…€¥ct“ÏÔ\≥„œì≠‡‚û[[;l◊zK[™lÓïˆÌ°ÜsZˆöÈ]€.Øuç¸º“(ÆÙıÆ≠7“&•BÌxﬁVo˚àu|i¥ú• F¬@I¬·âÄÑ^Ìº`Lsπ:ÊrscKÔΩñ¶f‚⁄”ø≥∂EÔ*´p÷ñïπ∞ÿesG6≠Bß(ÅPØÜ{P.$†{âPbQ$b+F”acØuqŸ≤[“Ñülw÷µóÌﬂy˛µ6óÀÁÍmªu‡Ï„c|%~næ`¥ˇlWmlSÁΩÔΩ∂;◊Nú8vlÁÀvl'N¸'é?c;±„Ø¯ì–ê4MX°î‡Ç≠IXÉÑhÉîQ‘©ö÷j≠˙c[•iîuï⁄M£Eõ÷f¥[È$∫Í‹Ïπ◊N`“˛˘Z∫Ô=œyüÁ9Á∏4Ù∆ØèÜ6mZq_˚lcø?ÙìªÄƒ	Hz â
{H)[ÅFxıE%¶ó*ÓÇ+¢%ÖÕZú,1 °ä dã∆´&+π‘ãUS ·Hô5U‘À‹*~“q≥+Ú-ƒ'1ßQ„nõç≤|èm<lhèéŸà_»Lvë9=HT´À%õâíXe∑âlêë’BHbhP+‡≠k3ΩË’e® ;ZBSÏ#ZòÃk
UÓÇ4!÷´ˇ˙™VëÙ€˙6‘ñ›t':´ﬂ˘®FìÌßÂ~G u⁄Ì	Ò=©"Ù'óâù˘[6Z¬ìàødı]±≠„˘+ÑbÛho(;ûøM˙"é®ΩÂ±ºzÀpØ?»–3Wy;÷Íi¨A∏úTCÑ·6Bé,%•5’|≤åç#å7Z€∂'È;Â¢ı)ê3qÚ°€(L∫ñÀ%N° ıO≠6‹·
8o}Q◊¢ioËÏãR∑ëMßQ∫¥:{ìl„óçrçE’—K˛6∫Í⁄‘¢ÛÖ∆©E¥EÔ—U˚⁄|ª©J·N©Uv• F?¶FLÕqèªjhÖ>`úYçGP»:âf§X1√∫!`Ó`NIQe—2u¶]∑;›nTâ™• SSgX”FùH{{íãË}º5ún0˜&)z´•”(¥±¿ ™}àq>∞Lÿ0yı‡s0Z¶Ñ]≤ºMBÀ´ÄW.(c#å3R%+@ÇeRÖ÷«èAÚà5≤∏˛Ôïú?=;í+¢4‡˜Ú¡'∆*‰î%~Ë0ö›ßÇŸ—¸õ]f´kcH™Sw1nâ:åø\TcOfí§/Öa\¿6åY“f¯d+*∆:∆âpÁ““ÃÃ}g\ùæÔı∞®ŸÌSÕ	'˚#Év„ú,_]∆’p≤„yXÂ‡øhÎ\Ö‡›ÇΩ,vÛ∑®¶zR◊Z)§Óà¨∆n€¸›·§bPmÌeÕdÂ:ÉüF)îÙ‰Jhî» T$B%Q≤ÖÖ¨≤fÿ .Û‰æ‰Ò˘<ﬂlŒ§áø°]c_Ìn7té<®ﬁDˇ¢œﬂç_gŸ‡|VÈ·3)äÉP5´£ 2É≠F'®ø°‹«Ë)Í≥wÒÎDC˛ØËsxwıﬁ*∆"W'0Íd'påGøCX’$´fõò†œO≤Æ°Øÿø¡ ±2á≠‰ì$s∞Ñ!É7∫¢ó∑ˆt’ﬁ2œv;ÿÈtkÖ¥NG~π47	=;≈rÉ´µÉ´∞6!Ω	;Íx§òáªz4Å0dÌ÷—·O´¿1Lœ«öòîáœôJ¯ÃÇ•]Ea‡Äõ∑,√#H¥˝/â≤D@â≈tÏ∞ÓÒ7vo{){¸†ÏΩìYv4∑u[∏¡‹Êõ¯”ÖÎÔe2«M∫§«ÒÈ‡¿H$1ﬂ®ûâFS«Sﬂ?'ÁËT“'øgﬂ£ÓnŒf~yzÙŸdt©Fà£≈Fâœ·⁄ÿ◊È:5ŒBçØ3s©«åûFëêŒ¬‚q·&Me”‚[GŒïjxçPﬁ¬zÑ>ÆP‹ó’è∆¿*¶é¢eÇ=øwÓ∆‹˚_ôtÔåŸÙ˝]ˆÄœ·ˆÛ_»Mæ‡⁄â=›À∂QèdfæærÊÈTΩ—bëG„Ò(ÎJ*ì»{˘g?_zr1ìπ@ﬂÓ‡Í÷(‹çSzdÕjâcÀîHf$y§“¬¶'zÆÆ ßå)†·a¥ï˚˙OìÕ§1÷®Û–€˚V®ø?ÛüW¶^;‡Yî˙Z”étÓyMp¬ôú÷KÌ:SÍ2ÔŸÊA⁄oØ |¡5∂”`Ù´¥ë»[?çŒµGbmñ^ Øu¿´…£+˙5ü·ïçÜ+çröX©°I≠©Ã’Ûxkƒ™≠B≠ïÙ:|®«Ù&dDz›ã""g€~®lÈi˜ÉﬂÔΩıπ\æ`Wghe9∞ø/∏ØØ/Ôıïª„-©3»¡«Íit2ùçGøãƒb	tkÁb<|vœéSôó ˘cÄ|+0…”xÍIxµµ<“€ÑÒÿv∑å(¡ThI ◊¯U0Y∑1(i≤1°eM◊9jC51ªÚ9
ÂB∆DƒcÆ÷Í,ˆÈ◊vS˜©[¡cø;p˛”]{W£ªº£€'é¢õ√«Écß°≤Mßr†Ân>ü˝pÁ§ÛÏs?Z†w¿ó´À÷@i∆∞20Ù+á‰“›°@Xçµí«ÖæÂbR§F–∏Ûï
Y§ \òºB# ¥∫¬CÎz¢cÜsü◊{vˆÆIYì˜Î|ã©ê/Í¥G√Œñ:y‰T`Z”AnLxG|M+˙D&ì¿?∞m£Ω˙ ïdÂXN¨ÎOk/Gµ"® ÓΩ√ª,j¶ ï…RÀ-upJÄO>ó˛kF«PVÀ£Ωë_Ï†WXØÇ8Ç[e∏^[)åëÌ=qåoá¢X9˚ëõg>ŸÔ78Ù‚ˆÆÀ‘t{)Óæ¥k˛∆SæÉüÿs5‘kã[ÚwNÏˆÁ"'˜O/”˘Âπ_q≈ıò‹VπM[’=ï{vpÛs˘K~;ÿÙ∏∫/6I._ù‹∂ÙÊÎ¿4Ω?“Ã-l(È∫J^mdÛ∏%Md=∑ú[äÊI!lJ4/S◊mN`q0∞°? ac–êK8ÎèL9ß-„˚[/¥’â¬ÆŸÿé–tù8‰ùÌÛxCl=µ›—´LsÒïØìÈÀË∆—ÖT–πHùJd.≥ŒßRi∏âÖ’eté˝.∆«§XÉG,Pâ@ x,.êÑ–®¥–§GwóVY‘Jht.ÊpÑ√Gl∂+ë≤Yìƒ≈¸…tvÄ‡'í…˜{=ˆ∞ﬂÎÓÉª_ù¢íË<|Qä©°/µíU ô™ë≥‰∞PEß¶^¬É	¬Í ÜŒ£*lÕo–J8™‚ßµ‚ˇÁ<üÙ|àΩù#∑ÚlÍàÀ^v&?6~®ˆUø◊‡$XŸùƒ….˜ÿ¶Œ3åüÔﬂ„KÏÿq;v;q‚«vÏÿâÔv|ø%ÿâsÅê“—
ÑÀÄ$ÖBπC!Te4ö^–Uî±
uLö¶n+SµÆõ&ÑPˇôÑ™MïVMÍ‚Ì=æ“EV‰»ëœÛ~ﬂÛæœÔΩ¥.≥Óœ´vÓ+	˜•≈î>Q[¬Ú(Ü·t
ÁV)hå`ÆÊ!*ÃHâ¿©–÷TXu¸˚b÷ÊçÜ˝ﬁ8≤tπHKp«™Q…#év€:{ˆAO_Üvv˝hÆoe\≠~≥k‚X>j∂H˝	Ë)ﬁ–pCBªÇM„ûbÒ$ÿ◊åΩπò«ìLπ]â9⁄µL_6˚d,õÕ¡7ºÚﬂ«åK–m.¨√G÷‰`ùHØU\≥\hbW±il=:f∞¥Ë8∆‰)—qÅîG<g≈rô≈@XcÉ∫b—“‚Ôj…⁄ˇe2h≤¥œì‚{∫è˜ßºûûà£3YﬁºÂ¢)telÁr≥>Ì∫mõ‰JîœøûÉÙÀ-ªb˜ﬁœœ˜ÙºTo"P€ﬂõ…ˆ≠ÃƒØÆ¸3óËG˜'£>[àöe«‡∆2P_3¶˜¡>6b"åêò!¢ôJ6üÕDß*†√†¡x´íó˚´ÈGV™Oâ–±Ë≠€nÍÂï	ó;ôÿ€Øß‹Œd–©uhà˜‘£CsÌ{ÜÛ4 ÓË˜'ÊíÓÎ˘õpÙΩÑ$ùjBó%A·PX˚¶∆'«êTÖ§Vá´*%1&Êúîó¬m5é©Ø8ùí∆KO;ì<ˇáWf?YH$œ}:=˚È˘D˛Î≈ŸﬁÈÄˇ@fvMv±ß˜ı˚3≥ü]ËÈΩ¯ßôÎgó∑mΩ÷ˇkäf`Úﬁ%
‡H›Z™Á j’%ûóÎÃ<*u´ò'Yu-ïºï“g8#ygötBÒ3'†í=ä`ÊΩó˛u&2{c”ﬁ´—◊RÌAß#ÜK{#So^ﬁ‹&ﬁÅ≥;Ú√≠É_Ãß6Æœˇ‰Ó»Ìr:’ìoŸˆfˆŒ/ﬁ˛UœïrVÃÄb9FR¸UE)†+∑(°z3ç,cƒJ¸ì
÷*&–Ö´)Äû•Ä§†˚9L¿©Ù=–sÎ≈CüÔ€ˇ∑#€?Dª∫¢á{Õ+_Eˆt«¶„d|Ã∂˝¬wËpOˆ¯ìõ|d˝à:ëN%üL|4NåmøöJ]Ÿì9:@~ßyróJ∑:ò®RåÉ™p¢¨•ÏHcÛ–)åU‹ü(ñ≠∂⁄BÂƒÂ„h)Ìr&è]ÑyK.∑jÏnu%ıïhÍ0ª3¯w˜r}}π\§›ﬂËùΩœÌÉÁ>ÖÁ⁄1Øœf’K˘√ 3Éé«ná-t—(ª¡gÑÿÑ¥Ë4&ÊQÅÑÒ—yìÉC[≈A¥ßTè(Ä/˘è	Iï8Òt˚ﬂ//˛e¬g&€$˙Ω/d^z˘ïπ'«sbÚ∆î”Î–;õT}—¯xtzÎ°∑≤(9ıVv¯D–‡”7≈¢1c4†‘§n»\hçìFó…‘lÚIª∂Vï€Ky¥6∑<˝6f,“¬Z&È‡sÿJ ò‹¨•\¿‚BpP3$oÕJ©+ù2Ö2Ö¬ áN-í≈dYR2++]çVΩB0·p¨≥∞u≠5©∫„¸âWè∂hù?≠Òù@BÆ–Ëj°èÌ§Ω5œÒÖHaá.Œ]:Ñs;I“˛ì	éÖ≥&™Õt6ã©‚90ì4rÄ∞‚Ÿd*ímìÓYÆu⁄mk∆=ë1o{5≥˘Á§%Óˆ$Î≥ë–¥Bötª„ëŒŒÿaçßØ%xØÀ@¿Â£ácôÄ„w(	eû~X˙Ï†O˙‘Xµè´‚àÿt⁄∆ísJ)Á5!y9”¯àâ¯uJ:T∂A5J?˙Za≥[c<aE˛á
È58Bj]˛)ªä◊‡“-ƒ‚ E¸D⁄nôÙÚïü*rÓÜÔ˛Zç©]§∞k“‘E!ü®S2aı>QG√V’≤+9™"KZJôKÈ)@≥¥¯Ñ1â"˙È*P¡¥∏é(ë ≤ﬂYÆïÖ\ÓêB∂|WTm5õ£™/ÎÍC.O§AºÙÜ2<hÍÎŸè‘aK–RØ‡ˆ!ø”Í_˘#>pÇm˙˛ï]Ÿ∏√3≈≈+ˇ⁄1•Ò’‚Á6hZ√)¨x~ƒJ˜´™Ø¿Î$à«lbÀ8Bù]ØR¿±q+8ÏöR«‚¥±(D⁄´ RU»^Ó~&QU¯£OÓ∑∫ç÷XÁ∑ªÇvìWˇ·˚§◊hã‘)~Îàv˝ÉHì‰∂˙ıd/G∫òMÔ±9æ˘∆euì™.]˛A˛JVOz(ä√≠•zäB5Öé—µ◊1YL!áÀ‚`‡£¨Gc´ÑVÏ#h•€QSytñè^R∞^Ü0ii‹ÀÚ∑UZoÉ”%}¸∞Vo*öàó_j\òŸøø´≥ZR[e¥ëN7ëé©5.m"º2ÜO%sJuß™*¨}∫aÊl¬2ZE!’• É2Z#¶°v,Üãw¿éÖLljÜ©j ≥0∆:óW⁄±ÿH]ÏduAô›CÿãÔ,Í‚ŒEÏŒsq©?‡¨(“)[ˇ‚¡¨,?ŸóÛª›#¢Í&Ç∂Úπ€‘Ê:5ë—âÂπqç“gÏ¥™çJí“‰Ãg«¿b&LÊjπ|&f(¨RË<MT¬d¢Ü£ß¿B\%ı"‡≤AOi•bÚqx°±Ho=[ﬁ‘÷‘æ∏~>çC‡mvD›2ç∏1∑h÷9⁄¯8.Ô¡E≠/ﬂ8∫y£Y¿§˚¨ígÜ/›ìwùFKº—‡›º˜À”ÔÓ≥yË¨˙Gøªtﬁ∆û_eF.ç˘3ƒ*3„ZäGÛn≥ŸÁ3õ›Ù¯˜¡P∏õ±£;Lq∞j} ﬂa)‘ p©BMPÎ|}µV™0Ë8*)
])Ç›ZíO0K˜Ä±âéÓ⁄Ç≠"VŸ⁄hYô[á¨Jœ Ÿˆ ËqÎ\8Q£ìZ•L\ë∆EÒ…ÖÒ—⁄Ñt∫«∂/qf(WuX;“øÈ∑N_˜8’v%¡µo9Ω¥ì∫õ Œ¢ΩH,Åo>∞(^TM¡Äıa≥Ä(‘—÷?∂À=¶≠Îé„Á‹{mcÁ0∆¡`∆Äc_„˜cLxõWBx$@í&4åJ€îPRRË“dŸÜ“VNH÷6—÷≠]"e ¶v™–¬:F™uˇ,ißVŸ4u’‘ÆùŸπ˜7éˆü˝±}Æœ˜˜˙˛x"vÑ—-Uƒ˙,ÿ<?Ì9›Â?v‚ôBÁiO^ﬂ†68µ4àù~b!ß ¥#à˝K·T+Ω ÕM∫Í9≥<0£†Á-¿<ö‡g¸cö£6ãpé#%õAã´6TUâ;¸y9X°Éçû$”§∆¸•Ö¸Sö“p
/ÁA>Är7,ÑX"‰©©]∂9wY|T;Kë√·1v≤„ò›ã–›ÿóm3tÑPÀŒ0´åÑtkt£õcâ—≤’„π∏ñªÔp¯¬A”n#/Õ†MœP®»◊¨:±èó±=<;ièV›ÜÿôPz6h‘Vg´¶~ÒQÔõ„≥∑≤ïC¶05XÛ˝,©®%l€EëiXÓ∂|ƒà≤\ò/u¶sU:◊ÕOO\áÚ˜Ü÷vwj¥µkbüoÇkéúﬂ7™¨|i÷8åÙ| éÄgAzñ0zŒ«ué"ùGxƒøÁæÒØò∏Tƒ„Ú%√_G¸(√-qŒ~øMøúﬂ"Ócœ˜¯?‹õƒ◊|#âG|!âê‡˜Â\EÇLsî'±A¢óp"ZÔÚ8vî„´\ÇÅt*i5˛6!ìÈ;ô¸ÿŒß3$ÉBûØ©9Ùßxí ﬂJê‰aáMrr:3û.aÈP≈'l*ƒ^&’ü;¯À\1—X≥JMzuj÷ˆÖ/b±Áˇ}Ì¿ı)w-e*r˜Lú-⁄#ùzù¡{èYô¸é[ß! ŒMâ( ¯EΩDã˛~bÛé˛Ω¡gÏjª≠?ﬁ≠Ûº@Ö¥ﬁé–˙t!}Ü˝ÉIqyú{ì¯ZÇo$ÒhÇo≈Â%‰$5Ã9¢kÃˇé¶9õÉÔ<BΩ4›\Cﬂ=ƒúÕ“Ü>D¥ô9ô•Ã	å€c‚›îof˚cNnN∫œ„‹õƒ◊|#âG|!âê‡[œeˇ}~G“sÁﬁ$æñ‡I<ö‡Ò|«∆âqŒ{@ThßEùKé2∏ºÌBdA˙+g“˘q3ÅºÑhkoŸÿ≠yÕN$¯IÏs∑«ÎÇR_•≈ehNªcü˘-ïæ/ãMß∑¡Ã˙∫∫˙ÿ√*ÉŒˆÕ˚·∫:¥F∂ézk⁄hïÆl ≥≈0€¡!IáXàñ¿(_*∏îÿuy1˜0l√¨§wU¥Ÿ09°⁄G›mg#ë3Ì'n^ﬁÂptjj‘Œnb—Ûtõ°Ìl{d±ı›igGª´,†È¶7”éÿ1¢óÛ6®~pYô¬¬ÖL	 ëßÖ. (‡€!”±”®\z9±í&Å2èÙBt≈*¸§Ø,>Këª•/<^Ü»4‡“Ô*ıj5ŒVp•òµﬂïÙg21k)†ò^—µïûÜqG»X™n—¨j≈ÒRtª5n∑tëJπ7≥uœå?ﬂ•”Oæ‹mÀÈ%∂€b≤ﬂdrwN˙9æÿüÛïÈ˝ö£9ˇ}äãj≤VoÚcüîTÿEn»’ú~≤Ìïg( õK@≠Z„ï~s;J¥\πCá;uÛ>qá≥éÚøŒÂ÷BûòÈV¶ú$øZ ®@¶Ä4ùe <!ip^≠†òÄYÉkÖû$N6ÿ‚∫–¢l-l¥ubydk+¢Áÿ#fM@5Û∆ˆùsï&u6)¸«+Õ]’˙Î›G
‹MzÔ?’÷ië6´Óÿ›îbã∫‘µî[\õm±˝Ç÷P›≥6√ËΩSSo˘F√ï}˘€˜µÌ:"GŒ“^Jâˆ]}6%uõB4¥t02EÓÚ[$;l˙≤’e;TÊ˛wM›>dLºh?1<0ﬁc@Y”àú¯§Q tÇfW∞±ﬁÔ†*t˘r ôŸ‹"ä ˘fJÕC>∑¶±^é[3QãGÇ5ÁÛÒ9•ΩÚñc†∂Ü˛)w.ƒªΩéÕpòhÊ¥6t/áå-„Ú‚©D'êôFœåµ®≈≤¯∑°,N· ¿ØOÙ/è9Â•∫¶o}˜ŒwÚ:N=ÂÏõµÔıæ±«ÌA≥§LP!≠Zl∞Ïø7R⁄ÂS8≥Ì›ØxÇ/lı˘àSÁª©ˆ!câC3@Ö∆⁄Ωb™iœ±÷ûÊ'|ÆﬂÏ<<aÆ®ëN›L{Uâ?8SìÎıyﬁ\Øk–‹ŒwnõWe∑∏ıj5 5\¡Òoâ<Æ ãè¸›‡nô<÷‚2^bãoMLÆ\õjòkƒ>úZYôö|≥qéŒV,vÑ‰º$Lˇ ô€V…ÁIpÙÚßbI⁄g[áı/X(*Ì¿’Ù–DH–{ºıÊPÕ°√Ω%37Íˇ∫ﬂ¯…0Á¿◊<|O-∞®g~ˇüY[A„◊<Ù¨	‘CßPürØ´™ ‚Sbàõ§$πj∞ §°ªÑ⁄y∞ [,™:´ >ß∞≈péó&ƒô(”A±Âû∞ÚvÃcJ≈PF' ]qGè3Î+Õÿù∞«›X≤ŸB¸lπıˆ¬Û?Ô÷zF¬⁄Æ•æ›Á#ˆrSY©ÀÏ	÷ÑÇƒ9ì◊˝LÁ∑ãçÕÕçxác∞_≥wO˝âV„”˙.á≠ﬂ˜‰®w˜ÖH`H´±;Ï!£qí≤Ãõ∫∆ébÛ´ÕŒóËﬁêt¿	¬.ozö‘{$¬•…%BãßÑøç‡ÈÈxé^UUêâ /ƒ^Â°»‡%	ñvÖ*	
—aÔú∞y⁄2(í∞W-#Øõ!…ƒàB•ävø*ôí@™d∆
UÜâ¬TòÁ2<ﬁ5È2πÕΩ´^ù«£/õÈÍié(ñ†l}l5vÒÓ›ÿ≈’Uÿ˜áÂÿÉÀÀ0˜ÚUòç∆>Ö6\k›ÔèKÕlËâNw¥Â¡ûøËz|8∂˚l)˛≥ªwaﬂÍπK±ÀÀ±˚—K0w˘
ÃçÄ#]>btë∞∑À".Ä•û,íÑ¯ex*Í>AZZÖGIÎRö%DÄkÊ¬´yf¡ˇØˆÿ¶Æ3~æsØÔıu¸H‚Gﬁâ_â?;~êáÌƒ	qBIB¬3$Y†!Â1
…F™"√ÿ∆XHxV@GEêBE°⁄≠÷—âuïJ[¥I®ö∫iÉ°©€$‘u!æŸw∑ m“‚\˘ÿÁ¯º~ﬂ˜˚˝æsÇ^u…[•zbU6’˛pµdÄg!ˇÔ¯æ¡…ëÌﬁu—ü˙œ˜ _nº<6|ÌÖØÂ˘Ã‹ñœ›˛ù¸ZÊ0óÂ/BÒ%ºáã≥Ú}n qËƒK~î∏ñÁG~˝ì‘ç≠∞:s˙OÒÙ√Ü€ô”„»◊/·//@—ÂYºA¶úøßD3O$“˜m5‰QS≤MÅ˘ßœUK†QÁpπò’Â™∞„uÉJ{QÑÏÅ}Ïo1#Éòá,J¿ÇÈ…Ÿ8:9+”WæÇGgÄ?Ò2g˛Ú[Ù Ωp¯pzê§o—‡¸'t:˝=:Õ8‡&Öé† %˘Ò…
jµ8…Â|C#LZYQƒt7QÄŸÅù¶%-Æbè£AÒÅN9±9ß¨(œπ≤≥öùÀ∆ﬂ§—)Â Æeq#sî@è@àx*◊§:%eÈi:KOLö*cxë±éª⁄[Ωû∂6XW*oı∫€€¯õMı˛ÿíH}”›ÚPY}SSΩßw^±	ﬂ«è=iå˚wÂYNyB0mp›ÂÇUAEÿ©œ’©sTí††ÿπQ©Õà´œÁ¨ÖŒb¥dáﬁ¥∞áo:}Ú¯9ÍKø>zRæ˚^Mﬂ£√¸Ë˘o;ÂøÏîﬂ^y;°l'°sƒYƒ“ãUW8Óc¥¶ÅBoæZÚ[T5µÄ{P‡™î⁄º.I…ã~R§»~õwq∏ã¯D¬%˛[g¯_ƒêÊŒ§ˇ9`ÌO4.ïrÙ–ikmÂ+ó∂∑u§ØSc[¢-ë~Háí…txhï‹Wg`‰vÔ@ãª‹YTÕª÷5Tƒ˛F˘X4hí˚"ı¡hˇz8KOcnfÍ»9TË@o∑&ﬁ¨w9MËkΩa»eºm‘®9oç§F«B ¿\A√5v∆‹ıN⁄ËD‹ƒÑÉ¯ΩÖç$s~ØﬂëUjÃÿ∞ÕŸôgÿ®SûÅ
ºÕÏôR≥àêÄfÓ$`ñıK[¢u√uP^:ro®8ñ∞ö´kˆ^óΩ)ˇıö©0¥öù>®°˚}Gª'ﬂ„
“©?õ∏1˛YÂ∆Gá/CÒo∂$í•≠>ßΩÈ;Æ_…zC˛‚„Ô*)õΩ•’]¢oxC{û?«“c_^ùb∑RO˛•8¬µ‚‹B‹qs>BÖPìµDå9Ã<â5Üµná]9$ïhƒßÚ4J√°rZ`“˙áñ/
á*UÄF∑JKçÂØ Ã∆‡[»Ùﬁ≤éNOrfwó†\vt›“Ω´¯¬ñµ{ìÎé.Sä]ªg:<ù µ€Íöü]jÖ‰Û°´ˇﬁ÷ïåÑüOçÌÈ˜o•#â&Ø¡,uN¥vüíƒpbWOÑEiËtwb")ôﬁ¶/Î 3È£+*#Î´4˙ÿ¶DKïFSµ>R∑≠Æ4ÀÍï‡j≈(fµéx‚ïDô—%;O	dT\g◊0ÙE¶·¯Õ¥®x◊yﬂæXõﬁëey§Ä¬>9˚À<ÖQò&Â˝Ú\∫∂b#ÆTî·≠´à9^î/®Tt9ë–ïH1ùî∞ôÉÃ*Œ⁄ R ¡(Å±ëõõ9»Ω8>N?L¡g)y≥º%ıøÊT	*‰ãÃúòû8-Œ	\vŒJ£gÑ†A>òôR‡^ú?8é≥ﬁI…5)8	ßRå?ó†Ø˘u,L"qØÃ@*ÅDDö)ÿt∏1‰k•"µNmnú%»AÕ⁄˚^R »¯µ kVLDπEn3å÷?˚f∞Yõ3eT‹Ω;3ìíÔÿM1 ÊÑXrÌ÷ÄÕ+*ëˇúöûæwüÔŒ¿/é¬ùHmY},⁄.«“fWi≥€÷‡ñ+á±≥˜÷≠ﬁ¡a∂ÂSÚf~òØƒ*◊∑3pE†yn^Rä&®H$?,0hÎ¢Jóas<EÃUk	f(ÃëA0ÇMn≠sº°o–!¶\Âs…·P∫Ø˜ô˛ŒÙ≈{≤%zºuÎ´g©ÂÒÁàQp·SÓÅ"ó∂2]¥YY·◊äQg>O‚—∆zø”a≠»ÁsÏôÕ±kKÅpØEä4Ùi]‘;¢øhE¶`Ë¸®£*^ÏÖCÃ
≤Ã√K‰¨ã∞'ÃF¸°˜ôèÜ∆ﬁlw∫’Ü∫ ⁄5›cwVyñ)Èo84¥ˆÖM˘<Á)(‹≥2íˆ¡„∆ï=ªzj\z[ìª«˜\‘ÓR¨≥⁄MÖ?ÿ”˘ˆî”˜˛Á=cﬂwGt=…ÔF;ñs\§˜Ÿ©ñ€¡∆]¢Ç◊V•!—‹∂Ü-€∫¶kJ©¡stÌàEŸÇMqX‡Ib·(—QNTû∑øB‘ÁSPô¥T,-—"8(k“ÄÆ8C:ÃÈmX˙X$∞ ]ÜxH°V&JÄ¿ˇP◊ò+˜ºîæè
7KøÓà;|ì——g¸o≠«£••Ã«läØ‰w«∫“÷tóchÙù›Øà:é„|‹y™ŒÑ˜Bù∞—™ ÒxàÄFÀÀ4*bÃWrƒ dµBƒ–/Wó®Àqí9	jÊJçò'µE$=l√yÃπa“-∆ÃSÍô√±*f}kZ“”£#ikLçm∏)¯ﬁW(Á‰ˆdëœ◊:™òö€ıMìﬁÚ˘ÿ˛øÂõπ˚§ôt«[	)–rh≤öàëÍ‹J)XCkÌÕ»cÂ%g,Êpƒµ∫ZM§ä^±<œ0jê‘ﬁ*.—°eõı˘bÃw	T»ÜUr;˛Î—}Í¿∂Xá†õ≤ÒÑ]D	âü\ò^}êg.œ’¯Î™{îÇêk»·bfæiCMó¡e”:+À6∂–yY.*7ïÆpŒÖeÇŸ>R›j’ˇáÌ™èm„,„Ô{wˆ≈;Æøc;9Ál_Ó‚≥ù¯„ÓÏ$v'qæL>'M≥¶i⁄|-î¡H?¶∂•+¨c•0!U´J◊mB¥B 4°
M”‘!Ñ&¥ä	V¡`Àï˜Œi©ñˇ∞ü˜,øœÛ¸ûﬂÛ˚È∏∏©‹}£ÿ÷e¢íA/€‡1ﬁ‰<9n%!t\˙ËÔ·í”cf¨—êc¸…Q´”‡m9ÿ˛Km≤âªl?9$@ÁÏBMHeÔxÉ'.oÖ≤Q~-«‘âÄ⁄Ä†Iq™;	Ì-’fi[*’‘–jJ»n9≠Nx√∫çñ/Eùi¨e˝"]œÌ¿0Ç¿àjáÖíΩûL´ŸÎıöS)õìu`PÔ4‚(ÂŸ€≈òìwT«—¸X-µ~:yx†¯¯ ;´êõ˛Ìw◊2˛qÀ‹NY ~´KÔp^ªß_˘Ë¶¶6q{q/ètJ6'6˘™Ò§´T-j
nUû 2∞?Ü´PÛ◊aÍÜÇ/|To™x[˜‰&Wƒ∆∂€&aª¶Ωêß‡Dç)µa∆ﬁÂ¡Ö«{◊>f°0È¸…û≥KØ|B&Õ⁄y¶ë∫!&√#3¯âH”F„|KU≤90ÚG'Âµß;äQa÷∆4◊≤ˇ0bQ∫°!<©e‘Ñ›A ´xÄ?Á–Z≠˘j£1_K Â|ò©Û≤¢°’[€∏(ÍH≤‚Å¥Î›ôziu„SÀÀ;7'&JÉ≈ÒÿÅ ?}˛¿Ö……fÊÁgvÕÕ©ÿ( â˙'›)ƒ∫CπÓV)d<vìP©*8·JQ!kÑ AUS7}=e°§x§â2ı√ö6e[Ì$`XÉ∏ÈÅπ∂1ñfF•ﬂ(î*QWúJœPÖôëî$',å-ãÀí±t¿OÍ1´ã∆±SÃ÷mOt¬.bÁ·9æGÑì+˝=õá6{˙ó≈p@ËiˇŒ	Òßh•∑6w&õØc˘â≈Î◊&Ú∂Æ3◊
eeáö”^±‘v›C≥”°¶X¨)4µwË∆ª'˜rÈXQπÂjox≤≥qHñK øî≠rg9ÍAä°å4æïË@¢åÇπ‹ÆF wõq≤àòWÇ ”0$ –¨∫–ƒ:3§jCÄ÷√bªœPÖì f™ÇêÎ«†›åù—eL†=
”ıÿô*ƒ·zøﬂÑk4B™ ’°.¿–jßV4¥Ã0Ñ´ƒeQÌ¯∂NÆî5qFE∞ﬁ°ıƒ6–ØuUÓK_›⁄ƒÛ_¯∫?&˙f‚´Wèœø∏Î„ΩâÓø/>ƒ‹ûBckºm·Ê_˘a~Ë˘'‡áÜìã´O)JLyqvl$Ì¢àé£ßÊ6ˆÆ˜eÑªÏzhOWp0ÛÚ+ß˛ôÎuóf2è	m±±≥Âd>õR¢Où˛˛ Â~sgwv≤7≈w£j¶Ôﬁ".›»_ƒ@+œ$‚ÇÍƒBÄHâi ∏ò¨ß–¸ö!ŸH≤JE]<Ñµ§!ß…*	-boQù™∑≥[O◊˛◊[@“Y)V#wœXIPõÔ›Ü^3íò‘¡∆ä√ f˚øπy|ˇ´›l8dßyöèÏ)>˝Î£Ûó{bM^7ÁS>PJΩK«œm}_Ó[9ö«_L>˜Ûcø˘÷pkÇ=tòè<Û≥„ø{fXJ&h÷Á)*•Åü¸`¯}x±o¸•Â¢ ^e•D¥)–í„‚>Å2™Çãg‹f÷ë(c`®ÅùdT2≠”™í “å∫m(à€î,i˘hãFk˘Ω1ÉZVïà∂¸ì◊èûΩıÂ¶˛∂œÁf˚~±‡ì;≤ÂæG˙‹^ŸaOKÈ≈õù
l®ßi'’uÓdqÈµ•Ï ¥t†Ωghæª+?7⁄!N∑=úûÌí[á	˜pÅ-|ó–;§fuyÕ€(´jPèˆåCÔîëÙZIµìN‚ÜäU]Q≈—jÕÒ¬˚üe[ÂÊÂÏ‘t6µ{ÁEøa¢<C
dXî¬Df∏êù⁄ùÍ⁄ZU|ﬂêKª◊ß·_wŒŒ"+¡#DôÅÿsF,®Cˇœ HiªMÿ∂#DYQ∂ 2G‡Ud7Tùpôëe@Ké$ıéQ@[Öh⁄8÷ ë(¿g!—ß‹Pjr˜πœ~•ﬂG}2Oà?Ô˛ıÚ{∫∑ëGLÂök$“®È£(¢Õ8Õ$Ö$ÜDPg¿®h§ŒkCºQıà+n™ÿ ’ÿÓi~ãY˘"@ºØ	‘a∂Uæ¡◊ìiGp¯Ù√è|u¸9Bî}aKGÔÿXi≈]?ÙË∫‹bòé§≠+‹¿».úÇÌ´GSôlÌñ)€≈∂…ë≠3ª÷ÁRŸ4∑MŒaG¯x&ÇzXkO+`A(WÎgÍk]6s•Cπ"]GC0´¡}ª˝jÅ.§X$©IU~Îú≤‰Éˇ¡o∂˛~Vπë?‘√ßÜﬂ:≈Ó›yÓ~P0‹‚\lÔòw fé$ÕÚ¬@CŸŒ’}€?¢ÖR∆‘v›õxm/dÅ7g’ç!WG‚–8>1SEŸ-H£7vÎ¸¥+(ùxQwÍﬂ'à¿gù*rœÅb˛‰|ZP÷ïà|∫dÑÁ‹µ∫cu¨…±√åß?Nò*Ka
∑mCó√5ÙVFQØ˚ˇq‘Xﬂ´◊ΩG'ÿ¬R™Qv¡kWÆ◊Iº/¡^äD^K∂≥2eƒ# -ÂÌF&ò‡ehÃ”¡.hãººMçG<ïx_-S@Ò∏ﬂÊµ†.°"(7à>«ÄÄBª¡–FEåyÃ\kjdº›q>v/÷ÜG1^.çËÉƒ∑)Û¡ÁqÏ€◊Æk™S¡6È™ÀπiNV∆Æ]A≤ LKØÇ„•˜êKcv8Îm˛¯òr; ∏Îªî;2g˝¨v‚¶Õ⁄IÔÎTA†˝Ê›øêyhG‚˙„Â‘∆u≈Ò{wWHZÑ@ H BB<ÑÑ+ZI6†BºDyª&8mcRœ8∂À‡\Oj∑µu‹¶ıò§c”÷ÉõåÛ°nÍ0u”⁄ìÒáL>§ôv&ì∂”¥!˜ïÒ4mKœ]âáìÈå¥∫{¥s˜ú{Ó=ˇﬂAFT≈C%ÅvßXA!('–ÏÃtÏåúfg
sY:Éd˝Ä¿í∂3®yh Y’6¶»@RÏ&ñaM≤≠u`†µΩ´´=ê"øÈ˚∂‰⁄Ú¨-KNHΩ¿ÕUpå5(åS¯‡ÜΩu√˛˚å}ÏˇÌéå˝.>πIÆ-Àt@´ı(Ä¢</√Nyk>ïÁßƒÚ`√Nkµ¡*œÀ!ˆ[ıÑäÂ–5…·!õ—«ÛÌh∆md◊	ÍÜ!]F°∞m7@‰È¬)Ãœ¿Eãƒ õ¶
∑DAçvD;¢´¿ˇà¥∑Eûõ[ùöËèæ˙Ã…?Œ˜Ùû˚gnı‚⁄‘sW/.\´>ﬁ”?gÂ%◊É./,Ñõ‡:~‰P◊ÿó∆æ|ó\πäµ∑kÎ–ÆJGﬁ]V>9q˚D®72yM EçE›†.~gŒrã—◊[®'–ìÛ∂,æk≥)wS)YÄ*a[.¿ß[éî<o—R≥5˙ñ£Ç‰_TD"'dÛ¶yIî˘¥ô-Y°|êèHìIƒ_ºï˝Ë£'Æ≠æñ>ò:€QYÌÿ˚∆πsK}œﬁ˘˛›ì3ˇz˛–ıûƒµ√¯oÏÙ˛âS+Öèv<úÏ>:«Nº˘ƒ≈±ì;\ù!wM˝7˜u¸¯å¸WœtˆÙ&Ñ˙S'ü;0æˇBﬂ/.=~©ÔQãªxëQP{aEX^¬— O§é\FqÔ}¶/æúyJˆ–ßdäOﬁó•ü¢–=Eè¿Æ*Dµ‚â7n¢ö"JZ¨T»•5’EÙ¥∂"ß@ÖËiÜ›®YŒMÈÕ†ÄÉd´ïZ∑bJ…á#_Ïü≤WTY\≠¯Zé—=éÆ·*É—‚Ò2óÇ|Ô°˝c/åõıµÖe	ˇ@0ê˙⁄cù'«˝¶Ú:uyåxO„¢ß6dÊÀAe‡ûR#?≠⁄Y—OñY˜≥¿∏y|3µ∞∆ÙPÎﬂs¡´PlwÔdcπ≈Íj∆K
n◊H(>⁄;È®0[9/≥0‹ ÉW{_ÿg)≠+,è˙áÅÅ√„W∆ÕeµEÜvPÏ˙I|GÙ±àœ%K®êÆ/ëÌVG7◊Ho2ªZ∑¨à•¨N]ñÁûÁ."sÁBÿ
©:ÊŒf÷Á^èãÏ„Õ¿pâ,\ü¨ÌÀÑñéƒ5!”ã°ê™Ÿá^ˆ˘'åÚÄΩº÷êÕ∞Uàb≈*8&PPÄ=≠îâ ÖX»îÊ¬tPÙ÷&uO†(c–⁄«y˚˚8c®özÈî)Œz 6ÑcÒ◊∑ÚÆ-Xä≈É\?…±	π.˘7Ë∞<(!G[.À¢%Ü≤-Öos@ídõ›`îc'6 )™nJ8àOO¡GxI∏äì4C}º™§éØ>π˙Çö™zò2…‘‘±¶ûAãàÿmkÀÃõRÿõ”vRÉ.¨›¶fa≠Ûêúß
‰‘?√ó8ì8jbÂó5öz5›°-≠(Øî>}’c,-‘K¢µï¶r‰¨dÌÊ;í[–ıçÛú
µ∑Ë|ŒJgµ∑8[ú *YÆ±WIeôEFÀ(•%õw∑ üìÒ´tïå^˝ìò§a˜ÆõçÛç„¶„∑7Q√;7wëØ*ü„v©úyØ;ƒK£ÁãU9ù∆XâÄ¸HJú‡vfîop0Æ0C)œííjU_™÷§Gx…¯õ»§∑™Iﬂ˛Ù˙ØÑ?ó>ïoŒI1Sp}$àØ,·<æﬁŸ†)KÓy¸à
á‘&•E·((ùÉ∂c}÷ù≠œ¸k∞N[Ø™Ì-—∆)˘ØÁw4π€cÁ¥•ëΩuÍí≤¨–,
P ébTÃ´ ñXÈD ÏÎmIH˜≥Zó•º—LH®…gv≥yiÏ©2öÕ‹ÏQÎtÑ®
oﬂ¶·Û‘r5+Udga$9™‘d^ÊŸÜYnoG'üeêJÿƒkw`g’¡≤ 
¢œKD°j6∫r‚I%Æ∆%.+NgkÂzy∂´0‚∞ZF0:mµ#§≈&lÄ1ÿ3ç˝ÁfÒ"	,É›(VV•+ãJLµd˝N|öﬁ“,MDN¸|ÚiìsH“È]–˘Ì°vüØ=>¶Ö6ø7≤≥9‚=Êâ∆‹Æxî1ı\y…Ô´11Ú˛¡‡£%≈9´¶ÓŒdÇz{¨Œu~e%ôÏÓ¢K]C¯/	O†Ω£’C˙∏ç¯–”Ñyeì±÷ù·Á`‘ÄëŸ•'—€‰å‹àezl(§–i,SBø„¿@ùßı ç∞IµŸ˛?óÄ©k˜qm˛c+¸∂!K∏{âDO2…ºÿ’%Ù|^∞êµ∏pÑ9"y¯£â∑A~§áµC	)ÀÏP®(iCëŸåb°§ù-…œt¨5vâ+√ì¿XôA:ê≤œRX:[¯Ø¬á°`0ÑãÑ˘p(àãvzπ÷õ¡˙ÔèßÌ„˜|ˆFµËo∞˚ó„ÒŒÿ≤Ø—Ó[MëÎ{±xº_§jÔËØÄ[πºîA3Rînl°K]£,Û¢uGu`{œRo¡`†u¥≥ìhè∞ÑÔ Q´Q!Ø‘d)Ÿ¥¨±tÊ‘H¢<n‹⁄3 €›9§ÎéRM„QP´ŒZ$L+,—Iq^+2Òz¢1∞ê¥ÒÇjs!=]^º.È}ìÈaFjÒ˛◊ü„Nµñ{–=$Eçk∑ÂSí7P.(b-‚P}ÌC¸^.–≈Ùî›C·6≤≥√∏ ñMN6¡©jö∂Î‡¸>Ç[paOÃ@8‘/GlƒG’5Öx*OC·˘ÿ ;øßóù◊◊±a<ﬂd Ò„yîó3Øë≤Y“ö@WoP=%% ÆÑ@E˙‹¯”}ﬂE˝†^auöÁ”[Ó˛y®ÖÀgáfì≠ﬂﬁü8‹S˝ä∑›Œz£.ÊïÀgágªø{1q®óÿ^◊q/Æ‹®®&“◊Vd(◊õMbv˜‡\ÚÏ•◊πH£∑∞ê≥«<LË∆ıÆÀì_q»>v&u¸˜’‘‡nzı\WilT◊æ˜ÕõÌy∆3„Ÿ<˚ÃõÕ≥oœxÏ±üÌÒÇ˜›`¿qÀ^·RBÄ÷00(íFi	JR•–QÒÉàPJhTMQ’™©T!µäh§¥àöÁû˜f¡ÆÿûoÆÓ=ÁﬁsæÛ}~r≥ˇÚÙùª—…”£áˆ¶ß∆éÌ?Hˆî¶ß€Ì¥hˇ˚ÕÃ˝Ôˇ‡”ﬂ‹ækvååÌÃÃ†ío ï|”√Ço∫Äêê‚Ò™¯ˇ˚ØπÎı•ıßV‡È^Ùk'ó>Ê˜Y∫œ·KÄOÒÁÊÒáê‰˜œ„ßÚ82-=∆ü/€ß•ÄÁ}_∫‰˚Ê8ﬂW¬s%¸·
¸≈˙ñ~]<û.Ï3∑œïá+Î[8z~‚ú'≥HéTå¥å"•'∞ÑÁã∆∆ïl¨√ÛΩıı]]ııΩÇããˇÌ»a	˘qI∏ ›cb4àõh0⁄"ª
4˚n}~;^û∫Å±qÉ†«u6ı
H„õ7˙≠æ~ümGπÀTMßõc—]ñP∑’i'üÓﬁ◊ïóyè™BÍ2{˝¨G¨Rπ‡TÇº@| ¸è¿Ë@≥í©ï"MnhQÒ+ï‚¬πjZ¸BâmQüáââä
óŒÏÖzE-áTÈ—”#kËéB[ÆŒÁéØOÎTO∆ÔJœÈ”ïúÎ˙í|B‹ÓÀªÆ∂eÆã∏ı<@|N>yùõ˛Ú1'íÅñ◊2≤$£ƒ¬=EÅé9/Z•º§ÍıVåWwníóáMt˜‹¯Ïó!†VnfªõõºfffËÍ&ÉøïÈ‰ˆD^«˜@ÔÚL/AgHIëÈÛ.WƒmâG-’ˆù;[Ñó¨Ik{:›n·4¯QÚ·Ÿ`rõÕQø\V÷ßQÑaΩ_Ë©+Jä èf†ß‚Öqº¢ßE<˘4¿á0ÅáG¶ßGj'“”#¡L]¿1)ç^ëmzdd:=Q;2Ω-‘√f≠◊®‰¢˛ªôÿ±Ù%≤Éø≥öDeØô¨à®Ï"§“ä>J\Fàﬂi˘d¸Å®~ÁÁYﬁ0…ˇÆ¯°ÙXœts«©≠˜,¡§ßΩ;U´K
TïOÆ™_©ã6k,í†áÆí[’§≤%.Xä]	l·dÃBÄ1/•1Té√nVïÀE$›©){aË }q>(_ÏX4`Ä\{<±´j0Ö|µx~6q‰%ÂêP“ê…ﬁUP˚◊ñõÔ™*ud˛ó®Uä·Xîøó	véËF)x£1ÿT^©ìbåŒ…ê¢‡ÖÙ•	.Ü'Äk(UOOtn†≠aç>–Æ€©µy˚gjZ∑en%wı$Lì1`â8&w Z÷±Vdd‘»åπÛ	ï]ƒ5¨§≤ÿ8zï–ßZçó¯>ç`Æ§∏ﬁ˝z„∑˝6?4Ïw:‚Há˙‡.ã¬‹ÎwO;÷j’KUïâY%#å´OÅ^|∆≥SœB+∞Ó“c¡"ƒSÉFÛ8Á‹‡ù>b1Á–‰p+f¶¬ ´(#≈HÅë£w∞§ π¿∂πWPïØ Æ”twåab±l6ñˇ˚€–÷Bê-mÌ§Ô˘b[Æ-«‡ŒÑ·¨&úCY&È˜…d†Û0wK)_™p[6_%7Ï#f¬e≈3*+ÄÄ0:d£b”§x}Záπ0@Èu*¡ïåÉc<ßäg"ÆÉ@œÊıb`Ôﬁ¿Ë$~Ì«¥u◊ÿ_Œ≤ÑÏÔ_y;;ﬁw¯Ã∆O/Ù÷,‡´¯˛‰h∫Á◊Ï˜Ó≥›“€[Éøaß‚#æ~ˇ∑ì&vª•)ál:ñëØ√¬=°&k–q	™q∂‰lMµT
≠îUπeæ*õ^áDô8Êæ&@∫fmÁñõÒÒ∏º®“#úLÎå–êƒ2…¢øúG#Œsôé+†|fò apm+R˚.ú¯œ{ó˛}ÏçØéu4⁄[]„›ã'TJ÷ÑCùëd‘≠±xœü∂ÔÎÓ|µÛ≠˝ﬂ?#Ùäˆ,!ˆÈÃ/ÿg'N-˛t˛_áM—^W,≠¥;ïÒò+„sXL ê¡Ê\¸dÍÏ@ˇŸÌØ˝
™+ U˜Äü}ı+¥ÅÜ$-¿5h]/T›Xœ¬ùôêGXm°¬6\(ì	•;1û1:)d≠ a©bô{)»˘B›ïÛä˛jï¸{s˘{=ƒüÿ'√ÕÕ}9_[ÖRàïÛwª≤ôÁo}ˆŸñS]µ∂]3æv59ªz‹Î0∂ˆ5Eª≤?Ÿ¿fàÛl≥√‡˙¶&.∆Yà˝ƒhF~î`¸|QbG5IqÍ)±7&Á<äQ¶óX(‘ÊúRØ‡ıuﬁiÒ„ê£UBˆ™4À¶:åR‰x|¢ÁÚ∂ÿ◊æˇgﬂ⁄˝n«k=Ò\]f°oﬁ›æÛ‹ŸósØ¥	Sl˜Kk?˚¿É”=kŸÕ◊◊ØE˙zz∏˝‹–µ+Ô˝≤oûcò)ÙO≤éºâ êè°ëSïI%b°PMÇórΩUFI@;à¶ƒî'!∑WäSR¨ób1∆Ó8ƒ.‹ä\g‡»«ÏÔø«>fp‰ª¿}Éìrƒ=B$ºÉ¥H√PjπLÄœ´ä6®∆£™ ö\yÚπ„Óì1kh]”Pì›ÊMTU‹¯Ú®◊ú∞ËÍ{M1ˇÛÖó„∞s-ÒÄ∏*º™ës2HA+∫L2iç°@<—ôû∑ ¯¯πö»KèT¡◊>€…"çócqﬁ	£lo"ÔøùmI¶S{Œù‹¸Œèˆ¸ŸéµâTàxß]MÕ¬-9_0s˙Ëÿ¶ÊÉkáˆΩÈÚ“ñ ƒñ nÉ"∫ùûf¢!≈#D]í¿ràP∆UD'Í™£$]…*J F^Ä∂Á›È|¥.] ¯¸ÄÖ¯
“§X-"1ˇ˚Ö√–ÛŒ¢êv⁄Éü;–ëä˙£=È’8Bmá«Ü^ÕÖ˝M◊ﬂX≤#Ó—V	mŸ∫‘PK¶\°”í&⁄bsá˝Æ†ﬁ¢4s`8]Ω:muZ◊•7æŸæŸoiÀ[Îôd¢ö+∑t_t¸ö1h u2˘A¸·ÆòíÃ˝èÙ™çmÚ∫¬Áµﬂÿ	dÄiJ'$˛à?;q^€1'qåÛÅÉCHeqñ–,âƒ™vö`Bûƒ¯—VUK«¢b¸≤¯Åÿ“~tB˚U°löP~lö&MU¥MJ˜cc“¥uˆû˚8Ae“¶E:œ{rÓπ˜ú{>|Ô≈[lDã%ÍU˝è÷™‰ß^Ì⁄Ø∑€pnÀDÃÑ√„„pªåõP_©¥/ ÇM±M]º8ÅïÓŸÃ`Õ<ƒ˛Ω†™vî∆B—Jé{"}nßß˝`‚ΩØΩÒ›√£ﬂˇF≥\˙…?m˜4^6'Î[¥8∂)¬Z>+ü·õÙ∫°˘#Òπÿ´o,çp∑Ÿ˝U|d’µV•<Ì;n¨:cˆ)c÷Éﬂª>lHXjùöªÎ≈:XÎkgßDåﬁ÷ñ&À>õÊCk%µ>Mnªˆ…¿°Á√’çøˇˆ!3f}[°®ún˛J›∏Õ=·/=ZÕ€«Jœî>;ÙäΩYãµÏ¡>Ø'∞–tπÇOûdæ¯‰@Gﬁ§…õ≠qÔÅˆÌB49÷„mp∑h9á£7X˙»k?:÷Ÿâ˙ss˜≥˜ÁÆÊ∫ZgÛ^ƒ&ºõ&‹áÇr^ﬁ:¸ı°£≠ÊÅ»‹WMÀ’V”Ãn3^.®-è6pl¥?±8&OhëcÀ;™qs≈œòvlaFƒÆ·XD@qA—≠Ìû÷Êj+Æõ'µó¥}Z@Éﬁw©_Á∏À$'é0|rqÛTÌFÎπµÌ˘òm˝v¸üÕZu´ÙŸÖ∆6-Í∂{˝^ˇBC¿=ı‰I"ÏkË™c	∂:jˆ˛£¯?wuz,◊–Ê–rÆ∂≠¯w˘µÓJ¯ùM*¸™2wÓ∑ó~˛ﬂ∂Ëêj≠¸‘Ú∂^k˘MÂÌu‹$|{ô√m/◊Íñ∑ÁÁ’ÈxV≥Ë;Ùª®Ù!T˙aõE]cÍw’àÓŸâÁètµõ§«Áj÷Ω˝HAkùw5◊Ô“ø◊8 ˆ†YçC˝##,<3}_ro›j*∞˘à¥V†Ú<rwT`Û"d ÍÎˆ©˜ä
∫∫˙XÓ˘]Á!˜‚ÚÇø≥◊ËËË›øﬂ„>l8BÁﬁJÃD=˝Œ»Ä«˛sﬂkÜq⁄0ŒÙπ∞πÿŸÎ5éx;å÷ÜNg"ÏÈwÁWb˘^wÃN¥¬çÕœ—>HWÚKK∆Îò1Ná˚Œà™[Ì;ÔgÆ|˙¯ı›Òø Œj^aÔæÚŒÁÍ˚£ﬂ˛>[∫Yö®π`˝ˇ÷Tn¿<,ƒ˙ai¢"∆o÷\êÕÀÔ≥øø‡ÿŒàT.Õ§¢|b^ìÛ˙¢Ï—…òeMÇñ:π†mHŒ¥&–úπ mzQNò
r˙.|ã¶iÇ˛YPt4j-ÉŒÄÆÉ¶AG®_ê∞∆µø◊d∆∫&˝8ó–™6dtªjJnÈkr√2%s„6Ê›Öná£º(W!øÉÒú“ÂWÕüíÂ*ëΩjNUAY‚Ä~d˛*ø‘bWïœ¯÷√˛õ∫îüb/¯óÅŒÂ+æc¯ŒòäÂ?Åü¿¸+&øºgÚó·√-≈[Î‰€ê_•’<•á¯º£O!>kbÁÿûÈ÷˝bÄØ√∑ﬁ\'˝∞ﬂ.ÿ?≤πoÉ˚V˚ÿ‹ìÚ_˘ÙRÒú˘2¡ßwAMÒó†ç-ﬂ∂°Àœ—#Iõ˝2µπÊ.–¸OË1ÅˇV’F˘oäPyøBú~rËs“j›(ˇù1ˇ±Ù2ós“ØqàÍr›¸T¬≥[ÆI‰u¶†Ë∏8∞oá≈%C÷Eÿ\ÉÓ5ôRµ∑πFù˛®¸;|Ì˙∫‘¬˛U–=ÿ~§jt+V nıÄLXã»ÚW2%J≥6Aj=¯‡RqWπ◊¸•õ™.MÚ>Ë.ÏlTàsT]ﬁ¡¸âö¢iπxˆa¸]S±-î7¿71G[Ñ\mÎ§(’ ÍÁè¯⁄AÎ†À†Eê⁄Ô•£jïıÇz@˛ÒH*_È≥≤´Í±(À*†(®}ôÿ§∞⁄;˙ıl•„w¸œà_XD™ı_„ûﬁU^¶ Î¿Qπ/ªÂa˘æÿàNqc‘)>b:NÈ%Â40Bùh˘:0^æ<EÕÍ< ˇËí›–tâö.qíègây‚9†õönhﬁêóÄ∂Ú<PÕÍÄ≠«¿n8∞®$≥DµÇ˙ç@[YÄNÃÚ‚N¥
Lr4Øº2NÃPí%ŒR3O\¢˛
Ò"F}XshÉƒG|à∆∫t—∑.˙÷%vJZàNhvaMÖy`@j1+ÄHﬁ ˙à!J––∑ ˝	»4ÒV ÜJ3«(_¢˛
Ò"%`7,Æ’˙›Xˇ0Dæè£¢—çh+IÒÈñu‚•pÜ:9‚uŒPÁaπ∑%Å #§≠ vß01_!f6ƒ¯Ñ`Q° Tôjˆcnà˘
1_!Ê´Gvó÷Å∂“*–âäÍALî<IÃg)œW ÈÂ˙ΩX®*°+ﬂ éHò¢dT.'…Á‡CYX∫1+ÃÜ±Œ`ÑÚ(Qyf^¬AI2ƒi‚)‚Gsƒsî,ë_!^§§ ÏCd⁄∞¶¡ 4d,¨O5£¯¢—6ÿk{Õ`ØÏ5˛(ù!Í$â«(O'∏~ÜÚ,˘)Ú”ú5CIéxö+œr4O\‡
+–å0èˆ]˛(ú%ÊÅQ˙•ˇQ˙Öˇ´¿¢Ÿè2∂Q∆6Jˇ£Ù?Jˇ£\aöíyÂmî5•áQXTÎ‰â‘Tæ≈`]·Hb∞~	®¨«h=Üjj&»ìƒ1ÀY Jå›ìÍ´ÔáœèÅ>Ú Á~⁄ç√bPÌ7ãç@;˘¢ Wú˘äsnús„Ë8≈'8:LL”Õêü‰
'ªgé‚®´˚¿YéÊâV¿'d|Çøœ	ÃUxV¨∆Ú´PU„ £4»¯r÷ ÎaE·)‚±¢_ 1ÔCÃ˚Íj8F…8˘‚3Ãπ√ÚqKR?I˝$≠$È[íæ%ÈUíVíÚQ≠êDÌ≠£?Õ¢PGüéH-Q≠6¬’F§]ÊÅ	j&â#‘I√Óàå3î/Wàoø)´¿ã‰pùáòób¶ÿÉ)VHäµëÇœ
U|R¨ì˝O±ZR<R¨ê;zåøKcËA≈ìOSƒ4Â„ƒ%ì‰Oêü"?MÃó(øHTø„åÿ35¡º'úë?NIÜ± 0V 3à*Pesí£ìù‰jìõr˘,˚7À ≤≥<≥≤<≥≤åLª{&&)IG©3F~úº⁄cñÀrèY∆-ÀùfÂ§([”‰OQæD~Ö¯/ ´∏©ÎäI_≤lÀ¬ñºÈ˚„Eñe[í-áù4@\ª`TQc9ç6À*≤§»2â4'Å@(K⁄,B
Öî4RúêÑ•ìZ⁄,-ö”NJHY”I;ùﬁ≠`∆Ã§Ú¸ÎÛÔªÔº˜ﬂªÔﬁ˚ñ±Ω¸’.û≥ãÁÏbO^Hª÷àNŒ≠ùú[;Ÿ:yÂ;in2û√≤É•ìeòeÑ•Ïãà°ádeçEÃ∞àd9õÂñ,ù,√,#,eÜ.±ãÌªÿæãÌª∏’Õ¸nÊw3øõ˘›lÔf{7ü7˜r” »2Ã2¬rîG>S›‹∑õ˚vsﬂnÓ’Õ6^é3^é3^é3^é´^Æ¡º\GyπÛrÊÂ3ËerÊÂÃ«<>ÊÒ1èèy|Ã„cÛ¯ò««<>ÊÒ1èèyÇúÂÉúÖÉúÂÉúÂÉúÂÉúC{9ÉÑô!Ã;foå∞&¬ökñ±á,cO^∆öó®Ô	í^ñ>í∏¶:¿5’Æ©F8Œèê◊…“E#é∞◊ç0€xÉ¢7êõ¸saπ¢P±[yªÚCÂUUù™GuJÄ`⁄Ö>·q·í∫@ΩT}U3U≥=%#•5Âê÷§ıjwièi/•ÍRó§U•-I;óÓH_ì˛G]™n©ÓàÓBFiF<ck∆5˝˝˝ŸqÌ„^Õl»d>üy%Î€Y{≤Æ¨èaïaƒp ˜lmˆ˝ŸÔÂT‰ÂúŒ-œ›ú˚IﬁÑºxﬁ¡º∆∑éz¸Ö¸ñ¸«Úﬂ.òZd¡≈¬ö¬’ÖgãÏE+äN]+n/*^_º≈ÿdúe¸é±À4ˆ0Æ5>a‹a‹+6ä”ƒVq°Ë#‚†¯†∏^‹">'Óã'ƒ”‚_≈+‚øKRJÊñ¨í2•Ì•wîK∑N(ò∞≥¨º,T∂°ÏXyZy˘'.ù¯“ƒs©˜TOjö¥j“È ª*ﬂ¨≤TÖ´˛SΩ£¶¢fcÕ;5üöt¶~”	”Â⁄yµ˚køÆ˝⁄¨1Ã¢y[]YùΩnn›3uüYDKªeÉÂ5ÀqÀIÀøÍ©?RˇU√@√˘∆içÓ∆’çg¨€≠{¨≠«¨≤û≥^≤^≥)mz[°≠¬÷`õjª”Ê≤›g€o˚‹.ÿ≠ˆ˚z˚ªMEMÛõ÷5=’¥≥È£Ê;öè7ül>Ôhp<Í8Í∏‹2πe¯∂;o;3yÔ‰£SÊ»7|â8RË4	PR^— †ª€ Ω…≠ïäè˘ø¸´Ω±Ã•∑Q¨§ﬁ”ìXE˙ŸI,v'±öòÔIbXûƒ)s÷S/][Â—/2VŒƒU∆YØß»zE&c-câq*1πñ$V†ZÒp+°W'±äÙáíX |1â’»WíXÉreuß`ü≤ùqö<ßÀ„™tåu¨/f¨g\…8SWeeúMÿ†ö…8ámúåsôÁn∆y¨è1.‡æÀ±Õ∆F∂ŸÃ∏ÑÒ.∆Âløèq-„#2÷éŒ˘-∆£¸ÔÀX7™ˇòÒË¸øòç∆C¡ﬁÑ¥[™w8%ì‘çDÉ±Ä‰åEÉqO¨wP
'¸ÊÒê',uD"˛Ä_jsJ3£aG 8ˆƒ«lSÈ
ƒ˚C—àTo∂’≥A≤ΩÕyΩÀ/$g‹„Ùy‚ã•hœ≠&$≈¡P"'ÚPDJÙ§Ô.êÊyRÖ‰l3{"~)Ó‹€Kf™¢‰Î}PDçRdTd ÄP4˝ÑûÎmê†ˇ¯I∆·WmVΩ®z]uòûWTU/`Ÿ∆0Hm!äŸΩd-a7=ıTs;(K0—”FV2kÇ,c4é'£(ıâsåzí6L~∫èŒ`>y|âÍí(ù@yzd.'…ô§”{iÉ‘Ê˘}Û~ﬂ‹“E⁄8˙…Z˛˘ÀÃt3´øÅ·Ê˛rÔ±FŸ√_-≠l◊«Û]L∫(UôˇÔ
I§ìø;DÛJ¸Fg‚&»Vf† ä‰<Í-ÔJs∂—ÏG˜S"õ0ıPÕ€õ‰∏Ÿ/Æc˘-4f€ÖõÏ¬ƒq£«∞œ‹Ç3L6É7æ¢P/¥
≥Ö)$7ç!ﬁ[±¥ì\¬´*Øüº‚qﬁy∑Ó36Véw ˙=Î˜%«{%EÅb•Ü‚¢©HC:≈ÎË1ébu≈Ùl π»√x‰S5Qà"√%¥Í•t?)C9&“éLB%™PM˘√ÑZZ˝:X»≥Ë‹X…«ÏhB3ù¢∫MN∆L≈4 .3»ªf…˜9∫UÕ¶—\∫[¥“•Mæ9–nœ'\@;MU4’2ﬂ£¨≤à™M7UÅw·˚∏õæ”KòÏÉ=|bCtÍ”∑˜Ò˙≈(7≈Ÿ´hUÔ≈}¥G˜c)’TÀÒC<Ä¯Vb‚!<åUXçG∞kÒ(÷·«îø6`#6·1¸?≈„xO‚)l∆<ç≠x€,~ÜÌÿÅüc'v·9Öí¢≈Û¯%^¿ØËÑÏ≈0^ƒ>ÏßäÌ◊T£ç‡eºÇÉxØ)‘8Ñ√8Ç£¯çBEµŸoqo‚8~áﬂ„˛@˜∂∑6ﬁ¡ª¯3N‚ﬁ√iú¡_(_~ÄqÁŒì7˝çÓé) ]¬ß¯˛âÀ¯ü„⁄€´¯
◊>^Wﬂ'<˙X ä˙}ÅUMü«èFÑoƒ£‰”ÁOwµ®vª`≥ZÖFãE®´5&©J(ë‘%˙!CØÜu¯Yı∂M[Öçõ‘◊Æ÷≠V©W.\!∏™iÌ2tÈi©⁄çV3óv~›À*ˇC∆<,©.ÃüVì¸]G5Ö˘4Óˇ çõ”
endstreamendobj249 0 obj<</Length 717>>stream
Ôªø<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj218 0 obj<</Name(Headers/Footers)/Type/OCG/Usage<</PageElement<</Subtype/HF>>>>>>endobj6 0 obj<</BaseFont/Arial/Encoding/WinAnsiEncoding/Subtype/TrueType/Type/Font>>endobj19 0 obj<</BaseFont/Arial,Bold/Encoding/WinAnsiEncoding/Subtype/TrueType/Type/Font>>endobj246 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj244 0 obj[/Indexed/DeviceRGB 15 189 0 R]endobj245 0 obj[/Indexed/DeviceRGB 15 195 0 R]endobj238 0 obj<</Length 5870>>stream
q
1 0 0 1 -21.950348 -88.178864 cm
0 0 612 792 re
W n
1 0 0 1 21.950348 88.178864 cm
BT
0 0 0 rg
/TT0 7.92 Tf
0.0166 Tc -0.0583 Tw 86.05 660.141 Td
(ANTHRA PHARMACEUTICALS, INC.)Tj
-0.032 Tc -0.0098 Tw 0 -9.36 TD
(AD 32)Tj
-0.0421 Tc 0 Tw T*
(NDA 20,892)Tj
0 Tc -0.0418 Tw 421.2 0 Td
( )Tj
-0.0835 Tc 0 Tw (10)Tj
ET
q
437.76 0 0 -7.68 85.569652 640.461136 cm
/Im0 Do
Q
q
1 0 0 1 -21.950348 -88.178864 cm
108 726.96 432 0.96 re
f
Q
q
437.76 0 0 -7.68 85.569652 640.461136 cm
/Im1 Do
Q
q
1 0 0 1 -21.950348 -88.178864 cm
0 0 0 RG
0.24 w 1 j 1 J 
108 726.96 432 0.96 re
S
Q
BT
/TT0 10.08 Tf
-0.0166 Tc 0.0944 Tw 86.05 600.381 Td
(and intravenous tubing.  Valstar)Tj
/TT1 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0595 Tc 0.1372 Tw (  solutions should be prepared and stored in glass,)Tj
-0.0152 Tc 0.093 Tw 0 -11.52 TD
(polypropylene, or polyolefin containers and tubing.  It is recommended t\hat non-DEHP)Tj
-0.0318 Tc 0.1096 Tw T*
(containing administration sets, such as those that are polyethylene-line\d, be used.)Tj
-0.0422 Tc 0.12 Tw 0 -23.04 TD
(Procedures for proper handling and disposal of anticancer drugs should b\e used.  Spills should)Tj
-0.0249 Tc 0.1027 Tw 0 -11.52 TD
(be cleaned up with undiluted chlorine bleach.)Tj
/TT2 10.08 Tf
-0.0059 Tc 0.0837 Tw 0 -23.28 TD
(Preparation for Administration:)Tj
/TT0 10.08 Tf
-0.0241 Tc 0 Tw 0 -12.48 TD
(Valstar)Tj
/TT1 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
0.0115 Tc 0.0663 Tw (  Sterile Solution for Intravesical Instillation is a clear red solution\.  It should be visually)Tj
-0.0091 Tc 0.0869 Tw 0 -11.52 TD
(inspected for particulate matter and discoloration prior to administrati\on.  At temperatures below)Tj
-0.0845 Tc 0 Tw T*
(4)Tj
/TT0 6.48 Tf
-0.0029 Tc 5.52 5.04 Td
(o)Tj
/TT0 10.08 Tf
-0.0227 Tc 0.1005 Tw 3.6 -5.04 Td
(C, Cremophor)Tj
/TT3 10.08 Tf
0 Tc 0 Tw (7)Tj
/TT0 10.08 Tf
-0.0009 Tc 0.0786 Tw (EL may begin to form a waxy precipitate.  If this happens, the vial shou\ld be)Tj
-0.0047 Tc 0.0824 Tw -9.12 -12.24 Td
(warmed in the hand until the solution is clear.  If particulate matter i\s still seen, Valstar)Tj
/TT1 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0693 Tc 0.147 Tw (  should)Tj
-0.0156 Tc 0.0933 Tw T*
(not be administered.)Tj
/TT2 10.08 Tf
0.0152 Tc 0 Tw 0 -23.28 TD
(Stability:)Tj
/TT0 10.08 Tf
-0.0057 Tc 0.0834 Tw 0 -12.48 TD
(Unopened vials of Valstar)Tj
/TT1 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0411 Tc 0.1189 Tw (  are stable until the date indicated on the package when stored)Tj
-0.0208 Tc 0.0986 Tw 0 -12.24 TD
(under refrigerated conditions at 2)Tj
/TT0 6.48 Tf
-0.0029 Tc 0 Tw 147.6 5.04 Td
(o)Tj
/TT0 10.08 Tf
-0.0406 Tc 3.6 -5.04 Td
(-8)Tj
/TT0 6.48 Tf
-0.0029 Tc 8.88 5.04 Td
(o)Tj
/TT0 10.08 Tf
-0.0608 Tc 0.1386 Tw 3.6 -5.04 Td
(C \(36)Tj
/TT0 6.48 Tf
-0.0029 Tc 0 Tw 24.48 5.04 Td
(o)Tj
/TT0 10.08 Tf
-0.0552 Tc 3.6 -5.04 Td
(-46)Tj
/TT0 6.48 Tf
-0.0029 Tc 14.4 5.04 Td
(o)Tj
/TT0 10.08 Tf
-0.0289 Tc 0.1066 Tw 3.6 -5.04 Td
(F\).  Vials should not be heated.  Valstar)Tj
/TT1 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0092 Tc 0.0686 Tw (  diluted)Tj
-0.0076 Tc 0.0853 Tw -209.76 -11.52 Td
(in 0.9% Sodium Chloride Injection, USP for administration is stable for \12 hours at temperatures)Tj
-0.0574 Tc 0.1352 Tw T*
(up to 25)Tj
/TT0 6.48 Tf
-0.0029 Tc 0 Tw 36.24 5.04 Td
(o)Tj
/TT0 10.08 Tf
-0.0608 Tc 0.1386 Tw 3.6 -5.04 Td
(C \(77)Tj
/TT0 6.48 Tf
-0.0029 Tc 0 Tw 24.48 5.04 Td
(o)Tj
/TT0 10.08 Tf
0.0184 Tc 0.0594 Tw 3.6 -5.04 Td
(F\).  Since compatibility data are not available, Valstar)Tj
/TT1 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0124 Tc 0.0902 Tw (  should not be mixed)Tj
-0.0498 Tc 0.1276 Tw -67.92 -11.52 Td
(with other drugs.)Tj
/TT2 10.08 Tf
-0.0151 Tc 0.0928 Tw 0 -34.8 TD
(HOW SUPPLIED)Tj
/TT0 10.08 Tf
-0.0241 Tc 0 Tw 0 -24 TD
(Valstar)Tj
/TT1 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
0.0075 Tc 0.0702 Tw (  Sterile Solution for Intravesical Instillation is a clear red solution\ in Cremophor)Tj
/TT3 10.08 Tf
0 Tc 0 Tw (7)Tj
/TT0 10.08 Tf
-0.0034 Tc 0.0811 Tw (EL /)Tj
0 Tc 0.0783 Tw 0 -12.24 TD
(dehydrated alcohol, USP, containing 40 mg valrubicin per mL.  Valstar)Tj
/TT1 10.08 Tf
0.1488 Tc 0 Tw 313.92 0 Td
(\324)Tj
/TT0 10.08 Tf
0.0295 Tc 0.0483 Tw (  Sterile Solution for)Tj
0.013 Tc 0.0648 Tw -313.92 -11.52 Td
(Intravesical Instillation is available in single-use, clear glass vials,\ individually packaged in the)Tj
-0.0117 Tc 0.0895 Tw 0 -11.52 TD
(following sizes:)Tj
-0.0714 Tc 0.1492 Tw 36 -23.04 Td
(NDC 53014-216-70)Tj
-0.0056 Tc 0.0834 Tw 108 0 Td
(Carton of 4, 5 mL Single-Use Vials \(200 mg/ 5mL\))Tj
0.006 Tc 0.0718 Tw -144 -23.04 Td
(Store vials under refrigeration at 2)Tj
/TT0 6.48 Tf
-0.0029 Tc 0 Tw 152.4 5.04 Td
(o)Tj
/TT0 10.08 Tf
-0.0406 Tc 3.6 -5.04 Td
(-8)Tj
/TT0 6.48 Tf
-0.0029 Tc 8.88 5.04 Td
(o)Tj
/TT0 10.08 Tf
-0.0608 Tc 0.1386 Tw 3.6 -5.04 Td
(C \(36)Tj
/TT0 6.48 Tf
-0.0029 Tc 0 Tw 24.48 5.04 Td
(o)Tj
/TT0 10.08 Tf
-0.0552 Tc 3.6 -5.04 Td
(-46)Tj
/TT0 6.48 Tf
-0.0029 Tc 14.4 5.04 Td
(o)Tj
/TT0 10.08 Tf
0.0081 Tc 0.0697 Tw 3.6 -5.04 Td
(F\) in the carton.  DO NOT FREEZE.)Tj
0.0259 Tc 0.0518 Tw -214.56 -23.04 Td
(Rx only)Tj
-0.002 Tc 0.0797 Tw 0 -23.04 TD
(Manufactured for Anthra Pharmaceuticals, Inc. by:)Tj
-0.038 Tc 0.1157 Tw 0 -11.52 TD
(Ben Venue Laboratories, Inc.)Tj
-0.025 Tc 0.1027 Tw T*
(Bedford, OH 44146   USA)Tj
-0.0128 Tc 0.0905 Tw 0 -23.04 TD
(Distributed by:)Tj
0.0175 Tc 0.0603 Tw 0 -11.52 TD
([Medeva logo])Tj
0.0074 Tc 0.0703 Tw T*
(Medeva Pharmaceuticals, Inc.)Tj
-0.0542 Tc 0.132 Tw T*
(Rochester, NY 14623  USA)Tj
-0.0439 Tc 0 Tw 412.56 -11.52 Td
(6/98)Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS0 gs
/Fm0 Do
Q
EMC 

endstreamendobj242 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240612153311-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 248 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 255 0 R/LastModified(D:20240612153311-04'00')/Private/Header>>>>/Resources 256 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj175 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 174 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im23/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj181 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 180 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im24/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj180 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj174 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj256 0 obj<</Font 257 0 R>>endobj257 0 obj<</ArialRoundedMTBold 252 0 R>>endobj255 0 obj<</Length 717>>stream
Ôªø<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj25 0 obj<</BaseFont/Symbol/FirstChar 31/FontDescriptor 21 0 R/LastChar 255/Subtype/TrueType/Type/Font/Widths[600 250 333 713 500 549 833 778 439 333 333 500 549 250 549 250 278 500 500 500 500 500 500 500 500 500 500 278 278 549 549 549 444 549 722 667 722 612 611 763 603 722 333 631 722 686 889 722 722 768 741 556 592 611 690 439 768 645 795 611 333 863 333 658 500 500 631 549 549 494 439 521 411 603 329 603 549 549 576 521 549 549 521 549 603 439 576 713 686 493 686 494 480 200 480 549 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 620 247 549 167 713 500 753 753 753 753 1042 987 603 987 603 400 549 411 549 549 713 494 460 549 549 549 549 1000 603 1000 658 823 686 795 987 768 768 823 768 768 713 713 713 713 713 713 713 768 713 790 790 890 823 549 250 713 603 603 1042 987 603 987 603 494 329 790 790 786 713 384 384 384 384 384 384 494 494 494 494 600 329 274 686 686 686 384 384 384 384 384 384 494 494 494 600]>>endobj43 0 obj<</BaseFont/IJABAB+WPTypographicSymbols/FirstChar 31/FontDescriptor 44 0 R/LastChar 255/Subtype/TrueType/Type/Font/Widths[500 500 667 667 667 600 500 667 500 233 500 366 366 533 533 733 533 347 347 866 866 533 360 320 500 500 667 866 360 233 233 233 366 366 366 500 754 233 233 866 800 500 500 900 953 667 866 500 800 500 667 500 500 535 736 736 481 481 648 667 500 667 667 667 216 365 866 866 866 866 866 866 500 500 500 866 866 1219 1000 667 360 879 820 861 844 852 771 887 944 786 957 894 930 852 864 872 500 872 864 870 872 872 872 417 525 886 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500]>>endobj44 0 obj<</Ascent 810/AvgWidth 738/CapHeight 810/Descent 214/Flags 4/FontBBox[-250 -214 1457 810]/FontFile2 203 0 R/FontName/IJABAB+WPTypographicSymbols/ItalicAngle 0/Leading 24/MaxWidth 1214/MissingWidth 500/StemH 135/StemV 135/Type/FontDescriptor/XHeight 567>>endobj203 0 obj<</Length 4661/Length1 206 0 R/Length2 205 0 R/Length3 207 0 R>>stream
     Ä  POS/2kçtö   ‹   Ncmaps´¢ÿ  *  cvt Jˇ  H   äfpgmò\‹¢  “   dglyf$!≠  6   headøNQa      6hheaMŸ  6   $hmtx™
å  Z  ¨loca  ô    ∞maxp D  	∂    nameÜUk  	÷  jpostmQö‹  @  Ùprepc6f  4    ﬁê  ºä   èºä  ≈ 2                  Alts @ à  »  , ‚         $           $                               	
 !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`a bcdefghij                                                                                                                          ˙      ~àˇˇ   Äˇˇ       ¬         	 
                        ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i jbú%9¢Ì |çŸ ì  ∞`–Ô,ˇˇ ¿ Ÿò _	ˇxˇÙ!ˇçˇDˇ‰ Mˇiˇ≤ íˇú ü Ç < sˇRˇ > F L 	 ô É O ∏ Ç ´ ñ €[kÅ z V ¨ û ç j + ?  º J « 1@ ,vE ∞%E#ah#h`D-,E ∞%E#ah#h`D-,  ∏ˇ¿8±@68-,  ∞@8∞6∏ˇ¿8-,∞Fv Gh#Fah X ∞%#8∞%∞6e8Y-    ’    =@) )((   Fv/7 ?<?</<˝</<˝< ˝<˝<10≤ +3!'!∂˛à ¸‡‚˝   ¿¶   - 4 @A&(2"!))	10)$#32) "(("21! ("( .(* *-,+*(#"	 Fv/7 ??/<˝<›˝<˝˝<˝÷ ?<˝</<˝<˝˝÷< 9...10≤5+#"&546324&#"326#.54&+#532'4+32éffèéffè0sRQttRQs^.*1gU0+/+/¥féèedéçeQsrRQtsV›C)	Å4  =ò §ú 	 ,@	   x v??</<÷< ÷<...10≤
 +>=#3=70^&/òHDgzD       •≤∏,_<ı  Ë    -∆á    -∆á  ˇ≠,          ,ˇ  √  ˇˇ≠                kÙ     Ù  Ù  õ ]õ ]õ pX ÇÙ _õ ;Ù  È HÙ 'n 'n 2  › P [ [ b Ab A )h @ Ù Ù õ 0b h  È > È = È Bn >n Cn <Ù *Ú  È 3 È <b H  DÙ Ù Ñ π ,õ Cb GÙ >  CÙ Kõ 9Ù LÙ  ‡ ‡ · · à >õ @Ù ?õ #õ <õ X ÿ 6m 6b 0b b @b b b #Ù Ù Ù b b √ Ë Aõ :h Do >4 >] BL =T > 9w J∞ !  Ω B~ %¢ 'T "` (h ,h ,` *f *h *h *h .° ! v 8       d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d  v  v  v  v  v  v                                                                                                                                                                                                                                     k h        @ 
   øt              l           l         á         ì         Æ        8 …                6       R       m       s       é       ©       ≈   	   l‡   	  6L   	  Ç   	  6é   	  6ƒ   	  8˙   	  62 { c }   1 9 9 3   W o r d P e r f e c t   C o r p o r a t i o n .   A l l   R i g h t s   R e s e r v e d .IJABAB+WPTypographicSymbols N o r m a lIJABAB+WPTypographicSymbolsIJABAB+WPTypographicSymbols 1 . 0   T u e   M a y   0 3   1 3 : 1 7 : 1 2   1 9 9 4IJABAB+WPTypographicSymbols{c} 1993 WordPerfect Corporation. All Rights Reserved.IJABAB+WPTypographicSymbolsNormalIJABAB+WPTypographicSymbolsIJABAB+WPTypographicSymbols1.0 Tue May 03 13:17:12 1994IJABAB+WPTypographicSymbols { c }   1 9 9 3   W o r d P e r f e c t   C o r p o r a t i o n .   A l l   R i g h t s   R e s e r v e d . I J A B A B + W P T y p o g r a p h i c S y m b o l s N o r m a l I J A B A B + W P T y p o g r a p h i c S y m b o l s I J A B A B + W P T y p o g r a p h i c S y m b o l s 1 . 0   T u e   M a y   0 3   1 3 : 1 7 : 1 2   1 9 9 4 I J A B A B + W P T y p o g r a p h i c S y m b o l s       ˇ{                      k     	
 !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghexclamquotedbl
numbersigndollarpercent	ampersandquotesingle	parenleft
parenrightasteriskpluscommahyphenperiodslashzeroonetwothreefourfivesixseveneightninecolon	semicolonlessequalgreaterquestionatABCDEFGHIJKLMNOPQRSTUVWXYZbracketleft	backslashbracketrightasciicircum
underscoregraveabcdefghijklmnopqrstuvwxyz	braceleftbar
braceright
asciitildec128c129quotesinglbaseflorinquotedblbaseellipsisdagger	daggerdbl
circumflex@))((  Eç∏ˇÖvEhD≥ F +≥ F +≥F +≥ F +≥F +≥ F +≥F +≥	F +≥
F +≥ F +≥ F +≥ F +≥ F +≥ F +≥ F +≥F +≥F +≥F +≥F +≥F +≥F +≥F +≥F +≥F +≥F +≥F +≥F +≥F +≥ F +≥!F +≥"F +≥#F +≥$F +≥%F +≥&F +≥'F +EhDEhDEhDEhDEhD
endstreamendobj206 0 obj4661endobj205 0 obj0endobj207 0 obj0endobj21 0 obj<</Ascent 1000/AvgWidth 571/CapHeight 1000/Descent 214/Flags 16390/FontBBox[-250 -214 1258 1000]/FontName/Symbol/ItalicAngle 0/Leading 214/MaxWidth 1048/MissingWidth 595/StemH 182/StemV 182/Type/FontDescriptor/XHeight 700>>endobj241 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj239 0 obj[/Indexed/DeviceRGB 15 174 0 R]endobj240 0 obj[/Indexed/DeviceRGB 15 180 0 R]endobj233 0 obj<</Length 6992>>stream
q
1 0 0 1 -22.694885 -28.29892 cm
0 0 612 792 re
W n
1 0 0 1 22.694885 28.29892 cm
BT
0 0 0 rg
/TT0 7.92 Tf
0.0166 Tc -0.0583 Tw 85.305 720.021 Td
(ANTHRA PHARMACEUTICALS, INC.)Tj
-0.032 Tc -0.0098 Tw -0 -9.36 Td
(AD 32)Tj
-0.0421 Tc 0 Tw 0 -9.36 Td
(NDA 20,892)Tj
0 Tc -0.0418 Tw 425.52 0 Td
( )Tj
-0.0835 Tc 0 Tw (9)Tj
ET
q
437.76 0 0 -7.68 84.825115 700.34108 cm
/Im0 Do
Q
q
1 0 0 1 -22.694885 -28.29892 cm
108 726.96 432 0.96 re
f
Q
q
437.76 0 0 -7.68 84.825115 700.34108 cm
/Im1 Do
Q
q
1 0 0 1 -22.694885 -28.29892 cm
0 0 0 RG
0.24 w 1 j 1 J 
108 726.96 432 0.96 re
S
Q
BT
/TT1 10.08 Tf
-0.0646 Tc 0.1424 Tw 85.305 660.981 Td
(Skin and Appendages)Tj
/TT0 10.08 Tf
-0.001 Tc 0.0788 Tw (: Pruritus.)Tj
/TT1 10.08 Tf
-0.0515 Tc 0.1292 Tw -0 -23.52 Td
(Special Senses)Tj
/TT0 10.08 Tf
-0.0452 Tc 0.1229 Tw (: Taste loss.)Tj
/TT1 10.08 Tf
-0.0363 Tc 0.1141 Tw 0 -23.28 Td
(Urogenital System)Tj
/TT0 10.08 Tf
-0.0014 Tc 0.0791 Tw (: Local skin irritation, poor urine flow, and urethritis.)Tj
0.0051 Tc 0.0726 Tw -0 -24 Td
(Inadvertent paravenous extravasation of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0505 Tc 0.1283 Tw ( was not associated with skin ulceration or)Tj
-0.0545 Tc 0 Tw 0 -11.52 Td
(necrosis.)Tj
/TT3 10.08 Tf
-0.0253 Tc -0 -23.76 Td
(OVERDOSAGE)Tj
/TT0 10.08 Tf
-0.0281 Tc 0.1059 Tw 0 -24 Td
(There is no known antidote for overdoses of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0158 Tc 0.0619 Tw (.  The primary anticipated complications of)Tj
-0.02 Tc 0.0978 Tw -0 -11.52 Td
(overdosage associated with intravesical administration would be consiste\nt with irritable bladder)Tj
0 Tc 0 Tw 0 -11.52 Td
(symptoms.)Tj
-0.0379 Tc 0.1156 Tw -0 -23.76 Td
(Myelosuppression is possible if Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0195 Tc 0.0583 Tw (  is inadvertently administered systemically or if)Tj
-0.0013 Tc 0.0791 Tw 0 -11.52 Td
(significant systemic exposure occurs following intravesical administrati\on \(e.g., in patients with)Tj
-0.0056 Tc 0.0834 Tw 0 -11.52 TD
(bladder rupture/perforation\).  The maximum tolerated dose in humans by \either intraperitoneal or)Tj
0.0079 Tc 0.0699 Tw T*
(intravenous administration is 600 mg/m)Tj
/TT0 6.48 Tf
-0.0029 Tc 0 Tw 175.92 5.04 Td
(2)Tj
/TT0 10.08 Tf
0.0046 Tc 0.0732 Tw 3.6 -5.04 Td
(.  Dose limiting toxicities are leukopenia and)Tj
-0.0376 Tc 0.1154 Tw -179.52 -11.52 Td
(neutropenia,  beginning within 1 week of dose administration, with nadir\s by the second week,)Tj
-0.0091 Tc 0.0868 Tw 0 -12.24 TD
(and recovery generally by the third week. If Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0394 Tc 0.1171 Tw (  is administered when bladder rupture or)Tj
-0.016 Tc 0.0938 Tw 0 -11.52 TD
(perforation is suspected, weekly monitoring of complete blood counts for\ should be performed)Tj
-0.0638 Tc 0.1416 Tw T*
(for 3 weeks)Tj
/TT3 10.08 Tf
-0.031 Tc 0.1088 Tw 0 -34.8 TD
(DOSAGE AND ADMINISTRATION)Tj
/TT0 10.08 Tf
-0.0241 Tc 0 Tw 0 -24 TD
(Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
-0.0076 Tc 0.0854 Tw ( is recommended at a dose of 800 mg administered intravesically once a w\eek for six)Tj
-0.0395 Tc 0.1173 Tw 0 -11.52 TD
(weeks. Administration should be delayed at least two weeks after transur\ethral resection and/or)Tj
0.0155 Tc 0.0622 Tw T*
(fulguration.  For each instillation, four 5)Tj
0.0361 Tc 0.0417 Tw ( mL vials \(200 mg valrubicin/5 ml per vial\) should be)Tj
-0.0119 Tc 0.0897 Tw T*
(allowed to warm slowly to  room temperature, but should not be heated.  \Twenty milliliters of)Tj
-0.0241 Tc 0 Tw 0 -12.24 TD
(Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
-0.0131 Tc 0.0909 Tw (  should then be withdrawn from the four vials and diluted with 55 mL 0.\9% Sodium)Tj
0.0092 Tc 0.0686 Tw T*
(Chloride Injection, USP providing  75 mL of a diluted Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0143 Tc 0.092 Tw (  solution.  A urethral catheter)Tj
-0.0334 Tc 0.1111 Tw 0 -11.52 TD
(should then be inserted into the patient)Tj
/TT4 10.08 Tf
0.0514 Tc 0 Tw (=)Tj
/TT0 10.08 Tf
-0.0366 Tc 0.1144 Tw (s bladder under aseptic conditions, the bladder  drained,)Tj
-0.0191 Tc 0.0969 Tw 0 -12.24 TD
(and the diluted 75 mL Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0241 Tc 0.0537 Tw (  solution instilled slowly via gravity flow over a period of several)Tj
-0.0339 Tc 0.1116 Tw 0 -11.52 TD
(minutes.  The catheter should then be withdrawn.  The patient should ret\ain the drug for two)Tj
-0.0102 Tc 0.088 Tw T*
(hours before voiding. At the end of two hours, all patients should void.\  \(Some patients will be)Tj
-0.0178 Tc 0.0955 Tw T*
(unable to retain the drug for the full two hours.\)  Patients should be \instructed to maintain)Tj
-0.009 Tc 0.0868 Tw T*
(adequate hydration following treatment.)Tj
0.0051 Tc 0.0727 Tw 0 -23.76 TD
(Patients receiving Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0209 Tc 0.0569 Tw (  for refractory carcinoma )Tj
/TT1 10.08 Tf
-0.0411 Tc 0.1189 Tw (in situ)Tj
/TT0 10.08 Tf
0.0018 Tc 0.076 Tw ( must be monitored closely for)Tj
-0.0375 Tc 0.1152 Tw 0 -11.76 TD
(disease recurrence or progression.  Recommended evaluations include cyst\oscopy, biopsy, and)Tj
0.0013 Tc 0.0764 Tw 0 -11.52 TD
(urine cytology every 3 months.)Tj
/TT3 10.08 Tf
-0.0069 Tc 0.0846 Tw 0 -23.28 TD
(Administration Precautions:)Tj
/TT0 10.08 Tf
-0.0257 Tc 0.1034 Tw 0 -11.76 TD
(As recommended with other cytotoxic agents, caution should be exercised \in handling and)Tj
-0.0186 Tc 0.0964 Tw 0 -12.24 TD
(preparing the solution of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0061 Tc 0.0716 Tw (.  Contact toxicity, common and severe with other)Tj
-0.014 Tc 0.0917 Tw T*
(anthracyclines, is not typical with Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0308 Tc 0.1086 Tw (  and, when observed, has been mild.  Skin reactions)Tj
-0.0301 Tc 0.1078 Tw 0 -11.52 TD
(may occur with accidental exposure, and the use of gloves during dose pr\eparation and)Tj
-0.0151 Tc 0.0928 Tw T*
(administration is recommended.  Irritation of the eye has also been repo\rted with accidental)Tj
-0.0248 Tc 0.1026 Tw T*
(exposure.  If this happens, the eye should be flushed with water immedia\tely and thoroughly.)Tj
-0.0241 Tc 0 Tw 0 -23.76 TD
(Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
-0.024 Tc 0.1017 Tw (  sterile solution contains Cremophor)Tj
/TT4 10.08 Tf
0 Tc 0 Tw (7)Tj
/TT0 10.08 Tf
-0.0545 Tc 0.1323 Tw (EL, which has been known to cause leaching of)Tj
0.0082 Tc 0.0696 Tw 0 -11.52 TD
(di\(2-ethylhexyl\)phthalate\(DEHP\) a hepatotoxic plasticizer, from poly\vinyl chloride \(PVC\) bags)Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS0 gs
/Fm0 Do
Q
EMC 

endstreamendobj237 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240612153311-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 248 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 258 0 R/LastModified(D:20240612153311-04'00')/Private/Header>>>>/Resources 259 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj160 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 159 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im21/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj166 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 165 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im22/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj165 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj159 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj259 0 obj<</Font 260 0 R>>endobj260 0 obj<</ArialRoundedMTBold 252 0 R>>endobj258 0 obj<</Length 717>>stream
Ôªø<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj22 0 obj<</BaseFont/Arial,Italic/Encoding/WinAnsiEncoding/Subtype/TrueType/Type/Font>>endobj236 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj234 0 obj[/Indexed/DeviceRGB 15 159 0 R]endobj235 0 obj[/Indexed/DeviceRGB 15 165 0 R]endobj228 0 obj<</Length 12763>>stream
q
1 0 0 1 -19.979004 -32.618866 cm
0 0 612 792 re
W n
1 0 0 1 19.979004 32.618866 cm
BT
0 0 0 rg
/TT0 7.92 Tf
0.0166 Tc -0.0583 Tw 88.021 715.701 Td
(ANTHRA PHARMACEUTICALS, INC.)Tj
-0.032 Tc -0.0098 Tw 0 -9.36 TD
(AD 32)Tj
-0.0421 Tc 0 Tw T*
(NDA 20,892)Tj
0 Tc -0.0418 Tw 425.52 0 Td
( )Tj
-0.0835 Tc 0 Tw (8)Tj
ET
q
437.76 0 0 -7.68 87.540996 696.021134 cm
/Im0 Do
Q
q
1 0 0 1 -19.979004 -32.618866 cm
108 726.96 432 0.96 re
f
Q
q
437.76 0 0 -7.68 87.540996 696.021134 cm
/Im1 Do
Q
q
1 0 0 1 -19.979004 -32.618866 cm
0 0 0 RG
0.24 w 1 j 1 J 
108 726.96 432 0.96 re
S
Q
BT
/TT1 10.08 Tf
-0.0135 Tc 0.0913 Tw 285.301 655.701 Td
(TABLE 2)Tj
/TT0 10.08 Tf
0 Tc 0.0778 Tw -170.88 -14.16 Td
( )Tj
/TT1 10.08 Tf
-0.0284 Tc 0.1062 Tw (Most Commonly Reported Systemic Adverse Reactions)Tj
/TT1 7.44 Tf
-0.0566 Tc 0 Tw 268.08 6 Td
(1)Tj
/TT1 10.08 Tf
0.0213 Tc 0.0565 Tw 4.08 -6 Td
(  Following Intravesical)Tj
-0.0112 Tc 0.0889 Tw -182.4 -12.96 Td
(Administration of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0 Tc 0.0778 Tw ( )Tj
/TT1 10.08 Tf
-0.0432 Tc 0.1209 Tw ( \(% of Patients\))Tj
ET
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 697.92 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 697.92 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
117.36 697.92 417.6 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 697.92 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 697.92 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 656.64 0.72 41.28 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 656.64 0.72 41.28 re
f
Q
BT
/TT1 9.12 Tf
-0.052 Tc 0.1566 Tw 103.141 610.101 Td
(Body System)Tj
0.0211 Tc 0.0836 Tw 0 -11.04 TD
(     Preferred Term)Tj
-0.0106 Tc 0.1152 Tw 210.24 9.84 Td
(All Patients Who Received Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT1 9.12 Tf
-0.011 Tc 61.68 -11.04 Td
(\(N=230\))Tj
ET
q
1 0 0 1 -19.979004 -32.618866 cm
116.64 655.92 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
117.36 655.92 170.16 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
287.52 655.92 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
288.24 655.92 246.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
534.96 655.92 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 626.16 0.72 29.76 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 626.16 0.72 29.76 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 626.16 0.72 29.76 re
f
Q
BT
-0.0677 Tc 0.1723 Tw 103.141 579.621 Td
(Body as a Whole)Tj
/TT0 9.12 Tf
0.0308 Tc 0.0738 Tw 0 -10.56 TD
(     Abdominal pain)Tj
-0.0257 Tc 0.1304 Tw T*
(     Asthenia)Tj
-0.0088 Tc 0.1135 Tw T*
(     Back pain)Tj
-0.0287 Tc 0.1333 Tw T*
(     Chest pain)Tj
-0.1021 Tc 0.2068 Tw T*
(     Fever)Tj
-0.0961 Tc 0.2008 Tw T*
(     Headache)Tj
-0.0312 Tc 0.1358 Tw T*
(     Malaise)Tj
0 Tc 0.1046 Tw T*
(    )Tj
0.0108 Tc 0 Tw 282 74.4 Td
(5%)Tj
T*
(4%)Tj
T*
(3%)Tj
T*
(3%)Tj
T*
(2%)Tj
T*
(4%)Tj
T*
(4%)Tj
ET
q
1 0 0 1 -19.979004 -32.618866 cm
116.64 625.44 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
117.36 625.44 170.16 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
287.52 625.44 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
288.24 625.44 246.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
534.96 625.44 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 523.44 0.72 102 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 523.44 0.72 102 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 523.44 0.72 102 re
f
Q
BT
/TT1 9.12 Tf
-0.0094 Tc 103.141 476.901 Td
(Cardiovascular)Tj
/TT0 9.12 Tf
0.0203 Tc 0.0844 Tw T*
(     Vasodilation)Tj
0.0108 Tc 0 Tw 282 0.48 Td
(2%)Tj
ET
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 522.72 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
117.36 522.72 170.16 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 522.72 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
288.24 522.72 246.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 522.72 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 494.64 0.72 28.08 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 494.64 0.72 28.08 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 494.64 0.72 28.08 re
f
Q
BT
/TT1 9.12 Tf
0.0014 Tc 103.141 448.101 Td
(Digestive)Tj
/TT0 9.12 Tf
-0.0208 Tc 0.1254 Tw T*
(     Diarrhea)Tj
-0.0311 Tc 0.1357 Tw T*
(     Flatulence)Tj
-0.0779 Tc 0.1826 Tw T*
(     Nausea)Tj
0.0654 Tc 0.0392 Tw T*
(     Vomiting)Tj
0.0108 Tc 0 Tw 282 32.16 Td
(3%)Tj
T*
(1%)Tj
T*
(5%)Tj
T*
(2%)Tj
ET
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 493.92 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
117.36 493.92 170.16 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 493.92 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
288.24 493.92 246.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 493.92 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 434.16 0.72 59.76 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 434.16 0.72 59.76 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 434.16 0.72 59.76 re
f
Q
BT
/TT1 9.12 Tf
0.0051 Tc 0.0996 Tw 103.141 387.621 Td
(Hemic and Lymphatic)Tj
/TT0 9.12 Tf
0.0072 Tc 0.0974 Tw T*
(     Anemia)Tj
0.0108 Tc 0 Tw 282 0.48 Td
(2%)Tj
ET
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 433.44 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
117.36 433.44 170.16 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 433.44 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
288.24 433.44 246.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 433.44 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 405.36 0.72 28.08 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 405.36 0.72 28.08 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 405.36 0.72 28.08 re
f
Q
BT
/TT1 9.12 Tf
0.0227 Tc 0.0819 Tw 103.141 358.821 Td
(Metabolic and Nutritional)Tj
/TT0 9.12 Tf
-0.0047 Tc 0.1094 Tw T*
(     Hyperglycemia)Tj
-0.0373 Tc 0.142 Tw T*
(     Peripheral edema)Tj
0.0108 Tc 0 Tw 282 11.04 Td
(1%)Tj
T*
(1%)Tj
ET
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 404.64 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
117.36 404.64 170.16 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 404.64 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
288.24 404.64 246.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 404.64 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 366 0.72 38.64 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 366 0.72 38.64 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 366 0.72 38.64 re
f
Q
BT
/TT1 9.12 Tf
0.0232 Tc 103.141 319.461 Td
(Musculoskeletal)Tj
/TT0 9.12 Tf
0.0031 Tc 0.1016 Tw T*
(     Myalgia)Tj
0.0108 Tc 0 Tw 282 0.48 Td
(1%)Tj
ET
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 365.28 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
117.36 365.28 170.16 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 365.28 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
288.24 365.28 246.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 365.28 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 337.2 0.72 28.08 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 337.2 0.72 28.08 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 337.2 0.72 28.08 re
f
Q
BT
/TT1 9.12 Tf
-0.0356 Tc 103.141 290.661 Td
(Nervous)Tj
/TT0 9.12 Tf
-0.0684 Tc 0.173 Tw T*
(     Dizziness)Tj
0.0108 Tc 0 Tw 282 0.48 Td
(3%)Tj
ET
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 336.48 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
117.36 336.48 170.16 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 336.48 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
288.24 336.48 246.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 336.48 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 308.4 0.72 28.08 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 308.4 0.72 28.08 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 308.4 0.72 28.08 re
f
Q
BT
/TT1 9.12 Tf
-0.0254 Tc 103.141 261.861 Td
(Respiratory)Tj
/TT0 9.12 Tf
-0.0054 Tc 0.1101 Tw T*
(     Pneumonia)Tj
0.0108 Tc 0 Tw 282 0.48 Td
(1%)Tj
ET
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 307.68 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
117.36 307.68 170.16 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 307.68 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
288.24 307.68 246.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 307.68 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 279.6 0.72 28.08 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 279.6 0.72 28.08 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 279.6 0.72 28.08 re
f
Q
BT
/TT1 9.12 Tf
-0.0403 Tc 0.145 Tw 103.141 233.061 Td
(Skin and Appendages)Tj
/TT0 9.12 Tf
-0.0415 Tc 0.1462 Tw T*
(     Rash)Tj
0.0108 Tc 0 Tw 282 0.48 Td
(3%)Tj
ET
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 278.88 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
117.36 278.88 170.16 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 278.88 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
288.24 278.88 246.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 278.88 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 250.8 0.72 28.08 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 250.8 0.72 28.08 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 250.8 0.72 28.08 re
f
Q
BT
/TT1 9.12 Tf
0.0022 Tc 103.141 204.261 Td
(Urogenital)Tj
/TT0 9.12 Tf
0.0422 Tc 0.0624 Tw T*
(     Hematuria \(microscopic\))Tj
0 Tc 0.1046 Tw T*
(    )Tj
-0.0044 Tc 0.1091 Tw T*
(     Urinary retention)Tj
0 Tc 0.1046 Tw T*
(    )Tj
0.0245 Tc 0.0802 Tw T*
(     Urinary tract infection)Tj
0 Tc 0.1046 Tw T*
(    )Tj
0.0108 Tc 0 Tw 282 53.28 Td
(3%)Tj
T*
(4%)Tj
-0.003 Tc -2.64 -21.12 Td
(15%)Tj
ET
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 250.08 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
117.36 250.08 170.16 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 250.08 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
288.24 250.08 246.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 250.08 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 169.2 0.72 80.88 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
287.52 169.2 0.72 80.88 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 169.2 0.72 80.88 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
116.64 168.48 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
117.36 168.48 170.16 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
287.52 168.48 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
288.24 168.48 246.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
534.96 168.48 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 155.76 0.72 12.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 155.04 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
116.64 155.04 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
117.36 155.04 417.6 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 155.76 0.72 12.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 155.04 0.72 0.72 re
f
Q
q
1 0 0 1 -19.979004 -32.618866 cm
1 1 1 rg
534.96 155.04 0.72 0.72 re
f
Q
BT
/TT0 10.08 Tf
-0.0315 Tc 0.1093 Tw 88.021 113.061 Td
(Adverse reactions other than local reactions that occurred in less than \1% of the patients who)Tj
0.0092 Tc 0.0685 Tw 0 -12.24 TD
(received Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0069 Tc 0.0709 Tw ( intravesically in clinical trials are listed below.  This list includes\ only adverse)Tj
-0.0285 Tc 0.1062 Tw 0 -11.52 TD
(reactions that were suspected of being related to treatment.)Tj
/TT3 10.08 Tf
-0.0277 Tc 0.1055 Tw 0 -23.04 TD
(Digestive System)Tj
/TT0 10.08 Tf
-0.0338 Tc 0.1116 Tw (: Tenesmus.)Tj
/TT3 10.08 Tf
-0.0503 Tc 0.128 Tw 0 -23.28 TD
(Metabolic and Nutritional)Tj
/TT0 10.08 Tf
-0.0297 Tc 0.1075 Tw (: Nonprotein nitrogen increased.)Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS0 gs
/Fm0 Do
Q
EMC 

endstreamendobj232 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240612153311-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 248 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 261 0 R/LastModified(D:20240612153311-04'00')/Private/Header>>>>/Resources 262 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj145 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 144 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im19/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj151 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 150 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im20/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj150 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj144 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj262 0 obj<</Font 263 0 R>>endobj263 0 obj<</ArialRoundedMTBold 252 0 R>>endobj261 0 obj<</Length 717>>stream
Ôªø<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj231 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj229 0 obj[/Indexed/DeviceRGB 15 144 0 R]endobj230 0 obj[/Indexed/DeviceRGB 15 150 0 R]endobj223 0 obj<</Length 17700>>stream
q
1 0 0 1 -20.376373 -97.178894 cm
0 0 612 792 re
W n
1 0 0 1 20.376373 97.178894 cm
BT
0 0 0 rg
/TT0 7.92 Tf
0.0166 Tc -0.0583 Tw 87.624 651.141 Td
(ANTHRA PHARMACEUTICALS, INC.)Tj
-0.032 Tc -0.0098 Tw 0 -9.36 TD
(AD 32)Tj
-0.0421 Tc 0 Tw T*
(NDA 20,892)Tj
0 Tc -0.0418 Tw 425.52 0 Td
( )Tj
-0.0835 Tc 0 Tw (7)Tj
ET
q
437.76 0 0 -7.68 87.143627 631.461106 cm
/Im0 Do
Q
q
1 0 0 1 -20.376373 -97.178894 cm
108 726.96 432 0.96 re
f
Q
q
437.76 0 0 -7.68 87.143627 631.461106 cm
/Im1 Do
Q
q
1 0 0 1 -20.376373 -97.178894 cm
0 0 0 RG
0.24 w 1 j 1 J 
108 726.96 432 0.96 re
S
Q
BT
/TT1 10.08 Tf
-0.0135 Tc 0.0913 Tw 282.504 570.981 Td
(TABLE 1)Tj
-0.0353 Tc 0.1131 Tw -114.72 -12 Td
(Occurrence of Local Adverse Reactions Before and After)Tj
-0.0151 Tc 0.0928 Tw 4.56 -12.48 Td
(Intravesical Administration of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0 Tc 0.0778 Tw ( )Tj
/TT1 10.08 Tf
-0.0432 Tc 0.1209 Tw ( \(% of Patients\))Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 683.76 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 683.76 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 683.76 431.28 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 683.76 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 683.76 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 638.4 0.72 45.36 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 638.4 0.72 45.36 re
f
Q
BT
/TT1 9.12 Tf
0.0061 Tc 0.0985 Tw 255.624 525.621 Td
(Patients Who Received Multiple-Cycle Treatment Regimen)Tj
0.0116 Tc 0.0931 Tw 92.16 -11.04 Td
(at  800 mg/dose)Tj
/TT1 10.08 Tf
-0.0302 Tc 0 Tw 16.32 -11.76 Td
(\(N=170\))Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
107.52 637.68 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
108.24 637.68 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
264.96 637.68 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
265.68 637.68 273.84 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
539.52 637.68 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 594.72 0.72 42.96 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 594.72 0.72 42.96 re
f
Q
BT
/TT1 9.12 Tf
-0.0142 Tc 93.624 482.661 Td
(Reaction)Tj
0.0154 Tc 0.0892 Tw 180.96 0 Td
(Before Treatment)Tj
0.014 Tc 0.0907 Tw 137.04 0 Td
(During Treatment)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 574.8 0.72 19.92 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 574.8 0.72 19.92 re
f
Q
BT
/TT0 9.12 Tf
-0.0691 Tc 0.1737 Tw 93.624 462.501 Td
(ANY LOCAL BLADDER SYMPTOM)Tj
-0.003 Tc 0 Tw 209.76 0 Td
(45%)Tj
137.28 0 Td
(88%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
107.52 574.08 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
108.24 574.08 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
264.96 574.08 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
265.68 574.08 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
400.08 574.08 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
400.8 574.08 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
539.52 574.08 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 554.64 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 554.64 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 554.64 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 554.64 0.72 19.44 re
f
Q
BT
-0.0292 Tc 0.1339 Tw 93.624 442.341 Td
(Urinary Frequency)Tj
-0.003 Tc 0 Tw 209.76 0 Td
(30%)Tj
137.28 0 Td
(61%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 553.92 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 553.92 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 553.92 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 553.92 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 553.92 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 553.92 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 553.92 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 534.48 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 534.48 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 534.48 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 534.48 0.72 19.44 re
f
Q
BT
0.0075 Tc 93.624 422.181 Td
(Dysuria)Tj
-0.003 Tc 209.76 0 Td
(11%)Tj
137.28 0 Td
(56%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 533.76 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 533.76 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 533.76 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 533.76 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 533.76 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 533.76 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 533.76 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 514.32 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 514.32 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 514.32 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 514.32 0.72 19.44 re
f
Q
BT
-0.0156 Tc 0.1202 Tw 93.624 402.021 Td
(Urinary Urgency)Tj
-0.003 Tc 0 Tw 209.76 0 Td
(27%)Tj
137.28 0 Td
(57%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 513.6 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 513.6 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 513.6 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 513.6 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 513.6 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 513.6 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 513.6 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 494.16 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 494.16 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 494.16 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 494.16 0.72 19.44 re
f
Q
BT
-0.0041 Tc 0.1087 Tw 93.624 381.861 Td
(Bladder Spasm)Tj
0.0108 Tc 0 Tw 212.4 0 Td
(3%)Tj
-0.003 Tc 134.64 0 Td
(31%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 493.44 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 493.44 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 493.44 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 493.44 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 493.44 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 493.44 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 493.44 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 474 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 474 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 474 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 474 0.72 19.44 re
f
Q
BT
0.0198 Tc 93.624 361.701 Td
(Hematuria)Tj
-0.003 Tc 209.76 0 Td
(11%)Tj
137.28 0 Td
(29%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 473.28 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 473.28 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 473.28 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 473.28 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 473.28 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 473.28 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 473.28 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 453.84 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 453.84 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 453.84 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 453.84 0.72 19.44 re
f
Q
BT
-0.0215 Tc 0.1262 Tw 93.624 341.541 Td
(Bladder Pain)Tj
0.0108 Tc 0 Tw 212.4 0 Td
(6%)Tj
-0.003 Tc 134.64 0 Td
(28%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 453.12 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 453.12 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 453.12 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 453.12 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 453.12 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 453.12 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 453.12 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 433.68 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 433.68 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 433.68 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 433.68 0.72 19.44 re
f
Q
BT
-0.0113 Tc 0.116 Tw 93.624 321.381 Td
(Urinary Incontinence)Tj
0.0108 Tc 0 Tw 212.4 0 Td
(7%)Tj
-0.003 Tc 134.64 0 Td
(22%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 432.96 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 432.96 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 432.96 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 432.96 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 432.96 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 432.96 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 432.96 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 413.52 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 413.52 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 413.52 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 413.52 0.72 19.44 re
f
Q
BT
0.0469 Tc 93.624 301.221 Td
(Cystitis)Tj
0.0108 Tc 212.4 0 Td
(4%)Tj
-0.003 Tc 134.64 0 Td
(15%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 412.8 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 412.8 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 412.8 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 412.8 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 412.8 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 412.8 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 412.8 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 393.36 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 393.36 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 393.36 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 393.36 0.72 19.44 re
f
Q
BT
0.0158 Tc 93.624 281.061 Td
(Nocturia)Tj
0.0108 Tc 212.4 0 Td
(2%)Tj
137.28 0 Td
(7%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 392.64 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 392.64 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 392.64 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 392.64 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 392.64 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 392.64 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 392.64 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 373.2 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 373.2 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 373.2 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 373.2 0.72 19.44 re
f
Q
BT
0.0355 Tc 0.0692 Tw 93.624 260.901 Td
(Local Burning Symptoms -)Tj
-0.0636 Tc 0.1683 Tw 0 -10.56 TD
(   Procedure Related)Tj
0.0108 Tc 0 Tw 212.4 0 Td
(0%)Tj
137.28 0 Td
(5%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 372.48 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 372.48 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 372.48 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 372.48 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 372.48 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 372.48 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 372.48 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 342.48 0.72 30 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 342.48 0.72 30 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 342.48 0.72 30 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 342.48 0.72 30 re
f
Q
BT
-0.0033 Tc 0.108 Tw 93.624 230.181 Td
(Urethral Pain)Tj
0.0108 Tc 0 Tw 212.4 0 Td
(0%)Tj
137.28 0 Td
(3%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 341.76 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 341.76 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 341.76 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 341.76 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 341.76 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 341.76 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 341.76 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 322.32 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 322.32 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 322.32 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 322.32 0.72 19.44 re
f
Q
BT
-0.0092 Tc 0.1139 Tw 93.624 210.021 Td
(Pelvic Pain)Tj
0.0108 Tc 0 Tw 212.4 0 Td
(1%)Tj
137.28 0 Td
(1%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 321.6 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 321.6 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 321.6 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 321.6 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 321.6 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 321.6 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 321.6 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 302.16 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 302.16 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 302.16 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 302.16 0.72 19.44 re
f
Q
BT
0.0313 Tc 0.0733 Tw 93.624 189.861 Td
(Hematuria \(Gross\))Tj
0.0108 Tc 0 Tw 212.4 0 Td
(0%)Tj
137.28 0 Td
(1%)Tj
ET
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 301.44 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 301.44 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 301.44 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
265.68 301.44 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 301.44 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.8 301.44 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 301.44 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 282 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
264.96 282 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
400.08 282 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 282 0.72 19.44 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
107.52 281.28 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
108.24 281.28 156.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
264.96 281.28 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
265.68 281.28 134.4 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
400.08 281.28 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
400.8 281.28 138.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
539.52 281.28 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 261.6 0.72 19.68 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 260.88 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
107.52 260.88 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
108.24 260.88 431.28 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 261.6 0.72 19.68 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 260.88 0.72 0.72 re
f
Q
q
1 0 0 1 -20.376373 -97.178894 cm
1 1 1 rg
539.52 260.88 0.72 0.72 re
f
Q
BT
/TT0 10.08 Tf
-0.018 Tc 0.0958 Tw 87.624 154.341 Td
(Most systemic adverse events associated with use of Valstar have been mi\ld in nature and self-)Tj
-0.0026 Tc 0.0804 Tw 0 -11.52 TD
(limited, resolving within 24 hours after drug administration.  Table 2 d\isplays the adverse events)Tj
-0.0195 Tc 0.0972 Tw T*
(other than local bladder symptoms that occurred in 1% or more of the 230\ patients who received)Tj
-0.0373 Tc 0.1151 Tw 0 -12.24 TD
(at least one dose of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0047 Tc 0.0731 Tw (  \(200 to 900 mg\) in a clinical trial. It can not be determined)Tj
-0.0399 Tc 0.1176 Tw 0 -11.52 TD
(whether these events are drug-related.)Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS0 gs
/Fm0 Do
Q
EMC 

endstreamendobj227 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240612153311-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 248 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 264 0 R/LastModified(D:20240612153311-04'00')/Private/Header>>>>/Resources 265 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj130 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 129 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im17/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj136 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 135 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im18/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj135 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj129 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj265 0 obj<</Font 266 0 R>>endobj266 0 obj<</ArialRoundedMTBold 252 0 R>>endobj264 0 obj<</Length 717>>stream
Ôªø<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj226 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj224 0 obj[/Indexed/DeviceRGB 15 129 0 R]endobj225 0 obj[/Indexed/DeviceRGB 15 135 0 R]endobj4 0 obj<</Contents 267 0 R/Parent 5 0 R/Resources<</ColorSpace<</CS0 268 0 R/CS1 269 0 R>>/ExtGState<</GS0 270 0 R>>/Font<</TT0 6 0 R/TT1 19 0 R/TT2 20 0 R/TT3 22 0 R/TT4 25 0 R/TT5 43 0 R>>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/XObject<</Fm0 271 0 R/Im0 8 0 R/Im1 14 0 R/Im2 27 0 R/Im3 29 0 R/Im4 33 0 R/Im5 37 0 R>>>>/Type/Page>>endobj48 0 obj<</Contents 272 0 R/Parent 5 0 R/Resources<</ColorSpace<</CS0 273 0 R/CS1 274 0 R>>/ExtGState<</GS0 275 0 R>>/Font<</TT0 6 0 R/TT1 19 0 R/TT2 25 0 R/TT3 22 0 R/TT4 63 0 R/TT5 64 0 R>>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<</Fm0 276 0 R/Im0 50 0 R/Im1 56 0 R>>>>/Type/Page>>endobj67 0 obj<</Contents 277 0 R/Parent 5 0 R/Resources<</ColorSpace<</CS0 278 0 R/CS1 279 0 R>>/ExtGState<</GS0 280 0 R>>/Font<</TT0 6 0 R/TT1 19 0 R/TT2 25 0 R/TT3 22 0 R>>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<</Fm0 281 0 R/Im0 69 0 R/Im1 75 0 R>>>>/Type/Page>>endobj82 0 obj<</Contents 282 0 R/Parent 5 0 R/Resources<</ColorSpace<</CS0 283 0 R/CS1 284 0 R>>/ExtGState<</GS0 285 0 R>>/Font<</TT0 6 0 R/TT1 19 0 R/TT2 22 0 R/TT3 25 0 R/TT4 43 0 R>>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<</Fm0 286 0 R/Im0 84 0 R/Im1 90 0 R>>>>/Type/Page>>endobj97 0 obj<</Contents 287 0 R/Parent 5 0 R/Resources<</ColorSpace<</CS0 288 0 R/CS1 289 0 R>>/ExtGState<</GS0 290 0 R>>/Font<</TT0 6 0 R/TT1 19 0 R/TT2 25 0 R/TT3 22 0 R>>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<</Fm0 291 0 R/Im0 99 0 R/Im1 105 0 R>>>>/Type/Page>>endobj112 0 obj<</Contents 292 0 R/Parent 5 0 R/Resources<</ColorSpace<</CS0 293 0 R/CS1 294 0 R>>/ExtGState<</GS0 295 0 R>>/Font<</TT0 6 0 R/TT1 19 0 R/TT2 25 0 R/TT3 22 0 R>>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<</Fm0 296 0 R/Im0 114 0 R/Im1 120 0 R>>>>/Type/Page>>endobj292 0 obj<</Length 5887>>stream
q
1 0 0 1 -22.85907 -87.69873 cm
0 0 612 792 re
W n
1 0 0 1 22.85907 87.69873 cm
BT
0 0 0 rg
/TT0 7.92 Tf
0.0166 Tc -0.0583 Tw 85.141 660.621 Td
(ANTHRA PHARMACEUTICALS, INC.)Tj
-0.032 Tc -0.0098 Tw 0 -9.36 TD
(AD 32)Tj
-0.0421 Tc 0 Tw T*
(NDA 20,892)Tj
0 Tc -0.0418 Tw 425.52 0 Td
( )Tj
-0.0835 Tc 0 Tw (6)Tj
ET
q
437.76 0 0 -7.68 84.66093 640.94127 cm
/Im0 Do
Q
q
1 0 0 1 -22.85907 -87.69873 cm
108 726.96 432 0.96 re
f
Q
q
437.76 0 0 -7.68 84.66093 640.94127 cm
/Im1 Do
Q
q
1 0 0 1 -22.85907 -87.69873 cm
0 0 0 RG
0.24 w 1 j 1 J 
108 726.96 432 0.96 re
S
Q
BT
/TT1 10.08 Tf
-0.0176 Tc 85.141 601.341 Td
(Pregnancy:)Tj
/TT0 10.08 Tf
-0.0232 Tc 0.1009 Tw 0 -11.76 TD
(Pregnancy Category C.  Valrubicin can cause fetal harm if a pregnant wom\an is exposed to the)Tj
-0.0118 Tc 0.0896 Tw 0 -11.52 TD
(drug systemically.  Such exposure could occur after perforation of the u\rinary bladder during)Tj
-0.0031 Tc 0.0808 Tw T*
(valrubicin therapy.  Daily intravenous doses of 12 mg/kg \(about one six\th of the recommended)Tj
0.0039 Tc 0.0739 Tw T*
(human intravesical dose on a mg/m)Tj
/TT0 6.48 Tf
-0.0029 Tc 0 Tw 159.6 5.04 Td
(2)Tj
/TT0 10.08 Tf
0.0011 Tc 0.0767 Tw 3.6 -5.04 Td
( basis\) given to rats during fetal development caused fetal)Tj
-0.0052 Tc 0.083 Tw -163.2 -11.52 Td
(malformations.  A dose of 24 mg/kg \(about one third the recommended hum\an intravesical dose)Tj
0.0324 Tc 0.0454 Tw T*
(on a mg/m)Tj
/TT0 6.48 Tf
-0.0029 Tc 0 Tw 48 5.04 Td
(2)Tj
/TT0 10.08 Tf
-0.032 Tc 0.1098 Tw 3.6 -5.04 Td
( basis\) caused numerous, severe alterations in the skull and skeleton o\f the)Tj
-0.0402 Tc 0.118 Tw -51.6 -11.52 Td
(developing fetuses.  This dose also caused an increase in fetal resorpti\ons and a decrease in)Tj
0 Tc 0.0785 Tw T*
(viable fetuses. Thus, valrubicin is embryotoxic and teratogenic.  There \are no preclinical studies)Tj
0.013 Tc 0.0648 Tw T*
(of the effects of intravesical valrubicin on fetal development and no ad\equate and well controlled)Tj
-0.001 Tc 0.0787 Tw T*
(studies of valrubicin in pregnant women.  If valrubicin is used during p\regnancy, or if the patient)Tj
-0.0188 Tc 0.0965 Tw T*
(becomes pregnant while receiving this drug, the patient should be appriz\ed of the potential)Tj
-0.014 Tc 0.0918 Tw T*
(hazard to the fetus.  It should be used during pregnancy only if the pot\ential benefit justifies the)Tj
-0.0045 Tc 0.0822 Tw T*
(potential risk to the fetus.  Women who might become pregnant should be \advised to avoid)Tj
-0.037 Tc 0.1147 Tw T*
(doing so during therapy with Valstar.)Tj
/TT1 10.08 Tf
0 Tc 0.0778 Tw 0 -23.28 TD
(Nursing Mothers:)Tj
/TT0 10.08 Tf
-0.0511 Tc 0.1288 Tw 0 -12.48 TD
(It is not known whether Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0 Tc 0.0776 Tw ( is excreted in human milk. Nevertheless, the drug is highly)Tj
-0.0059 Tc 0.0836 Tw 0 -12.24 TD
(lipophilic and any exposure of infants to Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0283 Tc 0.106 Tw ( could pose serious health risks.  Women)Tj
-0.0144 Tc 0.0922 Tw T*
(should discontinue nursing before the initiation of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0224 Tc 0.1001 Tw ( therapy.)Tj
/TT1 10.08 Tf
-0.0263 Tc 0.104 Tw 0 -23.28 TD
(Pediatric Use:)Tj
/TT0 10.08 Tf
-0.0063 Tc 0.084 Tw 0 -11.76 TD
(Safety and effectiveness in pediatric patients have not been established\.)Tj
/TT1 10.08 Tf
-0.0325 Tc 0.1103 Tw 0 -23.28 TD
(Geriatric Use:)Tj
/TT0 10.08 Tf
-0.0319 Tc 0.1097 Tw 0 -11.76 TD
(Because carcinoma )Tj
/TT3 10.08 Tf
-0.0411 Tc 0.1189 Tw (in situ)Tj
/TT0 10.08 Tf
-0.0035 Tc 0.0813 Tw ( of the bladder generally occurs in older individuals, 85% of the)Tj
-0.0071 Tc 0.0848 Tw 0 -12.48 TD
(patients enrolled in the clinical studies of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0388 Tc 0.1166 Tw (  were more than 60 years of age \(49% of the)Tj
-0.0157 Tc 0.0935 Tw 0 -11.52 TD
(patients were more than 70 years of age\).  In the primary efficacy stud\ies, the mean age of the)Tj
-0.0381 Tc 0.1159 Tw T*
(population was 69.5 years.  There are no  specific precautions regarding\ use of Valstar product)Tj
-0.0343 Tc 0.1121 Tw T*
(in geriatric patients who are otherwise in good health. )Tj
/TT1 10.08 Tf
-0.0355 Tc 0.1133 Tw 0 -35.28 TD
(ADVERSE REACTIONS)Tj
/TT0 10.08 Tf
0.0055 Tc 0.0723 Tw 0 -24 TD
(Approximately 84% of patients who received intravesical Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0038 Tc 0.074 Tw (  in clinical studies)Tj
0.006 Tc 0.0717 Tw 0 -11.52 TD
(experienced local adverse events, but approximately half of the patients\ reported  irritable)Tj
-0.0193 Tc 0.097 Tw 0 -12.24 TD
(bladder symptoms prior to treatment.  The local adverse reactions associ\ated with Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0 Tc 0.0778 Tw ( )Tj
-0.0061 Tc 0.0838 Tw 0 -11.52 TD
(usually occur during or shortly after instillation and resolve within 1 \to 7 days after the instillate is)Tj
0.0272 Tc 0.0506 Tw T*
(removed from the bladder.  )Tj
-0.0178 Tc 0.0956 Tw 0 -23.04 TD
(Table 1 displays the frequency of the local adverse experiences at basel\ine and during treatment)Tj
-0.0337 Tc 0.1115 Tw 0 -12.24 TD
( among 170 patients who received 800 mg doses of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0296 Tc 0.0481 Tw (  in a multiple-cycle treatment)Tj
-0.007 Tc 0.0848 Tw 0 -11.52 TD
(regimen.   Only 7 of 143 patients who were scheduled to receive six dose\s failed to receive all of)Tj
-0.033 Tc 0.1108 Tw T*
(the planned doses because of the occurrence of local bladder symptoms.)Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS0 gs
/Fm0 Do
Q
EMC 

endstreamendobj296 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240612153311-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 248 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 297 0 R/LastModified(D:20240612153311-04'00')/Private/Header>>>>/Resources 298 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj114 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 113 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im15/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj120 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 119 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im16/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj119 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj113 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj298 0 obj<</Font 299 0 R>>endobj299 0 obj<</ArialRoundedMTBold 252 0 R>>endobj297 0 obj<</Length 717>>stream
Ôªø<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj295 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj293 0 obj[/Indexed/DeviceRGB 15 113 0 R]endobj294 0 obj[/Indexed/DeviceRGB 15 119 0 R]endobj287 0 obj<</Length 5543>>stream
q
1 0 0 1 -21.711304 -115.058838 cm
0 0 612 792 re
W n
1 0 0 1 21.711304 115.058838 cm
BT
0 0 0 rg
/TT0 7.92 Tf
0.0166 Tc -0.0583 Tw 86.289 633.261 Td
(ANTHRA PHARMACEUTICALS, INC.)Tj
-0.032 Tc -0.0098 Tw 0 -9.36 TD
(AD 32)Tj
-0.0421 Tc 0 Tw T*
(NDA 20,892)Tj
0 Tc -0.0418 Tw 425.52 0 Td
( )Tj
-0.0835 Tc 0 Tw (5)Tj
ET
q
437.76 0 0 -7.68 85.808696 613.581162 cm
/Im0 Do
Q
q
1 0 0 1 -21.711304 -115.058838 cm
108 726.96 432 0.96 re
f
Q
q
437.76 0 0 -7.68 85.808696 613.581162 cm
/Im1 Do
Q
q
1 0 0 1 -21.711304 -115.058838 cm
0 0 0 RG
0.24 w 1 j 1 J 
108 726.96 432 0.96 re
S
Q
BT
/TT1 10.08 Tf
-0.0147 Tc 86.289 573.981 Td
(PRECAUTIONS)Tj
-0.0118 Tc 0 -24 TD
(General:)Tj
/TT0 10.08 Tf
-0.0124 Tc 0.0901 Tw 0 -12.48 TD
(Aseptic techniques must be used during administration of intravesical Va\lstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0546 Tc 0.0232 Tw (  to avoid)Tj
-0.0078 Tc 0.0856 Tw 0 -11.52 TD
(introducing contaminants into the urinary tract or traumatizing unduly t\he urinary mucosa.)Tj
/TT1 10.08 Tf
0.0068 Tc 0.071 Tw 0 -23.28 TD
(Information for Patients:)Tj
/TT0 10.08 Tf
-0.0413 Tc 0.119 Tw 0 -11.76 TD
(Patients should be informed that Valstar has been shown to induce comple\te responses in only)Tj
-0.0045 Tc 0.0823 Tw 0 -11.52 TD
(about 1 in 5 patients, and that delaying cystectomy could lead to develo\pment of metastatic)Tj
-0.0185 Tc 0.0962 Tw T*
(bladder cancer, which is lethal. They should discuss with their physicia\n the relative risk of)Tj
-0.0276 Tc 0.1053 Tw T*
(cystectomy versus the risk of metastatic bladder cancer \(see CLINICAL T\RIALS\) and be aware)Tj
-0.0288 Tc 0.1066 Tw T*
(that the risk increases the longer cystectomy is delayed in the presence\ of persisting CIS.)Tj
0.006 Tc 0.0718 Tw 0 -23.76 TD
(Patients should be informed that the major acute toxicities from Valstar\)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0024 Tc 0.0753 Tw (  are related to irritable)Tj
-0.0066 Tc 0.0844 Tw 0 -12.24 TD
(bladder symptoms that may occur during instillation and retention of Val\star)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0384 Tc 0.0394 Tw (  and for a limited)Tj
0 Tc 0.0773 Tw 0 -11.52 TD
(period following voiding.  For the first 24 hours following administrati\on, red-tinged urine is)Tj
-0.0257 Tc 0.1034 Tw T*
(typical.  Patients should report prolonged irritable bladder symptoms or\ prolonged passage of)Tj
0.0042 Tc 0.0736 Tw T*
(red-colored urine immediately to their physician.)Tj
-0.0044 Tc 0.0821 Tw 0 -23.04 TD
(Women of child-bearing potential should be advised not to become pregnan\t during treatment.)Tj
0.0089 Tc 0.0689 Tw 0 -11.52 TD
(Men should be advised to refrain from engaging in procreative activities\ while receiving therapy)Tj
-0.0301 Tc 0.1079 Tw 0 -12.24 TD
(with Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0056 Tc 0.0722 Tw (.  All patients of reproductive age should be advised to use an effectiv\e)Tj
-0.0114 Tc 0.0892 Tw 0 -11.52 TD
(contraception method during the treatment period.)Tj
/TT1 10.08 Tf
-0.0107 Tc 0.0884 Tw 0 -23.28 TD
(Irritable Bladder Symptoms:)Tj
/TT0 10.08 Tf
-0.0241 Tc 0 Tw 0 -12.48 TD
(Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
-0.0241 Tc 0.1019 Tw (  should be used with caution in patients with severe irritable bladder \symptoms. )Tj
-0.0118 Tc 0.0895 Tw 0 -11.52 TD
(Bladder spasm and spontaneous discharge of the intravesical instillate m\ay occur; clamping of)Tj
-0.0087 Tc 0.0864 Tw T*
(the urinary catheter is not advised and, if performed, should be execute\d under medical)Tj
-0.0204 Tc 0.0982 Tw T*
(supervision and with caution.)Tj
/TT1 10.08 Tf
0 Tc 0.0782 Tw 0 -23.28 TD
(Drug Interactions:)Tj
/TT0 10.08 Tf
-0.0393 Tc 0.117 Tw 0 -12.48 TD
(Because systemic exposure to Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0159 Tc 0.0618 Tw (  is negligible following intravesical administration, the)Tj
-0.0285 Tc 0.1063 Tw 0 -11.52 TD
(potential for drug interactions is low.  No drug interaction studies wer\e conducted.)Tj
/TT1 10.08 Tf
-0.0012 Tc 0.0789 Tw 0 -23.28 TD
(Carcinogenesis, Mutagenesis, Impairment of Fertility:)Tj
/TT0 10.08 Tf
-0.0044 Tc 0.0822 Tw 0 -12.48 TD
(The carcinogenic potential of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0477 Tc 0.1254 Tw ( has not been evaluated, but the drug does cause damage)Tj
-0.0331 Tc 0.1109 Tw 0 -12.24 TD
(to DNA )Tj
/TT3 10.08 Tf
-0.0348 Tc 0.1125 Tw (in vitro)Tj
/TT0 10.08 Tf
-0.0114 Tc 0.0892 Tw (.  Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.036 Tc 0.1137 Tw (  was mutagenic in )Tj
/TT3 10.08 Tf
-0.0348 Tc 0.1125 Tw (in vitro)Tj
/TT0 10.08 Tf
-0.1014 Tc 0.1792 Tw ( assays in )Tj
/TT3 10.08 Tf
-0.0505 Tc 0.1283 Tw (Salmonella typhimurium)Tj
/TT0 10.08 Tf
-0.0845 Tc 0.1622 Tw ( and)Tj
/TT3 10.08 Tf
-0.0489 Tc 0.1267 Tw 0 -12.48 TD
(Escherichia coli)Tj
/TT0 10.08 Tf
-0.0114 Tc 0.0892 Tw (.  Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0314 Tc 0.1091 Tw ( was clastogenic in the chromosomal aberration assay in CHO cells. )Tj
0.0091 Tc 0.0687 Tw T*
(Studies of the effects of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0224 Tc 0.0554 Tw ( on male or female fertility have not been done.)Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS0 gs
/Fm0 Do
Q
EMC 

endstreamendobj291 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240612153311-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 248 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 300 0 R/LastModified(D:20240612153311-04'00')/Private/Header>>>>/Resources 301 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj99 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 98 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im13/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj105 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 104 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im14/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj104 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj98 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj301 0 obj<</Font 302 0 R>>endobj302 0 obj<</ArialRoundedMTBold 252 0 R>>endobj300 0 obj<</Length 717>>stream
Ôªø<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj290 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj288 0 obj[/Indexed/DeviceRGB 15 98 0 R]endobj289 0 obj[/Indexed/DeviceRGB 15 104 0 R]endobj282 0 obj<</Length 4932>>stream
q
1 0 0 1 -21.658539 -87.458862 cm
0 0 612 792 re
W n
1 0 0 1 21.658539 87.458862 cm
BT
0 0 0 rg
/TT0 7.92 Tf
0.0166 Tc -0.0583 Tw 86.341 660.861 Td
(ANTHRA PHARMACEUTICALS, INC.)Tj
-0.032 Tc -0.0098 Tw 0 -9.36 TD
(AD 32)Tj
-0.0421 Tc 0 Tw T*
(NDA 20,892)Tj
0 Tc -0.0418 Tw 425.52 0 Td
( )Tj
-0.0835 Tc 0 Tw (4)Tj
ET
q
437.76 0 0 -7.68 85.861461 641.181138 cm
/Im0 Do
Q
q
1 0 0 1 -21.658539 -87.458862 cm
108 726.96 432 0.96 re
f
Q
q
437.76 0 0 -7.68 85.861461 641.181138 cm
/Im1 Do
Q
q
1 0 0 1 -21.658539 -87.458862 cm
0 0 0 RG
0.24 w 1 j 1 J 
108 726.96 432 0.96 re
S
Q
BT
/TT0 10.08 Tf
-0.0113 Tc 0.089 Tw 86.341 601.821 Td
(. In the 10 patients documented to have invasive bladder cancer or metas\tatic disease, the delay)Tj
-0.0108 Tc 0.0885 Tw 0 -11.52 TD
(between the time of treatment failure \(when cystectomy should have been\ performed\) and)Tj
-0.0169 Tc 0.0947 Tw T*
(cystectomy or documentation of advanced bladder cancer was a median of 1\7.5 months.)Tj
/TT1 10.08 Tf
-0.042 Tc 0.1197 Tw 0 -34.8 TD
(INDICATIONS AND USAGE)Tj
/TT0 10.08 Tf
-0.0241 Tc 0 Tw 0 -23.28 TD
(Valstar)Tj
/TT0 6.48 Tf
0.0014 Tc 31.2 5.04 Td
(TM)Tj
/TT0 10.08 Tf
0.0139 Tc 0.0638 Tw 9.36 -5.04 Td
( is indicated for intravesical therapy of  BCG-refractory carcinoma )Tj
/TT2 10.08 Tf
-0.0411 Tc 0.1189 Tw (in situ )Tj
/TT0 10.08 Tf
0.0145 Tc 0.0632 Tw (\(CIS\) of the)Tj
-0.0196 Tc 0.0974 Tw -40.56 -11.76 Td
(urinary bladder  in patients for whom immediate cystectomy would be asso\ciated with)Tj
0.0156 Tc 0.0622 Tw 0 -11.52 TD
(unacceptable morbidity or mortality.)Tj
/TT1 10.08 Tf
-0.009 Tc 0 Tw 0 -23.76 TD
(CONTRAINDICATIONS)Tj
/TT0 10.08 Tf
-0.0241 Tc 0 -24 TD
(Valstar)Tj
/TT3 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
-0.0199 Tc 0.0976 Tw ( is contraindicated in patients with known hypersensitivity to anthracyc\lines or)Tj
-0.0278 Tc 0 Tw 0 -11.52 TD
(Cremophor)Tj
/TT4 10.08 Tf
0 Tc (7)Tj
/TT0 10.08 Tf
0.0127 Tc 0.0651 Tw ( EL \(polyoxyethyleneglycol triricinoleate\).)Tj
-0.0124 Tc 0.0902 Tw 0 -23.76 TD
(Patients with concurrent urinary tract infections should not receive Val\star)Tj
/TT3 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0778 Tc (.)Tj
-0.0241 Tc T*
(Valstar)Tj
/TT3 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
-0.0144 Tc 0.0922 Tw ( should not be administered to a patient with a small bladder capacity, \i.e., unable to)Tj
0.0137 Tc 0.0641 Tw 0 -11.52 TD
(tolerate a 75 mL instillation.)Tj
/TT1 10.08 Tf
-0.0693 Tc 0 Tw 0 -34.8 TD
(WARNINGS)Tj
/TT0 10.08 Tf
-0.0387 Tc 0.1165 Tw 0 -23.28 TD
(Patients should be informed that Valstar has been shown to induce comple\te response in only)Tj
-0.0148 Tc 0.0926 Tw 0 -11.52 TD
(about 1 in 5 patients with BCG-refractory CIS, and that delaying cystect\omy could lead to)Tj
0.0077 Tc 0.07 Tw T*
(development of metastatic bladder cancer, which is lethal.  The exact ri\sk of developing)Tj
-0.0129 Tc 0.0907 Tw T*
(metastatic bladder cancer from such a delay may be difficult to assess \(\See CLINICAL TRIALS\))Tj
-0.0309 Tc 0.1087 Tw 0 -11.76 TD
(but increases the longer cystectomy is delayed in the presence of persis\ting CIS.)Tj
/TT1 10.08 Tf
0.0062 Tc 0.0716 Tw (  If there is not)Tj
-0.0208 Tc 0.0985 Tw 0 -12 TD
(a complete response of CIS to treatment after 3 months or if CIS recurs,\ cystectomy must)Tj
-0.0133 Tc 0.091 Tw T*
(be reconsidered)Tj
/TT0 10.08 Tf
0.0778 Tc 0 Tw (.)Tj
-0.0241 Tc 0 -24 TD
(Valstar)Tj
/TT3 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
-0.0331 Tc 0.1109 Tw ( should not be administered to patients with a perforated bladder or to \those in whom)Tj
-0.0179 Tc 0.0957 Tw 0 -11.52 TD
(the integrity of the bladder mucosa has been compromised \(see PRECAUTIO\NS and Clinical)Tj
-0.0035 Tc 0.0813 Tw T*
(Pharmacology, Pharmacokinetics Figure 2\).)Tj
-0.0334 Tc 0.1111 Tw 0 -23.76 TD
(In order to avoid possible dangerous systemic exposure to Valstar)Tj
/TT3 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.026 Tc 0.1038 Tw ( for the patients undergoing)Tj
-0.024 Tc 0.1018 Tw 0 -11.52 TD
(transurethral resection of the bladder, the status of the bladder should\ be evaluated before the)Tj
0.0087 Tc 0.0691 Tw 0 -12.24 TD
(intravesical instillation of drug. In case of bladder perforation, the a\dministration of Valstar)Tj
/TT3 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0346 Tc 0.1124 Tw 0 -11.52 TD
(should be delayed until bladder integrity has been restored.)Tj
-0.0241 Tc 0 Tw 0 -35.28 TD
(Valstar)Tj
/TT3 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
-0.0234 Tc 0.1011 Tw (  should be administered under the supervision of a physician experience\d in the use of)Tj
-0.0097 Tc 0.0875 Tw 0 -11.52 TD
(intravesical cancer chemotherapeutic agents.)Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS0 gs
/Fm0 Do
Q
EMC 

endstreamendobj286 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240612153311-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 248 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 303 0 R/LastModified(D:20240612153311-04'00')/Private/Header>>>>/Resources 304 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj84 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 83 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im11/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj90 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 89 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im12/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj89 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj83 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj304 0 obj<</Font 305 0 R>>endobj305 0 obj<</ArialRoundedMTBold 252 0 R>>endobj303 0 obj<</Length 717>>stream
Ôªø<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj285 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj283 0 obj[/Indexed/DeviceRGB 15 83 0 R]endobj284 0 obj[/Indexed/DeviceRGB 15 89 0 R]endobj277 0 obj<</Length 11106>>stream
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 612 792 re
W n
1 0 0 1 21.553223 35.498901 cm
BT
0 0 0 rg
/TT0 7.92 Tf
0.0166 Tc -0.0583 Tw 86.447 712.821 Td
(ANTHRA PHARMACEUTICALS, INC.)Tj
-0.032 Tc -0.0098 Tw 0 -9.36 TD
(AD 32)Tj
-0.0421 Tc 0 Tw T*
(NDA 20,892)Tj
0 Tc -0.0418 Tw 425.52 0 Td
( )Tj
-0.0835 Tc 0 Tw (3)Tj
ET
q
437.76 0 0 -7.68 85.966777 693.141099 cm
/Im0 Do
Q
q
1 0 0 1 -21.553223 -35.498901 cm
108 726.96 432 0.96 re
f
Q
q
437.76 0 0 -7.68 85.966777 693.141099 cm
/Im1 Do
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
108 726.96 432 0.96 re
S
Q
q
1 0 0 1 -21.553223 -35.498901 cm
108 513.84 330 184.8 re
W n
1 1 1 rg
0 0 0 RG
1.2 w 1 j 1 J 
114.72 504.24 324.96 181.2 re
h
B
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 563.52 cm
0 0 m
268.56 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 572.16 cm
0 0 m
268.56 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 581.28 cm
0 0 m
268.56 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 590.16 cm
0 0 m
268.56 -0.24 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 599.28 cm
0 0 m
268.56 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 608.4 cm
0 0 m
268.56 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 617.04 cm
0 0 m
268.56 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 626.4 cm
0 0 m
268.56 -0.24 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 635.04 cm
0 0 m
268.56 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 644.16 cm
0 0 m
268.56 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
166.32 554.16 268.8 90 re
S
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0.6 0.6 1 rg
0 0 0 RG
0.48 w 1 j 1 J 
182.4 554.16 21.36 0.72 re
h
B
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0.6 0.6 1 rg
0 0 0 RG
0.48 w 1 j 1 J 
235.92 554.16 21.84 1.92 re
h
B
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0.6 0.6 1 rg
0 0 0 RG
0.48 w 1 j 1 J 
289.92 554.16 21.36 3.6 re
h
B
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0.6 0.6 1 rg
0 0 0 RG
0.48 w 1 j 1 J 
343.44 554.16 22.08 82.56 re
h
B
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0.6 0.6 1 rg
0 0 0 RG
0.48 w 1 j 1 J 
397.44 554.16 21.6 53.76 re
h
B
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 644.16 cm
0 0 m
0 -89.76 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 164.16 554.4 cm
0 0 m
2.16 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 164.16 563.52 cm
0 0 m
2.16 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 164.16 572.16 cm
0 0 m
2.16 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 164.16 581.28 cm
0 0 m
2.16 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 164.16 590.16 cm
0 0 m
2.16 -0.24 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 164.16 599.28 cm
0 0 m
2.16 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 164.16 608.4 cm
0 0 m
2.16 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 164.16 617.04 cm
0 0 m
2.16 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 164.16 626.4 cm
0 0 m
2.16 -0.24 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 164.16 635.04 cm
0 0 m
2.16 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 164.16 644.16 cm
0 0 m
2.16 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 554.4 cm
0 0 m
268.56 0 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 166.32 552.48 cm
0 0 m
0 1.92 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 219.84 552.48 cm
0 0 m
0 1.92 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 273.84 552.48 cm
0 0 m
0 1.92 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 327.36 552.48 cm
0 0 m
0 1.92 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 381.36 552.48 cm
0 0 m
0 1.92 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
0.24 w 1 j 1 J 
q 1 0 0 1 434.88 552.48 cm
0 0 m
0.24 1.92 l
S
Q
Q
q
1 0 0 1 -21.553223 -35.498901 cm
150.72 668.16 278.64 10.08 re
W n
1 0 0 1 21.553223 35.498901 cm
BT
/TT1 8.16 Tf
-0.0974 Tc 0.1089 Tw 129.167 633.621 Td
(Comparison of Mean AUC Values 0-6 Hours in )Tj
ET
Q
q
1 0 0 1 -21.553223 -35.498901 cm
150.72 668.16 278.64 10.08 re
W n
1 0 0 1 21.553223 35.498901 cm
BT
/TT1 8.16 Tf
-0.0778 Tc 0.0894 Tw 306.527 633.621 Td
(Valstar Clinical Studies)Tj
ET
Q
BT
/TT0 6 Tf
0.0312 Tc -0.0192 Tw 165.167 528.021 Td
(78 N=6)Tj
0.03 Tc -0.018 Tw 50.4 0 Td
[(409 N=8)-3360 (788 N=5)]TJ
0.0285 Tc -0.0165 Tw 93.6 79.2 Td
(18382 N=1)Tj
57.6 -28.8 Td
(11975 N=2)Tj
0.024 Tc 0 Tw -230.88 -62.64 Td
(0)Tj
-11.04 9.12 Td
(2000)Tj
0 8.64 TD
(4000)Tj
0 9.12 TD
(6000)Tj
0 8.88 TD
(8000)Tj
-3.6 9.12 Td
(10000)Tj
0 9.12 TD
(12000)Tj
0 8.64 TD
(14000)Tj
0 9.12 TD
(16000)Tj
0 8.88 TD
(18000)Tj
0 9.12 TD
(20000)Tj
0.0278 Tc -0.0158 Tw 36.72 -97.92 Td
(Two weeks)Tj
0.0248 Tc -0.0128 Tw 0 -6.96 TD
( After TUR)Tj
0.0276 Tc 0 Tw T*
(900mg)Tj
0.0108 Tc 0.0012 Tw 49.2 13.92 Td
(Typical TUR)Tj
0.0276 Tc -0.0156 Tw T*
(800 mg)Tj
0.005 Tc 0.007 Tw 51.6 6.96 Td
(Extensive TUR)Tj
0.0276 Tc 0 Tw 0 -7.2 TD
(800mg)Tj
0.0066 Tc 59.04 6.96 Td
(Perforated)Tj
0.0291 Tc 4.08 -7.2 Td
(Bladder)Tj
0.0276 Tc 0 -6.96 TD
(800mg)Tj
0.0198 Tc -0.0078 Tw 48.96 14.4 Td
(IV Infusion)Tj
0.0274 Tc 0 Tw T*
(600mg/m)Tj
/TT0 4.08 Tf
-0.1085 Tc 24.96 3.6 Td
(2)Tj
/TT1 6.96 Tf
0.0177 Tc -0.0325 Tw -170.16 -16.32 Td
(Clinical Study Patient Subset)Tj
ET
q
1 0 0 1 -21.553223 -35.498901 cm
122.4 561.12 8.4 104.4 re
W n
1 0 0 1 21.553223 35.498901 cm
BT
/TT1 6 Tf
0 Tc 0 Tw 0 1 -1 0 107.5668 561.8611 Tm
(Anthracyclines)Tj
ET
Q
q
1 0 0 1 -21.553223 -35.498901 cm
129.12 577.44 7.2 57.6 re
W n
1 0 0 1 21.553223 35.498901 cm
BT
/TT1 6 Tf
0 Tc 0 Tw 0 1 -1 0 114.0468 543.8611 Tm
(nmoles/L-hr\))Tj
ET
Q
q
1 0 0 1 -21.553223 -35.498901 cm
0 0 0 RG
1.2 w 1 j 1 J 
110.64 515.52 324.96 180.96 re
S
Q
BT
/TT0 10.08 Tf
-0.0161 Tc 0.0939 Tw 86.447 433.221 Td
(FIGURE 2.  Comparison of Mean AUC)Tj
/TT0 6.48 Tf
0.0137 Tc 0.1048 Tw 172.56 -1.44 Td
(0-6 hours)Tj
/TT0 10.08 Tf
-0.0101 Tc 0.0879 Tw 27.6 1.44 Td
( in Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0126 Tc 0.0652 Tw (  Clinical Studies \(N=number of)Tj
-0.0285 Tc 0 Tw -200.16 -11.52 Td
(patients\))Tj
-0.0162 Tc 0.094 Tw 0 -23.76 TD
(The patient with a perforated bladder who received 800 mg of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0297 Tc 0.0481 Tw (  intravesically developed)Tj
-0.0191 Tc 0.0969 Tw 0 -11.52 TD
(severe leukopenia and  neutropenia approximately two weeks after drug ad\ministration.)Tj
0.0327 Tc 0.0451 Tw 0 -12.24 TD
(Systemic hematologic toxicity from Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0263 Tc 0.104 Tw (  was not seen after an intravesical dose of 800 mg)Tj
0.0071 Tc 0.0706 Tw T*
(of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0215 Tc 0.0992 Tw ( unless perforation of the urinary bladder occurred.)Tj
/TT1 10.08 Tf
-0.0109 Tc 0.0886 Tw 0 -23.28 TD
(CLINICAL TRIALS)Tj
/TT0 10.08 Tf
-0.0241 Tc 0 Tw 0 -12.48 TD
(Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
-0.0051 Tc 0.0828 Tw (  has been administered intravesically to a total of 230 patients with t\ransitional cell)Tj
-0.0171 Tc 0.0949 Tw 0 -11.52 TD
(carcinoma of the bladder, including 205 patients who received multiple w\eekly doses ranging)Tj
-0.0143 Tc 0.0921 Tw T*
(from 200 to 900 mg.  One hundred seventy-nine of the 205 patients receiv\ed the approved dose)Tj
-0.0194 Tc 0.0972 Tw T*
(and schedule of 800 mg weekly for multiple weeks.)Tj
-0.017 Tc 0.0947 Tw 0 -23.04 TD
(In the 90 study patients with BCG-refractory carcinoma )Tj
/TT3 10.08 Tf
-0.0411 Tc 0.1189 Tw (in situ)Tj
/TT0 10.08 Tf
-0.0134 Tc 0.0911 Tw ( \(CIS\), 70% had received at least 2)Tj
-0.0317 Tc 0.1094 Tw 0 -11.76 TD
(courses of BCG and 30% had received one course of BCG and at least one a\dditional course of)Tj
0 Tc 0.0784 Tw 0 -12.24 TD
(treatment with another agent\(s\) - e.g., mitomycin, thiotepa, or interf\eron. Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw 355.92 0 Td
(\324)Tj
/TT0 10.08 Tf
-0.2141 Tc 0.2918 Tw ( was)Tj
-0.0205 Tc 0.0983 Tw -355.92 -11.52 Td
(administered beginning at least two weeks after transurethral resection \and/or fulguration.  After)Tj
0.0193 Tc 0.0584 Tw T*
(intravesical administration of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0425 Tc 0.1203 Tw (, 16 patients \(18%\) had a complete response documented)Tj
-0.0099 Tc 0.0877 Tw 0 -11.52 TD
(by bladder biopsies and cytology at 6 months following initiation of the\rapy.  Median duration of)Tj
-0.003 Tc 0.0807 Tw T*
(response from start of treatment varied according to the method of analy\sis \(13.5 months if)Tj
-0.0121 Tc 0.0898 Tw T*
(measured to last bladder biopsy without tumor and 21 months if measured \until time of)Tj
-0.0276 Tc 0.1054 Tw T*
(documented recurrence\). A retrospective analysis in the 16 patients wit\h complete response to)Tj
-0.0195 Tc 0.0973 Tw T*
(Valstar demonstrated that time to recurrence of their disease after trea\tment with Valstar was)Tj
-0.0041 Tc 0.0818 Tw T*
(longer than time to recurrence after previous courses of intravesical th\erapy.)Tj
-0.0099 Tc 0.0876 Tw 0 -23.76 TD
(Of the 90 patients with BCG-refractory CIS, 11% \(10 patients\) develope\d  metastatic or deeply-)Tj
-0.0219 Tc 0.0997 Tw 0 -11.52 TD
(invasive bladder cancer during follow-up; four of these patients, none w\ho underwent)Tj
-0.0167 Tc 0.0945 Tw T*
(cystectomy, died with metastatic bladder cancer and six were found to ha\ve developed stage)Tj
-0.0009 Tc 0.0787 Tw T*
(progression to deeply-invasive disease \(T3\), with lymph node involveme\nt in one patient, at the)Tj
0.0218 Tc 0.0559 Tw T*
(time of cystectomy.  It is difficult to ascertain to what extent the dev\elopment of advanced)Tj
-0.0273 Tc 0.105 Tw T*
(bladder cancer in these patients was due to the delay in cystectomy requ\ired to receive)Tj
-0.0095 Tc 0.0872 Tw 0 -12.24 TD
(treatment with Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0279 Tc 0.1056 Tw (  \(3 months was the time of follow-up to determine response\), as)Tj
-0.0127 Tc 0.0905 Tw T*
(cystectomy was often delayed or was never performed despite failure of t\reatment with Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS0 gs
/Fm0 Do
Q
EMC 

endstreamendobj281 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240612153311-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 248 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 306 0 R/LastModified(D:20240612153311-04'00')/Private/Header>>>>/Resources 307 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj69 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 68 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im9/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj75 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 74 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im10/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj74 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj68 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj307 0 obj<</Font 308 0 R>>endobj308 0 obj<</ArialRoundedMTBold 252 0 R>>endobj306 0 obj<</Length 717>>stream
Ôªø<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj280 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj278 0 obj[/Indexed/DeviceRGB 15 68 0 R]endobj279 0 obj[/Indexed/DeviceRGB 15 74 0 R]endobj272 0 obj<</Length 14185>>stream
q
1 0 0 1 -21.935669 -101.378876 cm
0 0 612 792 re
W n
1 0 0 1 21.935669 101.378876 cm
BT
0 0 0 rg
/TT0 7.92 Tf
0.0166 Tc -0.0583 Tw 86.064 646.941 Td
(ANTHRA PHARMACEUTICALS, INC.)Tj
-0.032 Tc -0.0098 Tw 0 -9.36 TD
(AD 32)Tj
-0.0421 Tc 0 Tw T*
(NDA 20,892)Tj
0 Tc -0.0418 Tw 425.52 0 Td
( )Tj
-0.0835 Tc 0 Tw (2)Tj
ET
q
437.76 0 0 -7.68 85.584331 627.261124 cm
/Im0 Do
Q
q
1 0 0 1 -21.935669 -101.378876 cm
108 726.96 432 0.96 re
f
Q
q
437.76 0 0 -7.68 85.584331 627.261124 cm
/Im1 Do
Q
q
1 0 0 1 -21.935669 -101.378876 cm
0 0 0 RG
0.24 w 1 j 1 J 
108 726.96 432 0.96 re
S
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
107.52 697.92 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
107.52 697.92 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
108.24 697.92 433.2 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
541.44 697.92 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
541.44 697.92 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
107.52 683.52 0.72 14.4 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
541.44 683.52 0.72 14.4 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
107.52 682.8 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
108.24 682.8 59.52 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
167.76 682.8 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
168.48 682.8 80.4 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
248.88 682.8 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
249.6 682.8 57.84 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
307.44 682.8 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
308.16 682.8 75.6 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
383.76 682.8 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
384.48 682.8 84.96 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
469.44 682.8 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
470.16 682.8 71.28 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
541.44 682.8 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
107.52 669.36 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
167.76 669.36 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
248.88 669.36 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
307.44 669.36 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
383.76 669.36 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
469.44 669.36 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
541.44 669.36 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
107.52 668.64 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
108.24 668.64 59.52 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
167.76 668.64 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
168.48 668.64 80.4 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
248.88 668.64 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
249.6 668.64 57.84 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
307.44 668.64 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
308.16 668.64 75.6 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
383.76 668.64 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
384.48 668.64 84.96 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
469.44 668.64 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
470.16 668.64 71.28 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
541.44 668.64 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
107.52 655.2 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
167.76 655.2 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
248.88 655.2 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
307.44 655.2 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
383.76 655.2 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
469.44 655.2 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
541.44 655.2 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
107.52 654.48 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
108.24 654.48 59.52 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
167.76 654.48 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
168.48 654.48 80.4 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
248.88 654.48 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
249.6 654.48 57.84 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
307.44 654.48 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
308.16 654.48 75.6 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
383.76 654.48 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
384.48 654.48 84.96 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
469.44 654.48 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
470.16 654.48 71.28 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
541.44 654.48 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
107.52 641.04 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
167.76 641.04 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
248.88 641.04 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
307.44 641.04 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
383.76 641.04 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
469.44 641.04 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
541.44 641.04 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
107.52 640.32 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
108.24 640.32 59.52 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
167.76 640.32 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
168.48 640.32 80.4 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
248.88 640.32 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
249.6 640.32 57.84 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
307.44 640.32 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
308.16 640.32 75.6 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
383.76 640.32 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
384.48 640.32 84.96 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
469.44 640.32 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
470.16 640.32 71.28 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
541.44 640.32 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
107.52 626.88 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
107.52 626.16 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
107.52 626.16 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
108.24 626.16 59.52 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
167.76 626.88 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
167.76 626.16 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
168.48 626.16 80.4 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
248.88 626.88 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
248.88 626.16 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
249.6 626.16 57.84 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
307.44 626.88 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
307.44 626.16 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
308.16 626.16 75.6 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
383.76 626.88 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
383.76 626.16 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
384.48 626.16 84.96 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
469.44 626.88 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
469.44 626.16 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
470.16 626.16 71.28 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
541.44 626.88 0.72 13.44 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
541.44 626.16 0.72 0.72 re
f
Q
q
1 0 0 1 -21.935669 -101.378876 cm
1 1 1 rg
541.44 626.16 0.72 0.72 re
f
Q
BT
/TT1 10.08 Tf
-0.0396 Tc 0.1173 Tw 86.064 515.181 Td
(CLINICAL PHARMACOLOGY)Tj
-0.0137 Tc 0.0915 Tw 0 -23.52 TD
(Mechanism of Action:)Tj
/TT0 10.08 Tf
0.0149 Tc 0.0629 Tw 0 -11.76 TD
(Valrubicin  is an anthracycline that affects a variety of inter-related \biological functions, most of)Tj
0.0074 Tc 0.0703 Tw 0 -11.52 TD
(which involve nucleic acid metabolism.   It readily penetrates into cell\s, where it inhibits the)Tj
-0.0171 Tc 0.0949 Tw T*
(incorporation of nucleosides into nucleic acids, causes extensive chromo\somal damage, and)Tj
-0.0048 Tc 0.0826 Tw T*
(arrests cell cycle in G)Tj
/TT0 6.48 Tf
-0.0029 Tc 0 Tw 96 -1.44 Td
(2)Tj
/TT0 10.08 Tf
-0.0078 Tc 0.0856 Tw 3.6 1.44 Td
(.   Although valrubicin does not bind strongly to  DNA, a  principal)Tj
0.0125 Tc 0.0653 Tw -99.6 -11.52 Td
(mechanism of  its action, mediated by  valrubicin metabolites, is interf\erence with the normal)Tj
-0.0216 Tc 0.0994 Tw T*
(DNA breaking-resealing action of DNA topoisomerase II.)Tj
/TT1 10.08 Tf
-0.0201 Tc 0.0979 Tw 0 -24.24 TD
(Pharmacokinetics after Intravesical Administration of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT1 10.08 Tf
0.0034 Tc (:)Tj
/TT0 10.08 Tf
0.003 Tc 0.0748 Tw 0 -12.48 TD
(When 800 mg Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.009 Tc 0.0867 Tw (  was administered intravesically to patients with carcinoma )Tj
/TT3 10.08 Tf
-0.0241 Tc 0.1019 Tw (in situ,)Tj
/TT0 10.08 Tf
0 Tw T*
(Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
-0.0193 Tc 0.097 Tw ( penetrated into the bladder wall.  The mean total anthracycline concent\ration measured)Tj
-0.0131 Tc 0.0908 Tw 0 -11.52 TD
(in bladder tissue exceeded the levels causing 90% cytoxicity to human bl\adder cells cultured )Tj
/TT3 10.08 Tf
-0.0811 Tc 0 Tw (in)Tj
0 Tc 0 -12.48 TD
(vitro.)Tj
/TT0 10.08 Tf
-0.0205 Tc 0.0983 Tw (  During the two-hour dose-retention period, the metabolism of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0233 Tc 0.0544 Tw (  to its major)Tj
0.0127 Tc 0.0651 Tw 0 -11.76 TD
(metabolites N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycino\l was neglible.  After)Tj
-0.006 Tc 0.0838 Tw 0 -11.52 TD
(retention, the drug was almost completely excreted by voiding the instil\late.  Mean percent)Tj
0.0175 Tc 0.0603 Tw 0 -12.24 TD
(recovery of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0014 Tc 0.0792 Tw (, N-trifluoroacetyladriamycin, and total anthracyclines in 14 urine samp\les)Tj
-0.016 Tc 0.0938 Tw 0 -11.52 TD
(from six patients was 98.6%, 0.4%, and 99.0% of the total administered d\rug,)Tj
-0.0185 Tc 0.0962 Tw 0 -12.24 TD
(respectively.During the two-hour dose-retention period, only nanogram qu\antities of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0 Tc 0.0778 Tw ( )Tj
-0.0085 Tc 0.0863 Tw 0 -11.52 TD
(were absorbed into the plasma. Valrubicin metabolites N-trifluoroacetyla\driamycin and N-)Tj
-0.0014 Tc 0.0791 Tw T*
(trifluoroacetyladriamycinol were measured in blood. )Tj
-0.0025 Tc 0.0803 Tw 0 -23.04 TD
(Total systemic exposure to anthracyclines during and after intravesical \administration of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw 0 -12.24 TD
(\324)Tj
/TT0 10.08 Tf
-0.0282 Tc 0.1059 Tw (  is dependent upon the condition of the bladder wall.)Tj
/TT4 12 Tf
0 Tc 0.12 Tw ( )Tj
/TT0 10.08 Tf
-0.0257 Tc 0.1034 Tw (The mean AUC)Tj
/TT0 6.48 Tf
0.0137 Tc 0.1048 Tw 317.04 -1.44 Td
(0-6 hours )Tj
/TT0 10.08 Tf
0.0254 Tc 0.0524 Tw 29.52 1.44 Td
( \(total)Tj
-0.0085 Tc 0.0863 Tw -346.56 -12.24 Td
(anthracyclines exposure\) for an intravesical dose of 900 mg of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0505 Tc 0.1283 Tw ( administered 2 weeks)Tj
-0.0218 Tc 0.0995 Tw T*
(after transurethral resection of bladder tumors \(n=6\) was 78 nmol/L)Tj
/TT2 10.08 Tf
0.12 Tc 0 Tw (\327)Tj
/TT0 10.08 Tf
-0.0022 Tc 0.0799 Tw (hr. In patients receiving 800)Tj
0.0203 Tc 0.0575 Tw T*
(mg of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
-0.0042 Tc 0.082 Tw ( 5 to 51 minutes after typical \(n=8\) and extensive \(n=5\) transurethr\al resection of)Tj
-0.0269 Tc 0.1047 Tw 0 -11.52 TD
(bladder tumors \(TURBs\), the mean AUC)Tj
/TT0 6.48 Tf
-0.002 Tc 0.1206 Tw 180.48 -1.44 Td
(0-6 hou)Tj
0.0611 Tc 0.0575 Tw (rs )Tj
/TT0 10.08 Tf
-0.0256 Tc 0.1034 Tw 29.52 1.44 Td
( values for total anthracyclines were 409 and 788)Tj
0.0383 Tc 0 Tw -210 -12.24 Td
(nmol/L)Tj
/TT2 10.08 Tf
0.12 Tc (\327)Tj
/TT0 10.08 Tf
0.0062 Tc 0.0716 Tw (hr, respectively.  The AUC)Tj
/TT0 6.48 Tf
0.0137 Tc 0.1048 Tw 151.2 -1.44 Td
(0-6 hours)Tj
/TT0 10.08 Tf
-0.0313 Tc 0.109 Tw 27.6 1.44 Td
( total exposure to anthracyclines was 18,382 nmol/L)Tj
/TT2 10.08 Tf
0.12 Tc 0 Tw (\327)Tj
/TT0 10.08 Tf
-0.0406 Tc (hr)Tj
-0.0252 Tc 0.103 Tw -178.8 -11.52 Td
(in one patient who experienced a perforated bladder following a transure\thral resection that)Tj
-0.0008 Tc 0.0785 Tw 0 -12.24 TD
(occurred 5 minutes before administration of an intravesical dose of 800 \mg of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0778 Tc (. )Tj
-0.0035 Tc 0.0813 Tw T*
(Administration of a comparable intravenous dose of Valstar)Tj
/TT2 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0287 Tc 0.049 Tw (  \(600 mg/m)Tj
/TT0 6.48 Tf
-0.0029 Tc 0 Tw 327.6 5.04 Td
(2)Tj
/TT0 10.08 Tf
-0.0552 Tc 0.133 Tw 3.6 -5.04 Td
(; n=2\) as a 24)Tj
-0.0493 Tc 0 Tw (-hour)Tj
-0.0226 Tc 0.1004 Tw -331.2 -11.52 Td
(infusion resulted in an AUC)Tj
/TT0 6.48 Tf
0.0137 Tc 0.1048 Tw 121.92 -1.44 Td
(0-6 hours)Tj
/TT0 10.08 Tf
0.0045 Tc 0.0732 Tw 27.6 1.44 Td
( for total anthracyclines of 11,975 nmol/L)Tj
/TT5 10.08 Tf
0.0998 Tc 0 Tw (@)Tj
/TT0 10.08 Tf
-0.0548 Tc 0.1326 Tw (hr.  These results are)Tj
-0.0442 Tc 0.1219 Tw -149.52 -11.76 Td
(shown in FIGURE 2.)Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS0 gs
/Fm0 Do
Q
EMC 

endstreamendobj276 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240612153311-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 248 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 309 0 R/LastModified(D:20240612153311-04'00')/Private/Header>>>>/Resources 310 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj50 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 49 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im7/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj56 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 55 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im8/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj55 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj49 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj310 0 obj<</Font 311 0 R>>endobj311 0 obj<</ArialRoundedMTBold 252 0 R>>endobj309 0 obj<</Length 717>>stream
Ôªø<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj63 0 obj<</BaseFont/TimesNewRoman/Encoding/WinAnsiEncoding/Subtype/TrueType/Type/Font>>endobj64 0 obj<</BaseFont/JJABAB+WPMathA/FirstChar 31/FontDescriptor 65 0 R/LastChar 255/Subtype/TrueType/Type/Font/Widths[500 500 600 600 600 600 600 193 600 600 600 400 333 333 600 600 600 564 600 400 733 600 600 600 600 533 533 600 533 500 500 500 500 252 252 400 400 667 500 600 500 564 500 843 600 600 480 333 500 500 333 333 500 667 800 667 600 600 767 767 500 500 767 667 500 500 500 500 600 600 600 600 600 600 600 333 333 333 333 600 600 600 600 600 600 600 600 600 600 600 600 600 600 500 500 747 500 747 667 667 333 333 600 600 600 570 600 500 693 800 667 667 600 600 600 600 667 1000 600 600 600 600 600 600 600 600 767 747 600 600 600 600 600 600 600 600 600 600 600 500 500 500 500 900 667 667 1100 667 667 667 667 667 667 667 667 667 667 600 600 600 600 600 584 600 600 600 600 600 600 600 750 800 800 600 528 600 600 600 600 600 600 600 600 600 600 467 500 1000 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 400 400 600 600 600 600 640 946 667 360 713 667 600 667 600 600 600]>>endobj65 0 obj<</Ascent 929/AvgWidth 548/CapHeight 929/Descent 238/Flags 4/FontBBox[-250 -238 1314 929]/FontFile2 208 0 R/FontName/JJABAB+WPMathA/ItalicAngle 0/Leading 167/MaxWidth 1095/MissingWidth 500/StemH 100/StemV 100/Type/FontDescriptor/XHeight 650>>endobj208 0 obj<</Length 6749/Length1 211 0 R/Length2 210 0 R/Length3 212 0 R>>stream
     Ä  POS/2O‘PÄ   ‹   Ncmap
+ú  *  cvt &®"3  6   ∞fpgmò\‹¢  Ê   dglyfËSÌ  J   ®headæßyí  Ú   6hhea√ú  (   $hmtx?ä;  L  àloca  ã  	‘  åmaxp,  `    name7Æ7  Ä  öpost0{a	    ‚prepzT ±  ¸  a  .ê  ºä   èºä  ≈ 2                  WPCO @ ˇ  »  ñ ˘         $           $                               	
 !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`a bcdefghijklmnopqrstuvwxyz{|}~ÄÅÇÉÑÖÜáàâäãåçéèêëíìîïñóòôöõúùûü†°¢£§•¶ß®©™´¨≠ÆØ∞±≤≥¥µ∂∑∏π∫ªºΩæø¿¡¬√ƒ≈∆«»… ÀÃÕŒœ–—“”‘’÷◊ÿŸ⁄€‹›ﬁﬂ‡·   Ë      ~ˇˇˇ   Äˇˇ       ¬         	 
                        ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~  Ä Å Ç É Ñ Ö Ü á à â ä ã å ç é è ê ë í ì î ï ñ ó ò ô ö õ ú ù û ü † ° ¢ £ § • ¶ ß ® © ™ ´ ¨ ≠ Æ Ø ∞ ± ≤ ≥ ¥ µ ∂ ∑ ∏ π ∫ ª º Ω æ ø ¿ ¡ ¬ √ ƒ ≈ ∆ « » …   À Ã Õ Œ œ – — “ ” ‘ ’ ÷ ◊ ÿ Ÿ ⁄ € ‹ › ﬁ ﬂ ‡ ·n±˚õÓòÉ€Ñ≥¬  bl34ñBUÃ K  ˇªˇ ïˇÌˇòˇX :  V • ) —ˇﬂ¶ ~ eˇr øˇ¨ˇå â pˇ,ˇ> K  „∂p ! ! |  H Q ß ¨ R Ë é » Ω c ◊ õ ı ! ≈ ; t F ¥ Y d ï ß ,   ä !@ ,vE ∞%E#ah#h`D-,E ∞%E#ah#h`D-,  ∏ˇ¿8±@68-,  ∞@8∞6∏ˇ¿8-,∞Fv Gh#Fah X ∞%#8∞%∞6e8Y-    ’    =@9 988   Fv/7 ?<?</<˝</<˝< ˝<˝<10≤ +3!'!∂˛à ¸‡‚˝  A æñ  @8 	* ??/˝ 10≤+#"&54632æ%$$&X%$$$       £&_<ı  Ë    -∆õ    -∆õˇﬂˇ'ñ          ñˇ  Lˇﬂˇã'                ‚Ù     Ù  Ù  X UX iX hX hX E ¡ X X X iê µM *M )X gX dX o4 JX 3ê x› X "X EX AX A £ £X O £Ù qÙ SÙ PÙ P ¸ A ¸ Bê @ê 2õ Ù ÄX Ù #4 IÙ JK X iXˇ˝‡ M sÙ ÄÙ +M 6M Ù õ .  Eõ PX HX Hˇ Aˇ @Ù |Ù |ˇ 6õ ªÙ TÙ TÙ SÙ TX =X 6X BX 6X <X £X HM >MˇÌM 7MˇﬂX X !X RX IX LX HX HX @X X X X DX DX Ù fÙ >Î *Î *õ Kõ >M KM KX wX pX i: iX pÙ >µ   =õ õ [X >X ,X &X õ jË ~X eX eX iX iX ÑX lX BX ˇ Î X -X VX /X 3X 3X AX AX :X @X :X ?Ù  Ù  Ù TÙ ]Ñ äõ Lõ GL 0õ õ õ õ õ õ õ õ õ õ X ØXX õXX AH @X &X &X èX èX 4X ?X 8Ó   =  YX d cX PX PX jX pX jX jX #X hX \X w” ñÙ `Ë @X aX uX ùX âX {X ìX ìX ÅX nX ÜX ÉX ÜX JX HX JX 6X :X AX AX 3ê ê X [X BX fX #Ä ≤ õ #h … õ X kõ JX KX >X =       d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   d   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®   ®    ‚ p  0    @ 
  .              l           l         z         Ü         î        8 ¢         ⁄        6 Ë              ,       2       @       N       j   	   lx   	  ‰   	      	     	  (   	  8D   	  | { c }   1 9 9 3   W o r d P e r f e c t   C o r p o r a t i o n .   A l l   R i g h t s   R e s e r v e d .JJABAB+WPMathA N o r m a lJJABAB+WPMathAJJABAB+WPMathA 1 . 0   T u e   M a y   0 3   1 4 : 4 2 : 1 4   1 9 9 4JJABAB+WPMathA{c} 1993 WordPerfect Corporation. All Rights Reserved.JJABAB+WPMathANormalJJABAB+WPMathAJJABAB+WPMathA1.0 Tue May 03 14:42:14 1994JJABAB+WPMathA { c }   1 9 9 3   W o r d P e r f e c t   C o r p o r a t i o n .   A l l   R i g h t s   R e s e r v e d . J J A B A B + W P M a t h A N o r m a l J J A B A B + W P M a t h A J J A B A B + W P M a t h A 1 . 0   T u e   M a y   0 3   1 4 : 4 2 : 1 4   1 9 9 4 J J A B A B + W P M a t h A       ˇ{                      ‚     	
 !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~ÄÅÇÉÑÖÜáàâäãåçéèêëíìîïñóòôöõúùûü†°¢£§•¶ß®©™´¨≠ÆØ∞±≤≥¥µ∂∑∏π∫ªºΩæø¿¡¬√ƒ≈∆«»… ÀÃÕŒœ–—“”‘’÷◊ÿŸ⁄€‹›ﬁﬂexclamquotedbl
numbersigndollarpercent	ampersandquotesingle	parenleft
parenrightasteriskpluscommahyphenperiodslashzeroonetwothreefourfivesixseveneightninecolon	semicolonlessequalgreaterquestionatABCDEFGHIJKLMNOPQRSTUVWXYZbracketleft	backslashbracketrightasciicircum
underscoregraveabcdefghijklmnopqrstuvwxyz	braceleftbar
braceright
asciitildec128c129quotesinglbaseflorinquotedblbaseellipsisdagger	daggerdbl
circumflexperthousandScaronguilsinglleftOEc141c142c143c144	quoteleft
quoterightquotedblleftquotedblrightbulletendashemdashtilde	trademarkscaronguilsinglrightoec157c158	Ydieresisnbspace
exclamdowncentsterlingcurrencyyen	brokenbarsectiondieresis	copyrightordfeminineguillemotleft
logicalnotminus
registeredmacrondegree	plusminustwosuperiorthreesuperioracutemu	paragraphperiodcenteredcedillaonesuperiorordmasculineguillemotright
onequarteronehalfthreequartersquestiondownAgraveAacuteAcircumflexAtilde	AdieresisAringAECcedillaEgraveEacuteEcircumflex	EdieresisIgraveIacuteIcircumflex	IdieresisEthNtildeOgraveOacuteOcircumflexOtilde	OdieresismultiplyOslashUgraveUacuteUcircumflex	UdieresisYacuteThorn
germandblsagraveaacuteacircumflexatilde	adieresisaringaeccedillaegraveeacuteecircumflex	edieresisigraveiacuteicircumflex	idieresisethntildeograveoacuteocircumflexotilde	odieresisdivideoslashugraveuacuteucircumflex	udieresisyacutethorn	ydieresis@9988  Eç∏ˇÖvEhD≥ F +≥ F +≥ F +≥F +≥ F +≥ F +≥ F +≥	 F +≥
 F +≥ F +≥F +≥F +≥ F +≥F +≥ F +≥ F +≥ F +≥ F +≥ F +≥F +≥F +≥F +≥F +≥F +≥F +≥F +≥F +≥F +≥ F +≥!F +≥"F +≥#F +≥$F +≥% F +≥&F +≥'F +≥(F +≥)F +≥*F +≥+F +≥,F +≥-F +≥.F +≥/ F +≥0F +≥1 F +≥2F +≥3F +≥4F +≥5F +≥6 F +≥7F +EhDEhDEhDEhDEhD
endstreamendobj211 0 obj6749endobj210 0 obj0endobj212 0 obj0endobj275 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj273 0 obj[/Indexed/DeviceRGB 15 49 0 R]endobj274 0 obj[/Indexed/DeviceRGB 15 55 0 R]endobj267 0 obj<</Length 11258>>stream
q
1 0 0 1 -33.52002 -82.898865 cm
0 0 612 792 re
W n
1 0 0 1 33.52002 82.898865 cm
BT
0 0 0 rg
/TT0 7.92 Tf
0.0166 Tc -0.0583 Tw 74.48 665.421 Td
(ANTHRA PHARMACEUTICALS, INC.)Tj
-0.032 Tc -0.0098 Tw 0 -9.36 TD
(AD 32)Tj
-0.0421 Tc 0 Tw 0 -9.36 TD
(NDA 20,892)Tj
0 Tc -0.0418 Tw 425.52 0 Td
( )Tj
-0.0835 Tc 0 Tw (1)Tj
ET
q
437.76 0 0 -7.68 73.99998 645.741135 cm
/Im0 Do
Q
q
1 0 0 1 -33.52002 -82.898865 cm
108 726.96 432 0.96 re
f
Q
q
437.76 0 0 -7.68 73.99998 645.741135 cm
/Im1 Do
Q
q
1 0 0 1 -33.52002 -82.898865 cm
0 0 0 RG
0.24 w 1 j 1 J 
108 726.96 432 0.96 re
S
Q
BT
/TT1 10.08 Tf
-0.0367 Tc 74.48 605.661 Td
(Valstar)Tj
/TT2 10.08 Tf
0.6288 Tc 33.6 0 Td
[(\324)976.19 (\324)]TJ
/TT1 10.08 Tf
0.0124 Tc -33.6 -12 Td
(\(valrubicin\))Tj
0.014 Tc 0.0637 Tw 0 -12 TD
(Sterile Solution for Intravesical Instillation)Tj
/TT0 10.08 Tf
0.0063 Tc 0.0715 Tw 0 -23.28 TD
(For Intravesical Use Only)Tj
-0.0117 Tc 0.0895 Tw 0 -11.52 TD
(Not for IV or IM Use)Tj
/TT1 10.08 Tf
0.0212 Tc 0 Tw 0 -23.28 TD
(DESCRIPTION)Tj
/TT0 10.08 Tf
0.0085 Tc 0.0693 Tw T*
(Valrubicin \(N-trifluoroacetyladriamycin-14-valerate\), a semisynthetic \analog of the anthracycline)Tj
0.003 Tc 0.0748 Tw 0 -11.52 TD
(doxorubicin, is a cytotoxic agent with the chemical name, \(2)Tj
/TT3 10.08 Tf
0 Tc 0 Tw (S-)Tj
-0.0259 Tc 0 -11.76 TD
(cis)Tj
/TT0 10.08 Tf
0 Tc (\)-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[\2,3,6-trideoxy-3-)Tj
0.0345 Tc 0 -12.48 TD
([\(trifluoroacetyl\)amino]-)Tj
/TT4 10.08 Tf
-0.1205 Tc (a)Tj
/TT0 10.08 Tf
-0.0259 Tc (-L-)Tj
/TT3 10.08 Tf
-0.0406 Tc (lyxo)Tj
/TT0 10.08 Tf
-0.0132 Tc 0.0909 Tw (-hexopyranosyl]oxyl]-2-naphthacenyl]-2-oxoethyl  pentanoate. )Tj
-0.0179 Tc 0.0957 Tw 0 -11.76 TD
(Valrubicin is an orange or orange-red powder that is highly lipophilic, \soluble in methylene)Tj
0.002 Tc 0.0758 Tw 0 -11.52 TD
(chloride, ethanol, methanol and acetone and relatively insoluble in wate\r.  Its chemical formula is)Tj
-0.0778 Tc 0 Tw 0 -11.52 TD
(C)Tj
/TT0 6.48 Tf
-0.0029 Tc 7.2 -1.44 Td
(34)Tj
/TT0 10.08 Tf
-0.0778 Tc 7.2 1.44 Td
(H)Tj
/TT0 6.48 Tf
-0.0029 Tc 7.2 -1.44 Td
(36)Tj
/TT0 10.08 Tf
0.0811 Tc 7.2 1.44 Td
(F)Tj
/TT0 6.48 Tf
-0.0029 Tc 6.24 -1.44 Td
(3)Tj
/TT0 10.08 Tf
0 Tc 3.6 1.44 Td
(NO)Tj
/TT0 6.48 Tf
-0.0029 Tc 15.12 -1.44 Td
(13)Tj
/TT0 10.08 Tf
-0.023 Tc 0.1008 Tw 7.2 1.44 Td
( and its molecular weight is 723.65.  The chemical structure is shown in\ FIGURE 1.)Tj
ET
q
0 0 0 rg
47.52 0 0 48.48 80.23998 313.821135 cm
/Im2 Do
Q
q
0 0 0 rg
47.52 0 0 48.48 124.39998 313.821135 cm
/Im3 Do
Q
q
0 0 0 rg
47.52 0 0 48.48 170.23998 313.821135 cm
/Im4 Do
Q
q
0 0 0 rg
47.52 0 0 48.48 216.31998 313.821135 cm
/Im5 Do
Q
q
1 0 0 1 -33.52002 -82.898865 cm
0 0 0 RG
1.68 w 1 j 1 J 
q 1 0 0 1 154.08 421.2 cm
0 0 m
0 8.611 -7.903 15.6 -17.64 15.6 c
-27.377 15.6 -35.28 8.611 -35.28 0 c
-35.28 -8.611 -27.377 -15.6 -17.64 -15.6 c
-7.903 -15.6 0 -8.611 0 0 c
S
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
0 0 0 RG
1.68 w 1 j 1 J 
q 1 0 0 1 245.04 421.2 cm
0 0 m
0 8.611 -7.849 15.6 -17.52 15.6 c
-27.191 15.6 -35.04 8.611 -35.04 0 c
-35.04 -8.611 -27.191 -15.6 -17.52 -15.6 c
-7.849 -15.6 0 -8.611 0 0 c
S
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
0 0 0 RG
0.72 w 1 j 1 J 
q 1 0 0 1 178.56 444.48 cm
0 0 m
0 11.76 l
S
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
0 0 0 RG
0.72 w 1 j 1 J 
q 1 0 0 1 182.88 444.48 cm
0 0 m
0 11.76 l
S
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
0 0 0 RG
0.72 w 1 j 1 J 
q 1 0 0 1 178.56 385.92 cm
0 0 m
0 11.76 l
S
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
0 0 0 RG
0.72 w 1 j 1 J 
q 1 0 0 1 182.88 385.92 cm
0 0 m
0 11.76 l
S
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
0 0 0 RG
0.72 w 1 j 1 J 
q 1 0 0 1 224.64 444.48 cm
0 0 m
0 11.76 l
S
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
0 0 0 RG
0.72 w 1 j 1 J 
q 1 0 0 1 224.64 385.92 cm
0 0 m
0 11.76 l
S
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
0 0 0 RG
0.72 w 1 j 1 J 
q 1 0 0 1 136.56 385.92 cm
0 0 m
0 11.76 l
S
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
0 0 0 RG
0.48 w 1 j 1 J 
q 1 0 0 1 294.72 432.96 cm
0 0 m
13.2 6.72 l
S
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 296.88 433.92 cm
0 0 m
-0.24 0.24 l
-0.24 0 l
-0.48 0 l
-0.24 -0.24 l
-0.24 -0.48 l
0.24 0 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 297.84 433.44 cm
0 0 m
-0.24 0 l
-0.48 -0.24 l
-0.24 -0.48 l
0.24 -0.48 l
0.24 0 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 298.8 432.96 cm
0 0 m
-0.24 0 l
-0.48 -0.24 l
-0.48 -0.48 l
0.24 -0.48 l
0.24 -0.24 l
0 -0.24 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 299.76 432.24 cm
0 0 m
0 0.24 l
-0.24 0.24 l
-0.24 0 l
-0.48 0 l
-0.48 -0.24 l
-0.24 -0.48 l
0 -0.48 l
0 -0.24 l
0.24 -0.24 l
0.24 0 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 300.72 431.76 cm
0 0 m
-0.24 0 l
-0.48 -0.24 l
-0.24 -0.48 l
0.24 -0.48 l
0.24 0 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 301.68 431.28 cm
0 0 m
-0.24 0 l
-0.24 -0.72 l
0 -0.72 l
0 -0.48 l
0.24 -0.48 l
0.24 -0.24 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 302.64 430.56 cm
0 0 m
-0.48 0 l
-0.48 -0.24 l
-0.24 -0.48 l
0 -0.48 l
0 -0.24 l
0.24 -0.24 l
0.24 0 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 303.6 430.08 cm
0 0 m
-0.24 0 l
-0.48 -0.24 l
-0.24 -0.48 l
0.24 -0.48 l
0.24 0 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 304.56 429.6 cm
0 0 m
-0.24 0 l
-0.24 -0.72 l
0 -0.72 l
0 -0.48 l
0.24 -0.48 l
0.24 -0.24 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 305.52 428.88 cm
0 0 m
-0.24 0 l
-0.24 -0.48 l
0 -0.48 l
0.24 -0.24 l
0.24 0 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 306.48 428.4 cm
0 0 m
-0.24 0 l
-0.24 -0.24 l
-0.48 -0.24 l
-0.48 -0.48 l
0.24 -0.48 l
0.24 -0.24 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 307.44 427.68 cm
0 0 m
0 0.24 l
-0.24 0 l
-0.24 -0.48 l
0 -0.48 l
0.24 -0.24 l
0.24 0 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 308.4 427.2 cm
0 0 m
-0.24 0 l
-0.24 -0.48 l
0.24 -0.48 l
0.24 -0.24 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
309.12 426.24 0.48 0.48 re
f
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 270.96 397.68 cm
0 0 m
-0.24 0.24 l
-0.24 0 l
-0.48 0 l
-0.48 -0.24 l
-0.24 -0.48 l
-0.24 -0.24 l
0 -0.24 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 271.92 397.2 cm
0 0 m
-0.48 0 l
-0.48 -0.24 l
-0.24 -0.48 l
0 -0.48 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
272.4 396.24 0.48 0.48 re
f
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 273.84 396 cm
0 0 m
-0.24 0.24 l
-0.24 0 l
-0.48 0 l
-0.48 -0.24 l
-0.24 -0.48 l
0 -0.48 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 274.8 395.52 cm
0 0 m
-0.48 0 l
-0.48 -0.24 l
-0.24 -0.48 l
0 -0.48 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 275.76 395.04 cm
0 0 m
-0.24 0 l
-0.48 -0.24 l
-0.48 -0.48 l
0 -0.48 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 276.72 394.32 cm
0 0 m
-0.48 0 l
-0.48 -0.24 l
-0.24 -0.48 l
0 -0.48 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
277.2 393.36 0.48 0.48 re
f
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 278.64 393.36 cm
0 0 m
-0.24 0 l
-0.48 -0.24 l
-0.48 -0.48 l
-0.24 -0.48 l
-0.24 -0.72 l
0.24 -0.24 l
0 -0.24 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 279.6 392.64 cm
0 0 m
-0.48 0 l
-0.48 -0.24 l
-0.24 -0.24 l
-0.24 -0.48 l
0 -0.48 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
280.08 391.68 0.48 0.48 re
f
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 281.52 391.68 cm
0 0 m
-0.24 0 l
-0.48 -0.24 l
-0.48 -0.48 l
-0.24 -0.48 l
-0.24 -0.72 l
0.24 -0.24 l
0 -0.24 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 282.48 390.96 cm
0 0 m
-0.24 0 l
-0.48 -0.24 l
-0.24 -0.48 l
0.24 -0.48 l
0.24 0 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 283.44 390.48 cm
0 0 m
-0.24 0 l
-0.24 -0.24 l
-0.48 -0.24 l
-0.48 -0.48 l
0 -0.48 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 286.8 378 cm
0 0 m
-1.2 0 l
-1.2 -23.52 l
-0.48 -23.52 l
-0.96 -23.04 l
-0.72 -23.04 l
-22.8 -46.56 l
-22.56 -47.04 l
-22.56 -46.32 l
-22.8 -46.56 l
-22.32 -46.56 l
-61.92 -30.72 l
-62.4 -30.72 l
-110.64 -42.48 l
-110.64 -42.96 l
-110.16 -43.44 l
-110.16 -42.72 l
-110.4 -42.48 l
-110.64 -42.48 l
-110.16 -43.44 l
-83.76 -16.08 l
-84.24 -15.6 l
-84.24 -16.08 l
-84 -16.08 l
-84.24 -16.08 l
-40.32 -24 l
-40.08 -22.8 l
-84.24 -15.12 l
-84.48 -15.12 l
-110.88 -42.72 l
-111.12 -42.72 l
-111.12 -43.44 l
-110.88 -43.44 l
-110.64 -43.68 l
-110.4 -43.68 l
-62.16 -31.68 l
-62.16 -31.2 l
-62.4 -31.68 l
-22.8 -47.52 l
-22.08 -47.52 l
-0.24 -24 l
-0.24 -23.76 l
0 -23.52 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 202.8 361.92 cm
0 0 m
-0.24 0.96 l
-26.64 -2.88 l
-26.64 -4.08 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 225.12 346.8 cm
0 0 m
-0.96 -0.24 l
3.36 -15.84 l
4.32 -15.6 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
q 1 0 0 1 176.64 335.28 cm
0 0 m
-0.96 -0.48 l
3.36 -12.24 l
4.32 -11.76 l
0 0 l
f
Q
Q
q
1 0 0 1 -33.52002 -82.898865 cm
268.56 354 17.76 1.2 re
f
Q
BT
/TT0 11.04 Tf
-0.1891 Tc 0 Tw 141.68 378.141 Td
(O)Tj
-0.12 Tc 39.36 0 Td
(OH)Tj
-0.097 Tc -94.56 -91.2 Td
(OCH)Tj
/TT0 7.68 Tf
0.0499 Tc 24.24 0.72 Td
(3)Tj
/TT0 11.04 Tf
-0.1891 Tc 30.48 0.24 Td
(O)Tj
-0.12 Tc 39.84 -0.96 Td
(OH)Tj
-0.1891 Tc 70.56 11.04 Td
(O)Tj
-0.12 Tc 27.12 27.84 Td
(OH)Tj
-0.1891 Tc -61.68 -59.28 Td
(O)Tj
-0.1709 Tc -104.16 -5.04 Td
(CH)Tj
/TT0 7.68 Tf
0.0499 Tc 15.84 0.96 Td
(3)Tj
/TT0 11.04 Tf
-0.12 Tc 9.6 -41.28 Td
(OH)Tj
-0.1097 Tc 49.68 6.96 Td
(NHCOCF)Tj
/TT0 7.68 Tf
0.0499 Tc 46.56 0.72 Td
(3)Tj
/TT0 11.04 Tf
-0.0854 Tc 43.92 123.84 Td
(COCH)Tj
/TT0 7.68 Tf
0.0499 Tc 32.16 0.72 Td
(2)Tj
/TT0 11.04 Tf
-0.1012 Tc 4.32 -0.72 Td
(OCO\(CH)Tj
/TT0 7.68 Tf
0.0499 Tc 44.16 0.72 Td
(2)Tj
/TT0 11.04 Tf
-0.0763 Tc 4.32 -0.72 Td
(\))Tj
/TT0 7.68 Tf
0.0499 Tc 3.84 0.72 Td
(3)Tj
/TT0 11.04 Tf
-0.1709 Tc 4.32 -0.72 Td
(CH)Tj
/TT0 7.68 Tf
0.0499 Tc 15.6 0.72 Td
(3)Tj
/TT0 10.08 Tf
0.0089 Tc 0.0689 Tw -312.72 -166.56 Td
(FIGURE 1.)Tj
0.0181 Tc 0.0597 Tw 72 0 Td
(Chemical Structure of Valrubicin)Tj
-0.0241 Tc 0 Tw -72 -35.28 Td
(Valstar)Tj
/TT4 10.08 Tf
0.1488 Tc (\324)Tj
/TT0 10.08 Tf
0.0281 Tc 0.0496 Tw ( \(valrubicin\) Sterile Solution for Intravesical Instillation is intend\ed for intravesical)Tj
-0.0326 Tc 0.1104 Tw T*
(administration in the urinary bladder.  It is supplied as a nonaqueous s\olution that should be)Tj
0.0237 Tc 0.0541 Tw 0 -12.24 TD
(diluted before intravesical administration.  Each vial of Valstar)Tj
/TT4 10.08 Tf
0.1488 Tc 0 Tw (\324)Tj
/TT0 10.08 Tf
0.0097 Tc 0.0681 Tw ( contains valrubicin at a)Tj
-0.0121 Tc 0.0899 Tw 0 -11.52 TD
(concentration of 40)Tj
-0.0014 Tc 0.0792 Tw ( mg/mL in 50% Cremophor)Tj
/TT5 10.08 Tf
0 Tc 0 Tw (7)Tj
/TT0 10.08 Tf
0.006 Tc 0.0718 Tw (EL \(polyoxyethyleneglycol triricinoleate\)/50%)Tj
-0.0117 Tc 0.0895 Tw 0 -11.52 TD
(dehydrated alcohol,USP without preservatives or other additives.  The so\lution is sterile and)Tj
-0.0333 Tc 0 Tw T*
(nonpyrogenic.)Tj
ET
q
1 0 0 1 -33.52002 -82.898865 cm
18 18 576 756 re
W n
1 1 1 rg
0 0 0 RG
0.72 w 1 j 1 J 
86.4 260.16 532.8 237.6 re
h
B
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS0 gs
/Fm0 Do
Q
EMC 

endstreamendobj271 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240612153311-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 248 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 312 0 R/LastModified(D:20240612153311-04'00')/Private/Header>>>>/Resources 313 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj8 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 7 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im1/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj14 0 obj<</BitsPerComponent 4/ColorSpace[/Indexed/DeviceRGB 15 13 0 R]/Filter/LZWDecode/Height 8/Length 125/Name/im2/Subtype/Image/Type/XObject/Width 456>>stream
Ä`P8$ÑBaP∏d6àDbQ8§V-åFcQ∏‰v.Å» R åíM!îHÂ2Y\ûU/ñL%”§Œm-úLß3Y‹ﬁu?ûP'‘$zçG§RiT∫e6ùO®TjU:•VóC¨OkT*›≥\∞W´µ˚Ü…gï’≠Vªe&
endstreamendobj27 0 obj<</BitsPerComponent 1/Decode[1 0]/DecodeParms<</Columns 198/K -1>>/Filter/CCITTFaxDecode/Height 202/ImageMask true/Length 356/Name/im3/Subtype/Image/Type/XObject/Width 198>>stream
&†x5õ¡ÆxA·ÑxA·Ñja·xAAáÑa·xAAáÑo √¬0Ç< É √¬	áÑaË √¬0Ç< É √¬0Ç< É √¬7Ña·xAAáÑa·√¬0Ç< É √¬0Ç< É √¬0‚naÑ ·áˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇ˝ˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇáÜ0°Ö&®0ña,0¬0Ç√ ∞√,6XaÑaÜAaÜXa†∞√,0¬0Ç√ ∞√,0¬0Ç√aÜAaÜXaÑa∞¬0Ç√ ∞√,0–XaÑaÜ¬0Ç√ ∞√,0¬0Ç√ ∞√,0¬0Ç√ ∞√,1,0∞¬√-® Ä
endstreamendobj29 0 obj<</BitsPerComponent 1/Decode[1 0]/DecodeParms<</Columns 198/K -1>>/Filter/CCITTFaxDecode/Height 202/ImageMask true/Length 355/Name/im4/Subtype/Image/Type/XObject/Width 198>>stream
&†x5õ¡ÆxA·ÑxA·Ñja·xAAáÑa·xAAáÑo √¬	áÑa·xAAáÑaË √¬0Ç< É √¬0Ça·xAAº É √¬0Ç< É √¬0Ç< É&AáÑa·xAAáÉpÉ ·<?ˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇ‘0°Ö)5AÑ∞√	aÜXaÑ,0¬0Ç√ ∞√,0¬0Ç√ÜAaÜXl ∞√-ÜXaÑaÜAaÜXaÑaÜAa∞Ç√ ∞√,0¬4aÜAaÜXaÑ√,6XaÑaÜAaÜXaÑaÜAaÜXbXaaÖÜ[
  
endstreamendobj33 0 obj<</BitsPerComponent 1/Decode[1 0]/DecodeParms<</Columns 198/K -1>>/Filter/CCITTFaxDecode/Height 202/ImageMask true/Length 354/Name/im5/Subtype/Image/Type/XObject/Width 198>>stream
&†x5õ¡ÆxA·ÑxA·Ñja·xAAáÑa·xAAá†É √¬0Ç< É √¬	áÑa·¬0Ç< É √¬0Ç< É √–AáÑa·xAAáÑa·√¬0Ç< É √¬0Ç< É √¬0‚nl ·A·ˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇ_ˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇ··Ö(aIÆXaÑaÜAa∞Ç√ ∞√,0¬0Ç√ ∞√,0–XaÑaÜ¬0ÇÿaÜAaÜXaÑaÜAaÜXaÑ,0¬0Ç√ ∞√AaÜXaÑaÜAl0Ç√aÜAaÜXaÑaÜAaÜXaÑaÜ!aÖÜXaaÖµ 
endstreamendobj37 0 obj<</BitsPerComponent 1/Decode[1 0]/DecodeParms<</Columns 198/K -1>>/Filter/CCITTFaxDecode/Height 202/ImageMask true/Length 354/Name/im6/Subtype/Image/Type/XObject/Width 198>>stream
&†x5õ¡ÆxA·ÑxA·Ñja·xAAáÑa·xAAá†ÉxAAáÑa·xAL< É √¬0Ç< É √¬0Ç< É √–Aº É √¬0Ç< É&AáÑa·xAAáÑa·xAAáÉpÉ ·A·ˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇÜ°Ö(aIÆXaÑaÜAa∞Ç√ ∞√,0¬0Ç√ ∞√,0–XaÑaÜ¬0ÇÿaÜAaÜXaÑaÜAaÜXaÑ,0¬0Ç√ ∞√AaÜXaÑaÜAl0Ç√aÜAaÜXaÑaÜAaÜXaÑaÜ!aÖÜXaaÖµ 
endstreamendobj13 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj7 0 obj<</Filter/ASCII85Decode/Length 22>>stream
s8W-!s8N'!zzzzzzzzzz~>
endstreamendobj313 0 obj<</Font 314 0 R>>endobj314 0 obj<</ArialRoundedMTBold 252 0 R>>endobj312 0 obj<</Length 717>>stream
Ôªø<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj20 0 obj<</BaseFont/Symbol/FirstChar 31/FontDescriptor 21 0 R/LastChar 255/Subtype/TrueType/Type/Font/Widths[600 250 333 713 500 549 833 778 439 333 333 500 549 250 549 250 278 500 500 500 500 500 500 500 500 500 500 278 278 549 549 549 444 549 722 667 722 612 611 763 603 722 333 631 722 686 889 722 722 768 741 556 592 611 690 439 768 645 795 611 333 863 333 658 500 500 631 549 549 494 439 521 411 603 329 603 549 549 576 521 549 549 521 549 603 439 576 713 686 493 686 494 480 200 480 549 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 620 247 549 167 713 500 753 753 753 753 1042 987 603 987 603 400 549 411 549 549 713 494 460 549 549 549 549 1000 603 1000 658 823 686 795 987 768 768 823 768 768 713 713 713 713 713 713 713 768 713 790 790 890 823 549 250 713 603 603 1042 987 603 987 603 494 329 790 790 786 713 384 384 384 384 384 384 494 494 494 494 600 329 274 686 686 686 384 384 384 384 384 384 494 494 494 600]>>endobj270 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj268 0 obj[/Indexed/DeviceRGB 15 7 0 R]endobj269 0 obj[/Indexed/DeviceRGB 15 13 0 R]endobj222 0 obj[]endobj220 0 obj<</BaseFont/Helvetica/Encoding 219 0 R/Name/Helv/Subtype/Type1/Type/Font>>endobj221 0 obj<</BaseFont/ZapfDingbats/Name/ZaDb/Subtype/Type1/Type/Font>>endobj219 0 obj<</Differences[24/breve/caron/circumflex/dotaccent/hungarumlaut/ogonek/ring/tilde 39/quotesingle 96/grave 128/bullet/dagger/daggerdbl/ellipsis/emdash/endash/florin/fraction/guilsinglleft/guilsinglright/minus/perthousand/quotedblbase/quotedblleft/quotedblright/quoteleft/quoteright/quotesinglbase/trademark/fi/fl/Lslash/OE/Scaron/Ydieresis/Zcaron/dotlessi/lslash/oe/scaron/zcaron 160/Euro 164/currency 166/brokenbar 168/dieresis/copyright/ordfeminine 172/logicalnot/.notdef/registered/macron/degree/plusminus/twosuperior/threesuperior/acute/mu 183/periodcentered/cedilla/onesuperior/ordmasculine 188/onequarter/onehalf/threequarters 192/Agrave/Aacute/Acircumflex/Atilde/Adieresis/Aring/AE/Ccedilla/Egrave/Eacute/Ecircumflex/Edieresis/Igrave/Iacute/Icircumflex/Idieresis/Eth/Ntilde/Ograve/Oacute/Ocircumflex/Otilde/Odieresis/multiply/Oslash/Ugrave/Uacute/Ucircumflex/Udieresis/Yacute/Thorn/germandbls/agrave/aacute/acircumflex/atilde/adieresis/aring/ae/ccedilla/egrave/eacute/ecircumflex/edieresis/igrave/iacute/icircumflex/idieresis/eth/ntilde/ograve/oacute/ocircumflex/otilde/odieresis/divide/oslash/ugrave/uacute/ucircumflex/udieresis/yacute/thorn/ydieresis]/Type/Encoding>>endobj1 0 obj<</Author(Unknown)/CreationDate(Monday, September 28, 1998 3:41:15 PM)/CreationDate--Text(Monday, September 28, 1998 3:41:15 PM)/Creator(Microsoft Word )/Keywords()/ModDate(D:20240612153311-04'00')/Producer(Acrobat PDFWriter 3.02 for Windows)/Subject()/Title(20892LBL.PDF)>>endobjxref
0 315
0000000000 65535 f
0000190993 00000 n
0000000000 00000 f
0000000016 00000 n
0000107160 00000 n
0000004362 00000 n
0000045161 00000 n
0000187495 00000 n
0000184533 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000187402 00000 n
0000184839 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000045248 00000 n
0000188440 00000 n
0000061083 00000 n
0000071027 00000 n
0000000000 00000 f
0000000000 00000 f
0000053923 00000 n
0000000000 00000 f
0000185147 00000 n
0000000000 00000 f
0000185712 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000186276 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000186839 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000054947 00000 n
0000055990 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000107502 00000 n
0000162985 00000 n
0000162276 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000162892 00000 n
0000162584 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000163931 00000 n
0000164027 00000 n
0000165058 00000 n
0000000000 00000 f
0000107795 00000 n
0000146097 00000 n
0000145387 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000146004 00000 n
0000145695 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000108066 00000 n
0000132287 00000 n
0000131576 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000132194 00000 n
0000131885 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000108348 00000 n
0000124650 00000 n
0000123936 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000124556 00000 n
0000124245 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000108620 00000 n
0000116397 00000 n
0000115681 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000116303 00000 n
0000115992 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000004566 00000 n
0000004464 00000 n
0000106064 00000 n
0000105348 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000105970 00000 n
0000105659 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000004831 00000 n
0000085651 00000 n
0000084935 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000085557 00000 n
0000085246 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000005107 00000 n
0000070080 00000 n
0000069364 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000069986 00000 n
0000069675 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000005394 00000 n
0000052976 00000 n
0000052260 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000052882 00000 n
0000052571 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000005670 00000 n
0000010542 00000 n
0000009826 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000010448 00000 n
0000010137 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000056261 00000 n
0000000000 00000 f
0000061045 00000 n
0000061023 00000 n
0000061064 00000 n
0000165317 00000 n
0000000000 00000 f
0000172189 00000 n
0000172167 00000 n
0000172208 00000 n
0000004278 00000 n
0000000327 00000 n
0000000397 00000 n
0000000192 00000 n
0000000545 00000 n
0000045071 00000 n
0000189800 00000 n
0000189630 00000 n
0000189722 00000 n
0000189610 00000 n
0000086747 00000 n
0000107062 00000 n
0000107111 00000 n
0000107011 00000 n
0000104501 00000 n
0000071271 00000 n
0000086649 00000 n
0000086698 00000 n
0000086598 00000 n
0000084088 00000 n
0000061472 00000 n
0000071173 00000 n
0000071222 00000 n
0000071122 00000 n
0000068517 00000 n
0000045490 00000 n
0000061374 00000 n
0000061423 00000 n
0000061323 00000 n
0000051413 00000 n
0000005924 00000 n
0000045392 00000 n
0000045441 00000 n
0000045341 00000 n
0000008979 00000 n
0000010636 00000 n
0000044302 00000 n
0000010681 00000 n
0000010716 00000 n
0000010765 00000 n
0000011952 00000 n
0000012220 00000 n
0000053154 00000 n
0000053070 00000 n
0000053105 00000 n
0000070258 00000 n
0000070174 00000 n
0000070209 00000 n
0000085829 00000 n
0000085745 00000 n
0000085780 00000 n
0000106242 00000 n
0000106158 00000 n
0000106193 00000 n
0000172374 00000 n
0000189515 00000 n
0000189562 00000 n
0000189464 00000 n
0000183686 00000 n
0000147190 00000 n
0000172278 00000 n
0000172326 00000 n
0000172227 00000 n
0000161429 00000 n
0000133380 00000 n
0000147094 00000 n
0000147142 00000 n
0000147043 00000 n
0000144540 00000 n
0000125744 00000 n
0000133284 00000 n
0000133332 00000 n
0000133233 00000 n
0000130729 00000 n
0000117493 00000 n
0000125647 00000 n
0000125695 00000 n
0000125596 00000 n
0000123089 00000 n
0000108894 00000 n
0000117395 00000 n
0000117444 00000 n
0000117344 00000 n
0000114834 00000 n
0000116575 00000 n
0000116491 00000 n
0000116526 00000 n
0000124827 00000 n
0000124743 00000 n
0000124778 00000 n
0000132464 00000 n
0000132380 00000 n
0000132415 00000 n
0000146274 00000 n
0000146190 00000 n
0000146225 00000 n
0000163162 00000 n
0000163078 00000 n
0000163113 00000 n
0000187671 00000 n
0000187587 00000 n
0000187622 00000 n
trailer
<</Size 315/Root 3 0 R/Info 1 0 R/ID[<61C10D0E71BCB8927E1730DC31D84C17><FDA081DB63FBA84F903FAC96B28A5482>]>>
startxref
191283
%%EOF
